,direction,relation,relex_relcos,sentence,term1,term2
0,LIVER location HEPATOCELLULAR CARCINOMA,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
1,LIVER location HEPATOCELLULAR CARCINOMA,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
2,HEPATOCELLULAR CARCINOMA location LIVER,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
3,HEPATOCELLULAR CARCINOMA location LIVER,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
4,no_relation,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
5,no_relation,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
6,HEPATOCELLULAR CARCINOMA location LIVER,location,0.353553390593274,"Therefore, although serum P III P can be a useful marker in HEPATOCELLULAR CARCINOMA it may possibly be difficult to discriminate it from benign diseases involving the LIVER and biliary tract.",LIVER,HEPATOCELLULAR CARCINOMA
7,ENDOTOXEMIA diagnosis ESCHERICHIA COLI ENDOTOXIN,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
8,no_relation,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
9,no_relation,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
10,no_relation,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
11,no_relation,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
12,ENDOTOXEMIA diagnosis ESCHERICHIA COLI ENDOTOXIN,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
13,no_relation,diagnosis,0.31622776601683805,ENDOTOXEMIA was evoked by bolus injection of ESCHERICHIA COLI ENDOTOXIN (2 ng/kg body weight) in six healthy subjects to investigate the early kinetics of cytokine release in relation to the development of clinical and hematologic abnormalities frequently seen in gram negative septicemia.,ESCHERICHIA COLI ENDOTOXIN,ENDOTOXEMIA
14,TUBERCULOSIS diagnosis TUBERCULIN SENSITIVITY,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
15,TUBERCULIN SENSITIVITY diagnosis TUBERCULOSIS,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
16,no_relation,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
17,no_relation,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
18,TUBERCULOSIS diagnosis TUBERCULIN SENSITIVITY,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
19,TUBERCULIN SENSITIVITY diagnosis TUBERCULOSIS,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
20,no_relation,diagnosis,0.31622776601683805,The trends in tuberculin reactions of Mantoux test (2 TU) performed annually before and after the diagnosis of TUBERCULOSIS shows that the risk groups consist of subjects with increasing TUBERCULIN SENSITIVITY and those susceptible to acute respiratory virus infections.,TUBERCULOSIS,TUBERCULIN SENSITIVITY
21,THYROID causes GOITER,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
22,THYROID causes GOITER,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
23,GOITER causes THYROID,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
24,no_relation,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
25,no_relation,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
26,no_relation,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
27,no_relation,causes,0.625543242171224,"Ninety eight hypothyroid children without GOITER were divided into 6 groups: (i) athyreosis: RAIU low, no thyroid tissue identifiable (n = 39); (ii) hypoplasia: RAIU low, gland small, in normal position (n = 7); (iii) ectopia: RAIU low, gland in ectopic position (n = 24); (iv) THYROIDitis: TMA positive (n = 2); (v) iodine deficiency: low urinary iodine (n = 1); and (vi) cause unknown: RAIU.",THYROID,GOITER
28,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
29,no_relation,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
30,no_relation,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
31,no_relation,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
32,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
33,FLUMAZENIL treats OPIOID OVERDOSE,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
34,OPIOID OVERDOSE treats FLUMAZENIL,treats,0.589767824619588,"Clonidine, oxymetazoline, tetrahydozoline, brimonidine, tizanidine; barbiturates; opioids; benzodiazepines  Give naloxone for suspected OPIOID OVERDOSE; consider FLUMAZENIL for benzodiazepine overdose Cholinergic (pinpoint pupils; variable HR; sweaty skin; abdominal cramps and diarrhea)  Organophosphate and carbamate insecticides; chemical warfare nerve agents  Give atropine and pralidoxime; obtain measurements of serum and RBC cholinesterase activity Anticholinergic (agitation; delirium; dilated pupils; tachycardia; decreased peristalsis; dry, flushed skin)  Atropine and related drugs; antihistamines; carbamazepine; phenothiazines; tricyclic antidepressants  Obtain immediate ECG.",OPIOID OVERDOSE,FLUMAZENIL
35,ATENOLOL treats HYPERTENSION,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
36,HYPERTENSION treats ATENOLOL,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
37,ATENOLOL treats HYPERTENSION,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
38,ATENOLOL treats HYPERTENSION,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
39,ATENOLOL treats HYPERTENSION,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
40,ATENOLOL treats HYPERTENSION,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
41,ATENOLOL treats HYPERTENSION,treats,0.985527456652574,"Stumpe KO, Haworth D, Hoglund C et al et al. Comparison of the angiotensin II receptor antagonist, irbesartan, and ATENOLOL for the treatment of HYPERTENSION",HYPERTENSION,ATENOLOL
42,no_relation,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
43,IMIPRAMINE causes DEPRESSION,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
44,no_relation,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
45,no_relation,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
46,IMIPRAMINE causes DEPRESSION,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
47,IMIPRAMINE causes DEPRESSION,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
48,no_relation,causes,0.441726104299386,"With successful treatment of the patient's depression with IMIPRAMINE the tremors disappeared, but slowly began again after drug noncompliance resulted in recurrence of DEPRESSION.",DEPRESSION,IMIPRAMINE
49,ELEVATED BLOOD PRESSURE causes RELATED BLOOD PRESSURE/HYPERTENSION,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
50,no_relation,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
51,no_relation,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
52,RELATED BLOOD PRESSURE/HYPERTENSION causes ELEVATED BLOOD PRESSURE,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
53,no_relation,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
54,RELATED BLOOD PRESSURE/HYPERTENSION causes ELEVATED BLOOD PRESSURE,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
55,no_relation,causes,0.5303300858899109,OC RELATED BLOOD PRESSURE/HYPERTENSION is defined as: women with neither history of hypertension nor ELEVATED BLOOD PRESSURE before OC use develop increased blood pressure or hypertension that is reversible once OC use ceases.,ELEVATED BLOOD PRESSURE,RELATED BLOOD PRESSURE/HYPERTENSION
56,no_relation,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
57,no_relation,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
58,no_relation,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
59,no_relation,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
60,no_relation,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
61,HEPATOCELLULAR CARCINOMA causes HYPERTHERMIA,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
62,HEPATOCELLULAR CARCINOMA causes HYPERTHERMIA,causes,0.404519917477945,"The therapeutic results of Lp TAE (transcatheter arterial embolization in the presence or absence of Gelfoam particles preceded by the infusion of a mixture of lipiodol and an anticancer drug via the proper hepatic artery) or DSM TAE (transcatheter arterial embolization with degradable starch microspheres and the arterial injection of anticancer drugs via the hepatic artery) combined with HYPERTHERMIA were evaluated in 30 patients with HEPATOCELLULAR CARCINOMA (HCC), 5 subjects with hepatic cholangiocarcinoma, and 22 patients with metastatic liver carcinoma.",HYPERTHERMIA,HEPATOCELLULAR CARCINOMA
63,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
64,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
65,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
66,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
67,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
68,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
69,INTERFERON BETA 1A treats MULTIPLE SCLEROSIS,treats,0.985329278164293,Natalizumab plus INTERFERON BETA 1A for relapsing MULTIPLE SCLEROSIS,MULTIPLE SCLEROSIS,INTERFERON BETA 1A
70,no_relation,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
71,no_relation,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
72,no_relation,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
73,no_relation,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
74,no_relation,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
75,no_relation,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
76,PIGMENTED SEBORRHEIC KERATOSIS causes ISOLATED PAPULE ON THE FOREARM,causes,0.5,"These skin lesions included an intradermal nevus, a PIGMENTED SEBORRHEIC KERATOSIS an ISOLATED PAPULE ON THE FOREARM a perianal lesion, and an acantholytic acanthoma.",ISOLATED PAPULE ON THE FOREARM,PIGMENTED SEBORRHEIC KERATOSIS
77,no_relation,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
78,no_relation,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
79,GROUP B STREPTOCOCCAL INFECTIONS diagnosis STREPTOCOCCUS AGALACTIAE,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
80,STREPTOCOCCUS AGALACTIAE diagnosis GROUP B STREPTOCOCCAL INFECTIONS,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
81,no_relation,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
82,GROUP B STREPTOCOCCAL INFECTIONS diagnosis STREPTOCOCCUS AGALACTIAE,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
83,no_relation,diagnosis,0.6859943405700349,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
84,DIARRHEA causes IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
85,no_relation,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
86,no_relation,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
87,no_relation,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
88,no_relation,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
89,no_relation,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
90,no_relation,causes,0.529812942826018,"A 61 yr old woman with gallbladder stones, diabetes, weight loss, DIARRHEA and steatorrhea, IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy.",DIARRHEA,IMMUNOHISTOCHEMICAL DIAGNOSIS OF SOMATOSTATINOMA
91,no_relation,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
92,GROUP B STREPTOCOCCAL INFECTIONS causes STREPTOCOCCUS AGALACTIAE,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
93,no_relation,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
94,no_relation,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
95,STREPTOCOCCUS AGALACTIAE causes GROUP B STREPTOCOCCAL INFECTIONS,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
96,no_relation,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
97,no_relation,causes,0.514495755427526,A selected review is presented of the history of GROUP B STREPTOCOCCAL INFECTIONS and the laboratory tests used to identify Group B streptococcus (STREPTOCOCCUS AGALACTIAE an opportunistic pathogen which causes serious infections in newborn infants and compromised patients in other age groups.,STREPTOCOCCUS AGALACTIAE,GROUP B STREPTOCOCCAL INFECTIONS
98,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
99,no_relation,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
100,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
101,no_relation,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
102,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
103,no_relation,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
104,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.34188172937891403,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
105,HAEMATURIA causes RENAL CELL CARCINOMA,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
106,RENAL CELL CARCINOMA causes HAEMATURIA,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
107,RENAL CELL CARCINOMA causes HAEMATURIA,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
108,no_relation,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
109,no_relation,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
110,RENAL CELL CARCINOMA causes HAEMATURIA,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
111,RENAL CELL CARCINOMA causes HAEMATURIA,causes,0.927172649945531,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA
112,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
113,HANTAVIRUS PULMONARY SYNDROME causes HANTAVIRUS,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
114,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
115,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
116,HANTAVIRUS PULMONARY SYNDROME causes HANTAVIRUS,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
117,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
118,no_relation,causes,0.9438798074485388,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME
119,no_relation,causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
120,no_relation,causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
121,PRIMARY ACQUIRED THROMBOCYTOSES causes (ESSENTIAL THROMBOCYTHAEMIA (PT),causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
122,no_relation,causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
123,no_relation,causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
124,(ESSENTIAL THROMBOCYTHAEMIA (PT) causes PRIMARY ACQUIRED THROMBOCYTOSES,causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
125,PRIMARY ACQUIRED THROMBOCYTOSES causes (ESSENTIAL THROMBOCYTHAEMIA (PT),causes,0.625543242171224,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT)
126,TINEA PEDIS treats SULCONAZOLE NITRATE 1% CREAM,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
127,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
128,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
129,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
130,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
131,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
132,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,treats,0.993883734673619,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM
133,WORK RELATED ALLERGY causes DELAYED TYPE HYPERSENSITIVITIES,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
134,WORK RELATED ALLERGY causes DELAYED TYPE HYPERSENSITIVITIES,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
135,DELAYED TYPE HYPERSENSITIVITIES causes WORK RELATED ALLERGY,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
136,no_relation,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
137,no_relation,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
138,no_relation,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
139,WORK RELATED ALLERGY causes DELAYED TYPE HYPERSENSITIVITIES,causes,0.42426406871192895,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES
140,PURTSCHER'S RETINOPATHY causes TRAUMA,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
141,TRAUMA causes PURTSCHER'S RETINOPATHY,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
142,no_relation,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
143,TRAUMA causes PURTSCHER'S RETINOPATHY,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
144,TRAUMA causes PURTSCHER'S RETINOPATHY,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
145,TRAUMA causes PURTSCHER'S RETINOPATHY,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
146,PURTSCHER'S RETINOPATHY causes TRAUMA,causes,0.843274042711568,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA
147,FVIII treats HEMOPHILIA A,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
148,FVIII treats HEMOPHILIA A,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
149,FVIII treats HEMOPHILIA A,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
150,FVIII treats HEMOPHILIA A,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
151,HEMOPHILIA A treats FVIII,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
152,FVIII treats HEMOPHILIA A,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
153,FVIII treats HEMOPHILIA A,treats,0.962250448649376,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII
154,ATOPIC causes ATOPIC DERMATITIS,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
155,no_relation,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
156,no_relation,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
157,ATOPIC causes ATOPIC DERMATITIS,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
158,no_relation,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
159,no_relation,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
160,no_relation,causes,0.625543242171224,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC
161,NONTHROMBOCYTIC PURPURA diagnosis HENOCH SCHONLEIN PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
162,HENOCH SCHONLEIN PURPURA diagnosis NONTHROMBOCYTIC PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
163,HENOCH SCHONLEIN PURPURA diagnosis NONTHROMBOCYTIC PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
164,HENOCH SCHONLEIN PURPURA diagnosis NONTHROMBOCYTIC PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
165,HENOCH SCHONLEIN PURPURA diagnosis NONTHROMBOCYTIC PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
166,HENOCH SCHONLEIN PURPURA diagnosis NONTHROMBOCYTIC PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
167,HENOCH SCHONLEIN PURPURA diagnosis NONTHROMBOCYTIC PURPURA,diagnosis,0.393919298579168,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA
168,CF causes BRONCHIECTASIS,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
169,BRONCHIECTASIS causes CF,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
170,no_relation,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
171,BRONCHIECTASIS causes CF,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
172,BRONCHIECTASIS causes CF,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
173,CF causes BRONCHIECTASIS,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
174,CF causes BRONCHIECTASIS,causes,0.981980506061966,"DIFFERENTIAL DIAGNOSIS  In the differential diagnosis of PCD, other causes of BRONCHIECTASIS must be considered; these include CF immune deficiencies, severe respiratory illness in childhood, nontuberculous mycobacterial infection, and allergic bronchopulmonary aspergillosis.",BRONCHIECTASIS,CF
175,BREAST CANCERS causes SUBSET,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
176,no_relation,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
177,SUBSET causes BREAST CANCERS,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
178,no_relation,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
179,no_relation,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
180,no_relation,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
181,no_relation,causes,0.516397779494322,Inactivation of the breast cancer susceptibility gene BRCA1 plays a significant role in the development of a SUBSET of BREAST CANCERS although the major tumor suppressor function of this gene remains unclear.,SUBSET,BREAST CANCERS
182,BRONCHIAL HYPERREACTIVITY causes METHACHOLINE,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
183,METHACHOLINE causes BRONCHIAL HYPERREACTIVITY,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
184,METHACHOLINE causes BRONCHIAL HYPERREACTIVITY,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
185,BRONCHIAL HYPERREACTIVITY causes METHACHOLINE,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
186,no_relation,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
187,no_relation,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
188,no_relation,causes,0.5962847939999439,BRONCHIAL HYPERREACTIVITY to METHACHOLINE was confirmed at a pretrial bronchial challenge.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
189,FUNGI causes SUPERFICIAL MYCOSES,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
190,FUNGI causes SUPERFICIAL MYCOSES,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
191,FUNGI causes SUPERFICIAL MYCOSES,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
192,SUPERFICIAL MYCOSES causes FUNGI,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
193,no_relation,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
194,no_relation,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
195,FUNGI causes SUPERFICIAL MYCOSES,causes,0.64018439966448,"Although dermatophytes are the most common agents of SUPERFICIAL MYCOSES in humans and animals, the molecular basis of the pathogenicity of these FUNGI is largely unknown.",FUNGI,SUPERFICIAL MYCOSES
196,MATERNAL THROMBOCYTOPENIA causes AUTOIMMUNE THROMBOCYTOPENIA,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
197,MATERNAL THROMBOCYTOPENIA causes AUTOIMMUNE THROMBOCYTOPENIA,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
198,AUTOIMMUNE THROMBOCYTOPENIA causes MATERNAL THROMBOCYTOPENIA,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
199,AUTOIMMUNE THROMBOCYTOPENIA causes MATERNAL THROMBOCYTOPENIA,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
200,AUTOIMMUNE THROMBOCYTOPENIA causes MATERNAL THROMBOCYTOPENIA,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
201,no_relation,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
202,AUTOIMMUNE THROMBOCYTOPENIA causes MATERNAL THROMBOCYTOPENIA,causes,0.9878291611472622,The clinically important causes of MATERNAL THROMBOCYTOPENIA in pregnancy are gestational thrombocytopenia and AUTOIMMUNE THROMBOCYTOPENIA,MATERNAL THROMBOCYTOPENIA,AUTOIMMUNE THROMBOCYTOPENIA
203,MICROCALCIFICATIONS causes IN SITU (DCIS),causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
204,no_relation,causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
205,no_relation,causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
206,no_relation,causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
207,no_relation,causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
208,no_relation,causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
209,IN SITU (DCIS) causes MICROCALCIFICATIONS,causes,0.35921060405355,"This retrospective study correlated the mammographic manifestations and averaged nuclear grades using Holland, Van Nuys, and Lagios classifications in 37 cases of ductal carcinoma IN SITU (DCIS; microcalcifications alone were seen in 59.4%, MICROCALCIFICATIONS with associated mass in 19%, and mass alone in 21.6%.",MICROCALCIFICATIONS,IN SITU (DCIS)
210,ANEMIA treats EPOETIN ALFA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
211,ANEMIA treats EPOETIN ALFA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
212,EPOETIN ALFA treats ANEMIA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
213,EPOETIN ALFA treats ANEMIA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
214,EPOETIN ALFA treats ANEMIA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
215,EPOETIN ALFA treats ANEMIA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
216,EPOETIN ALFA treats ANEMIA,treats,0.997054485501582,"EPOETIN ALFA is, therefore, effective and safe in the management of ANEMIA in patients with breast cancer treated with chemotherapy.",ANEMIA,EPOETIN ALFA
217,no_relation,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
218,PRIMARY HEPATOCELLULAR CARCINOMA causes JAUNDICE,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
219,no_relation,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
220,PRIMARY HEPATOCELLULAR CARCINOMA causes JAUNDICE,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
221,no_relation,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
222,no_relation,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
223,no_relation,causes,0.4200840252084029,"A case of a 73 years old man with macronodular liver cirrhosis, ascites, JAUNDICE and a PRIMARY HEPATOCELLULAR CARCINOMA is presented.",JAUNDICE,PRIMARY HEPATOCELLULAR CARCINOMA
224,BONE MARROW location MYELODYSPLASTIC SYNDROME,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
225,BONE MARROW location MYELODYSPLASTIC SYNDROME,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
226,MYELODYSPLASTIC SYNDROME location BONE MARROW,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
227,no_relation,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
228,MYELODYSPLASTIC SYNDROME location BONE MARROW,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
229,BONE MARROW location MYELODYSPLASTIC SYNDROME,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
230,BONE MARROW location MYELODYSPLASTIC SYNDROME,location,0.5,Apoptosis and its dysregulation have been implicated in dysplastic and ineffective hematopoiesis and the neoplastic transformation of BONE MARROW in MYELODYSPLASTIC SYNDROME (MDS.,BONE MARROW,MYELODYSPLASTIC SYNDROME
231,FACTOR VIII (FVIII causes VON WILLEBRAND'S DISEASE,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
232,no_relation,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
233,VON WILLEBRAND'S DISEASE causes FACTOR VIII (FVIII,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
234,VON WILLEBRAND'S DISEASE causes FACTOR VIII (FVIII,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
235,no_relation,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
236,FACTOR VIII (FVIII causes VON WILLEBRAND'S DISEASE,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
237,no_relation,causes,0.416025147168922,"Patients with severe forms of VON WILLEBRAND'S DISEASE (VWD) may have frequent haemarthroses, especially when FACTOR VIII (FVIII) levels are below 10 U/dL, so that some of them develop target joints like patients with severe haemophilia A. Some patients have recurrent gastrointestinal bleeding, often without lesions in the gastrointestinal tract, and need treatment every day or every other day.",VON WILLEBRAND'S DISEASE,FACTOR VIII (FVIII
238,LIVERS location CHRONIC HEPATITIS,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
239,CHRONIC HEPATITIS location LIVERS,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
240,LIVERS location CHRONIC HEPATITIS,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
241,LIVERS location CHRONIC HEPATITIS,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
242,LIVERS location CHRONIC HEPATITIS,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
243,no_relation,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
244,LIVERS location CHRONIC HEPATITIS,location,0.9615239476408228,A variety of liver diseases including CHRONIC HEPATITIS and cirrhosis were seen in the LIVERS of a majority of the ducks from Chi tung.,LIVERS,CHRONIC HEPATITIS
245,GASTROINTESTINAL TRACT causes DIARRHEA,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
246,GASTROINTESTINAL TRACT causes DIARRHEA,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
247,GASTROINTESTINAL TRACT causes DIARRHEA,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
248,GASTROINTESTINAL TRACT causes DIARRHEA,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
249,no_relation,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
250,no_relation,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
251,no_relation,causes,0.943456353049726,"All patients had GASTROINTESTINAL TRACT symptoms, with 30 patients (91%) complaining of DIARRHEA and 23 patients (70%) complaining of vomiting; these symptoms occurred early in the disease and were of short duration.",GASTROINTESTINAL TRACT,DIARRHEA
252,no_relation,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
253,DIAGNOSIS OF ADVANCED SCOLIOSIS diagnosis SPINE,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
254,no_relation,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
255,no_relation,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
256,no_relation,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
257,no_relation,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
258,DIAGNOSIS OF ADVANCED SCOLIOSIS diagnosis SPINE,diagnosis,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
259,no_relation,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
260,no_relation,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
261,no_relation,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
262,METASTATIC MELANOMA CELL LINES causes METASTATIC LESIONS,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
263,METASTATIC MELANOMA CELL LINES causes METASTATIC LESIONS,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
264,METASTATIC MELANOMA CELL LINES causes METASTATIC LESIONS,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
265,METASTATIC MELANOMA CELL LINES causes METASTATIC LESIONS,causes,0.442325868464691,Three primary and 16 METASTATIC MELANOMA CELL LINES were established from primary and METASTATIC LESIONS of 4 patients with malignant melanoma.,METASTATIC LESIONS,METASTATIC MELANOMA CELL LINES
266,SPINE location DIAGNOSIS OF ADVANCED SCOLIOSIS,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
267,SPINE location DIAGNOSIS OF ADVANCED SCOLIOSIS,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
268,SPINE location DIAGNOSIS OF ADVANCED SCOLIOSIS,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
269,SPINE location DIAGNOSIS OF ADVANCED SCOLIOSIS,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
270,DIAGNOSIS OF ADVANCED SCOLIOSIS location SPINE,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
271,SPINE location DIAGNOSIS OF ADVANCED SCOLIOSIS,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
272,SPINE location DIAGNOSIS OF ADVANCED SCOLIOSIS,location,0.693375245281537,The standard radiological DIAGNOSIS OF ADVANCED SCOLIOSIS consists of roentgenograms of the total SPINE in anterior posterior and lateral views.,SPINE,DIAGNOSIS OF ADVANCED SCOLIOSIS
273,EPINEPHRINE treats VENTRICULAR FIBRILLATION,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
274,EPINEPHRINE treats VENTRICULAR FIBRILLATION,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
275,no_relation,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
276,VENTRICULAR FIBRILLATION treats EPINEPHRINE,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
277,no_relation,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
278,no_relation,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
279,EPINEPHRINE treats VENTRICULAR FIBRILLATION,treats,0.975900072948533,"The study demonstrated that vasopressin is similar to epinephrine for OOH CA due to VENTRICULAR FIBRILLATION or pulseless electrical activity, and superior to epinephrine for the initial treatment of asystolic arrest; it also demonstrated that the combination of vasopressin and EPINEPHRINE is superior to epinephrine alone in the treatment of refractory, out of hospital cardiac arrest.",VENTRICULAR FIBRILLATION,EPINEPHRINE
280,no_relation,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
281,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER diagnosis VITAMIN A DEFICIENCY,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
282,no_relation,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
283,no_relation,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
284,no_relation,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
285,VITAMIN A DEFICIENCY diagnosis DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
286,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER diagnosis VITAMIN A DEFICIENCY,diagnosis,0.353553390593274,The results suggest that the low serum vitamin A levels in primary biliary cirrhosis are not a consequence of VITAMIN A DEFICIENCY but instead reflect a DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER.,VITAMIN A DEFICIENCY,DEFECTIVE MOBILIZATION OF VITAMIN A FROM THE LIVER
287,no_relation,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
288,no_relation,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
289,ALPERS SYNDROME causes SPINO CEREBELLAR ATAXIA,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
290,no_relation,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
291,no_relation,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
292,SPINO CEREBELLAR ATAXIA causes ALPERS SYNDROME,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
293,no_relation,causes,0.384110639798688,"ANT1, TWINKLE and POLG genes affect mtDNA stability and are involved in autosomal dominant PEO, while mutations in POLG are responsible for numerous clinical presentations, including autosomal recessive PEO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO), SPINO CEREBELLAR ATAXIA and epilepsy (SCAE) or ALPERS SYNDROME",SPINO CEREBELLAR ATAXIA,ALPERS SYNDROME
294,TYPE 1 DIABETES treats INSULIN PEPTIDE B9 23,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
295,no_relation,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
296,INSULIN PEPTIDE B9 23 treats TYPE 1 DIABETES,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
297,INSULIN PEPTIDE B9 23 treats TYPE 1 DIABETES,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
298,INSULIN PEPTIDE B9 23 treats TYPE 1 DIABETES,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
299,no_relation,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
300,no_relation,treats,0.875,INSULIN PEPTIDE B9 23 is a major autoantigen in TYPE 1 DIABETES,TYPE 1 DIABETES,INSULIN PEPTIDE B9 23
301,ESOPHAGUS location ESOPHAGEAL CANCER,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
302,ESOPHAGUS location ESOPHAGEAL CANCER,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
303,ESOPHAGUS location ESOPHAGEAL CANCER,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
304,ESOPHAGUS location ESOPHAGEAL CANCER,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
305,ESOPHAGUS location ESOPHAGEAL CANCER,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
306,ESOPHAGEAL CANCER location ESOPHAGUS,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
307,no_relation,location,0.875113012593303,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
308,BONE causes PSEUDARTHROSIS,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
309,no_relation,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
310,no_relation,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
311,no_relation,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
312,BONE causes PSEUDARTHROSIS,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
313,no_relation,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
314,no_relation,causes,0.928587879040964,Instability of BONE fragments is regarded as the most important factor in pathogenesis of PSEUDARTHROSIS,BONE,PSEUDARTHROSIS
315,CHRONIC HEPATITIS causes LIVER BIOPSY SPECIMEN,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
316,no_relation,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
317,no_relation,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
318,CHRONIC HEPATITIS causes LIVER BIOPSY SPECIMEN,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
319,no_relation,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
320,CHRONIC HEPATITIS causes LIVER BIOPSY SPECIMEN,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
321,no_relation,causes,0.307793505625546,"In addition to the characterization of the degree of inflammation and fibrosis, the evaluation of a LIVER BIOPSY SPECIMEN from a patient with CHRONIC HEPATITIS includes a description of all of the findings present (e.g., steatosis, bile duct changes, granulomas, type of inflammatory cells, presence of iron, and Mallory hyaline) or a notation of their absence.",LIVER BIOPSY SPECIMEN,CHRONIC HEPATITIS
322,no_relation,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
323,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
324,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
325,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
326,THROMBOCYTOPENIA causes IDIOPATHIC THROMBOCYTOPENIC PURPURA,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
327,THROMBOCYTOPENIA causes IDIOPATHIC THROMBOCYTOPENIC PURPURA,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
328,IDIOPATHIC THROMBOCYTOPENIC PURPURA causes THROMBOCYTOPENIA,causes,0.802955068546966,"Acute idiopathic thrombocytopenic purpura is the most common cause of thrombocytopenia in childhood, and diagnosis of IDIOPATHIC THROMBOCYTOPENIC PURPURA is made clinically based on the exclusion of other causes of THROMBOCYTOPENIA.",THROMBOCYTOPENIA,IDIOPATHIC THROMBOCYTOPENIC PURPURA
329,HYPERTENSION causes NEPHROBLASTOMA,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
330,HYPERTENSION causes NEPHROBLASTOMA,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
331,no_relation,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
332,no_relation,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
333,NEPHROBLASTOMA causes HYPERTENSION,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
334,NEPHROBLASTOMA causes HYPERTENSION,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
335,no_relation,causes,0.6837634587578281,"NEPHROBLASTOMA must be included in the differential diagnosis of HYPERTENSION associated with increased renin concentrations, even in the absence of an abdominal mass..",HYPERTENSION,NEPHROBLASTOMA
336,INTRAEPITHELIAL LESION (HSIL) causes DYSPLASIA,causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
337,no_relation,causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
338,INTRAEPITHELIAL LESION (HSIL) causes DYSPLASIA,causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
339,DYSPLASIA causes INTRAEPITHELIAL LESION (HSIL),causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
340,no_relation,causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
341,INTRAEPITHELIAL LESION (HSIL) causes DYSPLASIA,causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
342,DYSPLASIA causes INTRAEPITHELIAL LESION (HSIL),causes,0.7947194142390258,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
343,DYSPLASIA diagnosis INTRAEPITHELIAL LESION (HSIL),diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
344,INTRAEPITHELIAL LESION (HSIL) diagnosis DYSPLASIA,diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
345,INTRAEPITHELIAL LESION (HSIL) diagnosis DYSPLASIA,diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
346,DYSPLASIA diagnosis INTRAEPITHELIAL LESION (HSIL),diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
347,DYSPLASIA diagnosis INTRAEPITHELIAL LESION (HSIL),diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
348,DYSPLASIA diagnosis INTRAEPITHELIAL LESION (HSIL),diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
349,no_relation,diagnosis,0.3973597071195129,Pap smears were reliable in screening for CIN; 75% of patients with CIN had high grade squamous INTRAEPITHELIAL LESION (HSIL) or LSIL in Pap smears taken at the time of DYSPLASIA,DYSPLASIA,INTRAEPITHELIAL LESION (HSIL)
350,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
351,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
352,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
353,no_relation,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
354,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
355,SODIUM FLUORIDE treats DENTAL CARIES,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
356,no_relation,treats,0.5656854249492379,"A sample of 1,824 schoolchildren was randomly assigned to either the SODIUM FLUORIDE dentifrice or the stannous fluoride dentifrice and examined clinically and radiographically for DENTAL CARIES initially and after one, two, and three years of dentifrice usage.",DENTAL CARIES,SODIUM FLUORIDE
357,no_relation,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
358,no_relation,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
359,no_relation,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
360,VESSELS location ISCHEMIA,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
361,VESSELS location ISCHEMIA,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
362,ISCHEMIA location VESSELS,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
363,VESSELS location ISCHEMIA,location,0.41099746826339295,Lacunes consist of small vascular lesions with a volume of between 2 and about 30 mm. These lacunar infarctions are determined by an ISCHEMIA caused by obstructive diseases of small terminal VESSELS in the deep areas of the brain.,VESSELS,ISCHEMIA
364,HEPATITIS A causes HEPATITIS A VIRUS,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
365,HEPATITIS A VIRUS causes HEPATITIS A,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
366,HEPATITIS A VIRUS causes HEPATITIS A,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
367,HEPATITIS A VIRUS causes HEPATITIS A,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
368,HEPATITIS A VIRUS causes HEPATITIS A,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
369,HEPATITIS A VIRUS causes HEPATITIS A,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
370,HEPATITIS A VIRUS causes HEPATITIS A,causes,0.9,Update: Prevention of HEPATITIS A after exposure to HEPATITIS A VIRUS and in international travelers.,HEPATITIS A VIRUS,HEPATITIS A
371,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
372,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
373,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
374,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
375,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
376,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
377,ALLERGIC REACTION causes CHRONIC ALLERGIC STATE,causes,0.9897433186107868,This results in the amplification of any subsequent ALLERGIC REACTION contributing to the CHRONIC ALLERGIC STATE,ALLERGIC REACTION,CHRONIC ALLERGIC STATE
378,no_relation,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
379,USDA TUBERCULIN treats TUBERCULOSIS,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
380,USDA TUBERCULIN treats TUBERCULOSIS,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
381,USDA TUBERCULIN treats TUBERCULOSIS,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
382,no_relation,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
383,TUBERCULOSIS treats USDA TUBERCULIN,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
384,USDA TUBERCULIN treats TUBERCULOSIS,treats,0.824163383692134,In a comparison group of 70 dogs without knwon exposure to TUBERCULOSIS two positive responses to USDA TUBERCULIN were demonstrated and none to PPD.,TUBERCULOSIS,USDA TUBERCULIN
385,no_relation,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
386,DEHYDRATION treats INCREASING TEMPERATURE AND SALT ADDITION,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
387,INCREASING TEMPERATURE AND SALT ADDITION treats DEHYDRATION,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
388,no_relation,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
389,DEHYDRATION treats INCREASING TEMPERATURE AND SALT ADDITION,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
390,no_relation,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
391,no_relation,treats,0.437594974493684,The most significant results of this study are the level of hydration of the PC headgroup and the lack of DEHYDRATION with INCREASING TEMPERATURE AND SALT ADDITION.,DEHYDRATION,INCREASING TEMPERATURE AND SALT ADDITION
392,no_relation,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
393,SEXUAL ASPHYXIATION causes AUTOEROTIC ASPHYXIA,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
394,AUTOEROTIC ASPHYXIA causes SEXUAL ASPHYXIATION,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
395,AUTOEROTIC ASPHYXIA causes SEXUAL ASPHYXIATION,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
396,no_relation,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
397,AUTOEROTIC ASPHYXIA causes SEXUAL ASPHYXIATION,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
398,SEXUAL ASPHYXIATION causes AUTOEROTIC ASPHYXIA,causes,0.625543242171224,"A case of a typical form of SEXUAL ASPHYXIATION is described, involving a young man hanging, in a context of AUTOEROTIC ASPHYXIA",AUTOEROTIC ASPHYXIA,SEXUAL ASPHYXIATION
399,PREGNANCY contraindicates WARFARIN,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
400,WARFARIN contraindicates PREGNANCY,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
401,no_relation,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
402,no_relation,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
403,PREGNANCY contraindicates WARFARIN,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
404,PREGNANCY contraindicates WARFARIN,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
405,no_relation,contraindicates,0.9284766908852592,"When patients receive long term treatment with warfarin, pregnancy should be avoided or planned, and WARFARIN should be discontinued before conception or as soon as PREGNANCY is confirmed and before 6 weeks' gestation.",PREGNANCY,WARFARIN
406,MECONIUM DOSE DEPENDENT RESPONSE causes MECONIUM ASPIRATION SYNDROME,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
407,no_relation,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
408,MECONIUM ASPIRATION SYNDROME causes MECONIUM DOSE DEPENDENT RESPONSE,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
409,MECONIUM ASPIRATION SYNDROME causes MECONIUM DOSE DEPENDENT RESPONSE,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
410,no_relation,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
411,no_relation,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
412,MECONIUM ASPIRATION SYNDROME causes MECONIUM DOSE DEPENDENT RESPONSE,causes,0.577350269189626,To better understand the mechanisms contributing to altered airway reactivity in the MECONIUM ASPIRATION SYNDROME in this study we investigated whether there could be a MECONIUM DOSE DEPENDENT RESPONSE of tracheal smooth muscle and lung tissue reactivity to histamine and acetylcholine in vitro.,MECONIUM DOSE DEPENDENT RESPONSE,MECONIUM ASPIRATION SYNDROME
413,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
414,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
415,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
416,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
417,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
418,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
419,900 MG OF IBUPROFEN treats PAIN RELATED TO OSTEOARTHROSIS,treats,0.995893206467704,Indoprofen at the daily dose of 600 mg was comparable in efficacy with 900 MG OF IBUPROFEN in the relief of PAIN RELATED TO OSTEOARTHROSIS.,PAIN RELATED TO OSTEOARTHROSIS,900 MG OF IBUPROFEN
420,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
421,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
422,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
423,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
424,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
425,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
426,JOINTS location ARTHRITIS,location,0.8660254037844392,ARTHRITIS developed in all JOINTS in which the prosthesis elongated or broke.,JOINTS,ARTHRITIS
427,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
428,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
429,no_relation,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
430,no_relation,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
431,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
432,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
433,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.6741998624632421,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
434,MILD TRANSIENT RESPIRATORY DISTRESS causes RESPIRATORY DISTRESS SYNDROME,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
435,no_relation,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
436,no_relation,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
437,MILD TRANSIENT RESPIRATORY DISTRESS causes RESPIRATORY DISTRESS SYNDROME,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
438,no_relation,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
439,no_relation,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
440,RESPIRATORY DISTRESS SYNDROME causes MILD TRANSIENT RESPIRATORY DISTRESS,causes,0.635000635000953,The association was not explained by 1) improper timing of elective Cesarean deliveries; 2) misclassification of cases of MILD TRANSIENT RESPIRATORY DISTRESS (which may be more common after Cesarean birth) as RESPIRATORY DISTRESS SYNDROME; or 3) the differences in the occurrence of pregnancy complications preceding Cesarean births compared with vaginal births.,MILD TRANSIENT RESPIRATORY DISTRESS,RESPIRATORY DISTRESS SYNDROME
441,HEPATOMA treats ASCITES FLUID,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
442,ASCITES FLUID treats HEPATOMA,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
443,no_relation,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
444,no_relation,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
445,no_relation,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
446,HEPATOMA treats ASCITES FLUID,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
447,ASCITES FLUID treats HEPATOMA,treats,0.338061701891407,"Human alpha fetoproteins were purified from umbilical cord serum and from ASCITES FLUID of a patient with HEPATOMA by affinity chromatography, and their chemical compositions and terminal sequences were compared.",ASCITES FLUID,HEPATOMA
448,IRON DEFICIENCY ANEMIA treats EPOETIN ALFA THERAPY,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
449,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
450,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
451,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
452,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
453,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
454,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.980196058819607,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
455,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
456,no_relation,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
457,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
458,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
459,no_relation,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
460,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
461,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,causes,0.8219949365267859,We also discuss a potential role for PLAC1 as a biomarker predictive of specific PREGNANCY COMPLICATIONS such as PREECLAMPSIA,PREGNANCY COMPLICATIONS,PREECLAMPSIA
462,POLYPOID LESION diagnosis GASTRO INTESTINAL POLYPS,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
463,no_relation,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
464,no_relation,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
465,GASTRO INTESTINAL POLYPS diagnosis POLYPOID LESION,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
466,GASTRO INTESTINAL POLYPS diagnosis POLYPOID LESION,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
467,GASTRO INTESTINAL POLYPS diagnosis POLYPOID LESION,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
468,GASTRO INTESTINAL POLYPS diagnosis POLYPOID LESION,diagnosis,0.38490017945975,"Although, according to T.Yamada, GASTRO INTESTINAL POLYPS are described with respect to shape and size of POLYPOID LESION only, microscopic structure of polyps manages to find its reflection to a considerable degree too: type I predominantly embraces hypertrophic folds of mucosa as well as non tumor polyps, both hyperplastic and inflammatory, while, at more advanced stages (II IV), tubular and tubulo villose adenomas and villose tumors prevail.",POLYPOID LESION,GASTRO INTESTINAL POLYPS
469,PELVIC PAIN causes ENDOMETRIOSIS,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
470,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
471,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
472,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
473,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
474,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
475,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.995893206467704,45   Aromatase inhibitors are not approved for the treatment of PELVIC PAIN caused by ENDOMETRIOSIS,PELVIC PAIN,ENDOMETRIOSIS
476,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
477,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
478,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
479,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
480,ANTHRAX causes BACILLUS ANTHRACIS,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
481,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
482,BACILLUS ANTHRACIS causes ANTHRAX,causes,0.9950371902099888,BACILLUS ANTHRACIS is a Gram positive bacillus that is the causative agent of ANTHRAX,BACILLUS ANTHRACIS,ANTHRAX
483,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
484,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
485,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
486,DEFICIT OF THE LIVER causes FRUCTOSE INTOLERANCE,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
487,FRUCTOSE INTOLERANCE causes DEFICIT OF THE LIVER,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
488,DEFICIT OF THE LIVER causes FRUCTOSE INTOLERANCE,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
489,DEFICIT OF THE LIVER causes FRUCTOSE INTOLERANCE,causes,1.0,FRUCTOSE INTOLERANCE is caused by a DEFICIT OF THE LIVER aldolase B enzyme.,DEFICIT OF THE LIVER,FRUCTOSE INTOLERANCE
490,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
491,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
492,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
493,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
494,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS causes TARDIVE DYSKINESIA,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
495,no_relation,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
496,TARDIVE DYSKINESIA causes LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,causes,0.99654575824488,TARDIVE DYSKINESIA (TD) is a common side effect of LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS.,LONG TERM MEDICATION WITH TYPICAL NEUROLEPTICS,TARDIVE DYSKINESIA
497,HYPERTENSION causes WILMS' TUMOR,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
498,WILMS' TUMOR causes HYPERTENSION,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
499,HYPERTENSION causes WILMS' TUMOR,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
500,HYPERTENSION causes WILMS' TUMOR,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
501,no_relation,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
502,no_relation,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
503,no_relation,causes,0.970494958830946,HYPERTENSION is a very frequent finding in patients presenting with WILMS' TUMOR,HYPERTENSION,WILMS' TUMOR
504,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
505,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
506,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
507,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
508,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
509,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
510,CARBAMAZEPINE treats TRIGEMINAL NEURALGIA,treats,0.98058067569092,Other trials studied chronic pain: CARBAMAZEPINE was effective in 3 of 4 trials in TRIGEMINAL NEURALGIA and lamotrigine was no more effective than placebo in 1 trial (Table.,TRIGEMINAL NEURALGIA,CARBAMAZEPINE
511,FLUCTUATING PARKINSON'S DISEASE treats LEVODOPA/DDCI,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
512,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
513,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
514,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
515,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
516,no_relation,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
517,LEVODOPA/DDCI treats FLUCTUATING PARKINSON'S DISEASE,treats,0.987878339907213,"Thus, tolcapone is a useful option in patients with FLUCTUATING PARKINSON'S DISEASE who are receiving LEVODOPA/DDCI and are not responding to, or are not candidates for, other adjunctive treatments.",FLUCTUATING PARKINSON'S DISEASE,LEVODOPA/DDCI
518,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA diagnosis POLYCYTHAEMIA VERA,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
519,no_relation,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
520,no_relation,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
521,no_relation,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
522,POLYCYTHAEMIA VERA diagnosis THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
523,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA diagnosis POLYCYTHAEMIA VERA,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
524,no_relation,diagnosis,0.3651483716701111,These endogenous erythroid colonies (EEC) are seen in the great majority of cases of POLYCYTHAEMIA VERA as well as in some cases of THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA and idiopathic myelofibrosis.,THROMBOCYTHAEMIA CHRONIC MYELOID LEUKAEMIA,POLYCYTHAEMIA VERA
525,DISSECTION OF AORTA location AORTA,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
526,DISSECTION OF AORTA location AORTA,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
527,no_relation,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
528,AORTA location DISSECTION OF AORTA,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
529,AORTA location DISSECTION OF AORTA,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
530,AORTA location DISSECTION OF AORTA,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
531,AORTA location DISSECTION OF AORTA,location,0.960768922830523,Cjest computerized tomography showed DISSECTION OF AORTA from ascending to descendig aorta and hemorrhage around ascending AORTA.,AORTA,DISSECTION OF AORTA
532,PHEOCHROMOCYTOMA treats ARTERIAL HYPERTENSION,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
533,no_relation,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
534,no_relation,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
535,PHEOCHROMOCYTOMA treats ARTERIAL HYPERTENSION,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
536,PHEOCHROMOCYTOMA treats ARTERIAL HYPERTENSION,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
537,ARTERIAL HYPERTENSION treats PHEOCHROMOCYTOMA,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
538,PHEOCHROMOCYTOMA treats ARTERIAL HYPERTENSION,treats,0.960768922830523,2]  Dimopoulos C. [Cure of ARTERIAL HYPERTENSION by excision of a PHEOCHROMOCYTOMA (2 cases.,ARTERIAL HYPERTENSION,PHEOCHROMOCYTOMA
539,INTERFERON treats MULTIPLE MYELOMA,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
540,no_relation,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
541,INTERFERON treats MULTIPLE MYELOMA,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
542,INTERFERON treats MULTIPLE MYELOMA,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
543,INTERFERON treats MULTIPLE MYELOMA,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
544,no_relation,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
545,no_relation,treats,0.625543242171224,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
546,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
547,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
548,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
549,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
550,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
551,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
552,INSULIN treats HYPERGLYCEMIA,treats,0.992277876713668,INSULIN and fluid and electrolyte therapy are initiated to control the HYPERGLYCEMIA and prevent shock and further complications.,HYPERGLYCEMIA,INSULIN
553,INTERFERON causes MULTIPLE MYELOMA,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
554,no_relation,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
555,no_relation,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
556,no_relation,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
557,no_relation,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
558,INTERFERON causes MULTIPLE MYELOMA,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
559,INTERFERON causes MULTIPLE MYELOMA,causes,0.4170288281141501,"Einhorn S, Ahre A, Blomgren H et alINTERFERON and naturl killer activity in MULTIPLE MYELOMA",MULTIPLE MYELOMA,INTERFERON
560,MIDDLE EAR location ACUTE OTITIS MEDIA,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
561,no_relation,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
562,MIDDLE EAR location ACUTE OTITIS MEDIA,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
563,no_relation,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
564,MIDDLE EAR location ACUTE OTITIS MEDIA,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
565,MIDDLE EAR location ACUTE OTITIS MEDIA,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
566,MIDDLE EAR location ACUTE OTITIS MEDIA,location,0.9761870601839532,The role of antibiotics in ACUTE OTITIS MEDIA is to eradicate the causative pathogen from the MIDDLE EAR,MIDDLE EAR,ACUTE OTITIS MEDIA
567,DIC causes APL,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
568,APL causes DIC,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
569,APL causes DIC,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
570,no_relation,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
571,no_relation,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
572,APL causes DIC,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
573,DIC causes APL,causes,0.328797974610715,"In APL with the translocation t(15;17), all  trans  retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long term survival in 65 to 70%.",DIC,APL
574,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
575,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
576,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
577,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
578,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
579,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
580,CADMIUM causes ITAI ITAI DISEASE,causes,0.970142500145332,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than CADMIUM may also be involved in the development of ITAI ITAI DISEASE.",CADMIUM,ITAI ITAI DISEASE
581,OSTEOMYELITIS diagnosis BONE,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
582,OSTEOMYELITIS diagnosis BONE,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
583,no_relation,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
584,OSTEOMYELITIS diagnosis BONE,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
585,no_relation,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
586,BONE diagnosis OSTEOMYELITIS,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
587,no_relation,diagnosis,0.549442255794756,"In a 5 1/2 year retrospective study of hospitalized children with OSTEOMYELITIS who had technetium BONE scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",BONE,OSTEOMYELITIS
588,ALBUTEROL treats ASTHMA,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
589,ASTHMA treats ALBUTEROL,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
590,ALBUTEROL treats ASTHMA,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
591,ALBUTEROL treats ASTHMA,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
592,ALBUTEROL treats ASTHMA,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
593,ALBUTEROL treats ASTHMA,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
594,ALBUTEROL treats ASTHMA,treats,0.9707253433941508,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse ASTHMA control with ALBUTEROL than when it was withdrawn.",ASTHMA,ALBUTEROL
595,OVARIAN MUCINOUS ADENOCARCINOMAS diagnosis ASCITES,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
596,no_relation,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
597,OVARIAN MUCINOUS ADENOCARCINOMAS diagnosis ASCITES,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
598,ASCITES diagnosis OVARIAN MUCINOUS ADENOCARCINOMAS,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
599,OVARIAN MUCINOUS ADENOCARCINOMAS diagnosis ASCITES,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
600,OVARIAN MUCINOUS ADENOCARCINOMAS diagnosis ASCITES,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
601,OVARIAN MUCINOUS ADENOCARCINOMAS diagnosis ASCITES,diagnosis,0.353553390593274,"On cytology it was found that cancer cells in the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, but tumor cells in ASCITES from other types of ovarian carcinomas were negative for HNF4 alpha.",ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS
602,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
603,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
604,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
605,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
606,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
607,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
608,TRIGEMINAL NEURALGIA causes PAIN,causes,0.993883734673619,Predictive model for PAIN recurrence after posterior fossa surgery for TRIGEMINAL NEURALGIA,PAIN,TRIGEMINAL NEURALGIA
609,no_relation,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
610,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
611,INDUCED NAUSEA AND VOMITING treats ANTIEMETICS,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
612,no_relation,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
613,INDUCED NAUSEA AND VOMITING treats ANTIEMETICS,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
614,no_relation,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
615,ANTIEMETICS treats INDUCED NAUSEA AND VOMITING,treats,0.753778361444409,51   The identification of neurotransmitter pathways involved in chemotherapy INDUCED NAUSEA AND VOMITING led to development of potent ANTIEMETICS such as the serotonin antagonists ondansetron and granisetron.,INDUCED NAUSEA AND VOMITING,ANTIEMETICS
616,no_relation,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
617,HYPEROSMOLAR NONKETOTIC COMA causes DIABETIC KETOACIDOSIS,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
618,no_relation,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
619,no_relation,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
620,DIABETIC KETOACIDOSIS causes HYPEROSMOLAR NONKETOTIC COMA,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
621,DIABETIC KETOACIDOSIS causes HYPEROSMOLAR NONKETOTIC COMA,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
622,no_relation,causes,0.3779644730092271,"Both DIABETIC KETOACIDOSIS (DKA) and hyperglycemic, HYPEROSMOLAR NONKETOTIC COMA (HHNC) are stressful metabolic occurrences brought about by the orchestration of numerous events.",HYPEROSMOLAR NONKETOTIC COMA,DIABETIC KETOACIDOSIS
623,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
624,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
625,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
626,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
627,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
628,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
629,MELPHALAN treats MULTIPLE MYELOMA,treats,0.970494958830946,"Combination chemotherapy versus MELPHALAN plus prednisone as treatment for MULTIPLE MYELOMA: an overview of 6,633 patients from 27 randomized trials.",MULTIPLE MYELOMA,MELPHALAN
630,PANIC DISORDER causes PANIC ATTACKS,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
631,no_relation,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
632,PANIC DISORDER causes PANIC ATTACKS,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
633,PANIC DISORDER causes PANIC ATTACKS,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
634,PANIC DISORDER causes PANIC ATTACKS,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
635,PANIC DISORDER causes PANIC ATTACKS,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
636,PANIC DISORDER causes PANIC ATTACKS,causes,0.738548945875996,"Hyperventilation syndrome is separate from panic disorder (see  PANIC ATTACKS and Panic Disorder ), although the 2 conditions overlap; about  1 / 2  of patients with PANIC DISORDER have hyperventilation syndrome and  1 / 4  of patients with hyperventilation syndrome have panic disorder.",PANIC ATTACKS,PANIC DISORDER
637,no_relation,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
638,no_relation,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
639,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA causes COMPLICATION OF PREGNANCY,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
640,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA causes COMPLICATION OF PREGNANCY,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
641,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA causes COMPLICATION OF PREGNANCY,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
642,COMPLICATION OF PREGNANCY causes PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
643,no_relation,causes,0.875189948987367,Late postpartum eclampsia without the classical PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA and hypertension is a rarely noticed COMPLICATION OF PREGNANCY,COMPLICATION OF PREGNANCY,PRE ECLAMPTIC SIGNS OEDEMA PROTEINURIA
644,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
645,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
646,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
647,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
648,no_relation,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
649,TACHYCARDIA causes SUSTAINED VENTRICULAR TACHYCARDIA,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
650,no_relation,causes,0.4472135954999579,"To determine if termination of hemodynamically tolerated, sustained ventricular tachycardia during intravenous infusion of procainamide predicts the success of procainamide therapy in preventing induction of TACHYCARDIA 15 patients with inducible, SUSTAINED VENTRICULAR TACHYCARDIA in the setting of chronic coronary artery disease were studied.",TACHYCARDIA,SUSTAINED VENTRICULAR TACHYCARDIA
651,no_relation,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
652,no_relation,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
653,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS location OSTEOPOROSIS,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
654,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS location OSTEOPOROSIS,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
655,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS location OSTEOPOROSIS,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
656,no_relation,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
657,CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS location OSTEOPOROSIS,location,0.353553390593274,"The alterations found in bone matrix CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS suggest that in OSTEOPOROSIS and fractures, not only bone mass changes, but also bone quality changes play a role in bone strength.",CONSTITUENTS IN OSTEOPOROTIC BONE RELATIVE TO CONTROLS,OSTEOPOROSIS
658,no_relation,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
659,no_relation,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
660,BRAIN causes EPILEPSY,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
661,no_relation,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
662,BRAIN causes EPILEPSY,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
663,no_relation,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
664,no_relation,causes,0.7947194142390258,"In the present study, the influence of organic alterations in the BRAIN on the age of manifestation of EPILEPSY was investigated by means of cranial computer tomography (CCT) in 307 children and adolescents.",BRAIN,EPILEPSY
665,no_relation,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
666,PERIPHERAL NERVES location PERIPHERAL NEUROPATHIES,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
667,PERIPHERAL NERVES location PERIPHERAL NEUROPATHIES,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
668,PERIPHERAL NERVES location PERIPHERAL NEUROPATHIES,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
669,no_relation,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
670,PERIPHERAL NERVES location PERIPHERAL NEUROPATHIES,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
671,PERIPHERAL NEUROPATHIES location PERIPHERAL NERVES,location,0.919145030018058,"PERIPHERAL NERVES show spontaneous regenerative responses, but recovery after injury or PERIPHERAL NEUROPATHIES (toxic, diabetic, or chronic inflammatory demyelinating polyneuropathy syndromes) is slow and often incomplete, and at present no efficient treatment is available.",PERIPHERAL NERVES,PERIPHERAL NEUROPATHIES
672,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
673,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
674,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
675,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
676,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
677,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
678,SUPPLEMENTARY FLUORIDE treats CARIES PROPHYLACTIC PURPOSE,treats,0.9950371902099888,The results show that high F groundwater is prevalent and emphasize that information on domestic water supply must be available before SUPPLEMENTARY FLUORIDE is prescribed for CARIES PROPHYLACTIC PURPOSE.,CARIES PROPHYLACTIC PURPOSE,SUPPLEMENTARY FLUORIDE
679,no_relation,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
680,no_relation,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
681,no_relation,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
682,CARIES causes FETAL FLUORIDE,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
683,no_relation,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
684,no_relation,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
685,no_relation,causes,0.34412360080584303,"No CARIES protective effect of the FETAL FLUORIDE however, has been substantiated by pertinent research.",CARIES,FETAL FLUORIDE
686,no_relation,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
687,LIVE POLIOVIRUS VACCINE causes PARALYTIC POLIOMYELITIS,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
688,no_relation,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
689,LIVE POLIOVIRUS VACCINE causes PARALYTIC POLIOMYELITIS,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
690,LIVE POLIOVIRUS VACCINE causes PARALYTIC POLIOMYELITIS,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
691,no_relation,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
692,LIVE POLIOVIRUS VACCINE causes PARALYTIC POLIOMYELITIS,causes,0.703526470681448,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of PARALYTIC POLIOMYELITIS associated with use of LIVE POLIOVIRUS VACCINE,PARALYTIC POLIOMYELITIS,LIVE POLIOVIRUS VACCINE
693,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
694,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
695,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
696,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
697,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
698,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
699,CITRATE treats RENAL STONE DISEASE,treats,0.9722718241315028,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of CITRATE has been suggested to be clinically useful in the management of RENAL STONE DISEASE.",RENAL STONE DISEASE,CITRATE
700,PHAEOCHROMOCYTOMA causes FEVER,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
701,PHAEOCHROMOCYTOMA causes FEVER,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
702,FEVER causes PHAEOCHROMOCYTOMA,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
703,no_relation,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
704,PHAEOCHROMOCYTOMA causes FEVER,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
705,PHAEOCHROMOCYTOMA causes FEVER,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
706,PHAEOCHROMOCYTOMA causes FEVER,causes,0.913811548620257,FEVER was secondary to a PHAEOCHROMOCYTOMA in one patient and sepsis in the other.,FEVER,PHAEOCHROMOCYTOMA
707,no_relation,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
708,BONE METASTASES location METASTATIC LESION OF THE SKULL,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
709,METASTATIC LESION OF THE SKULL location BONE METASTASES,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
710,BONE METASTASES location METASTATIC LESION OF THE SKULL,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
711,METASTATIC LESION OF THE SKULL location BONE METASTASES,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
712,METASTATIC LESION OF THE SKULL location BONE METASTASES,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
713,BONE METASTASES location METASTATIC LESION OF THE SKULL,location,0.42426406871192895,In the case of multiple BONE METASTASES the METASTATIC LESION OF THE SKULL was clearly demonstrated by Tl 201 but not by Ga 67.,METASTATIC LESION OF THE SKULL,BONE METASTASES
714,FALLOPIAN TUBES location FALLOPIAN TUBE INFECTION,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
715,FALLOPIAN TUBE INFECTION location FALLOPIAN TUBES,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
716,FALLOPIAN TUBE INFECTION location FALLOPIAN TUBES,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
717,FALLOPIAN TUBES location FALLOPIAN TUBE INFECTION,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
718,no_relation,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
719,FALLOPIAN TUBES location FALLOPIAN TUBE INFECTION,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
720,FALLOPIAN TUBES location FALLOPIAN TUBE INFECTION,location,0.975900072948533,The parasitic FALLOPIAN TUBE INFECTION may have predisposed the FALLOPIAN TUBES to a microbial tuboovarian abscess.,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION
721,PRIMARY MELANOMA location CUTANEOUS MELANOMA,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
722,no_relation,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
723,no_relation,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
724,CUTANEOUS MELANOMA location PRIMARY MELANOMA,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
725,no_relation,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
726,no_relation,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
727,no_relation,location,0.328797974610715,Depending on the Breslow depth of the PRIMARY MELANOMA sentinel lymph node biopsy is considered as standard of care for the staging of CUTANEOUS MELANOMA and is one of the most important prognostic factors.,PRIMARY MELANOMA,CUTANEOUS MELANOMA
728,THE BASAL JOINT OF THE THUMB location ARTHRITIS,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
729,THE BASAL JOINT OF THE THUMB location ARTHRITIS,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
730,THE BASAL JOINT OF THE THUMB location ARTHRITIS,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
731,ARTHRITIS location THE BASAL JOINT OF THE THUMB,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
732,THE BASAL JOINT OF THE THUMB location ARTHRITIS,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
733,THE BASAL JOINT OF THE THUMB location ARTHRITIS,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
734,THE BASAL JOINT OF THE THUMB location ARTHRITIS,location,0.985329278164293,The senior author has performed the Swanson implant arthroplasty for ARTHRITIS of THE BASAL JOINT OF THE THUMB for the past 12 years.,THE BASAL JOINT OF THE THUMB,ARTHRITIS
735,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
736,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
737,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
738,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
739,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
740,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
741,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
742,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
743,HYPERTENSION diagnosis PHEOCHROMOCYTOMA,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
744,HYPERTENSION diagnosis PHEOCHROMOCYTOMA,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
745,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
746,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
747,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
748,PHEOCHROMOCYTOMA diagnosis HYPERTENSION,diagnosis,0.6741998624632421,C]  4.1 Consider consulting an endocrinologist or specialist in HYPERTENSION to assist in confirming or excluding the diagnosis of PHEOCHROMOCYTOMA,HYPERTENSION,PHEOCHROMOCYTOMA
749,SPINE location SCOLIOSIS,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
750,SPINE location SCOLIOSIS,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
751,SPINE location SCOLIOSIS,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
752,no_relation,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
753,SPINE location SCOLIOSIS,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
754,SPINE location SCOLIOSIS,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
755,SPINE location SCOLIOSIS,location,0.848874687627165,"Hence, when analysing the biomechanics of the growing adolescent SPINE (for instance in SCOLIOSIS research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",SPINE,SCOLIOSIS
756,HAEMOPHAGOCYTOSIS causes HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
757,no_relation,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
758,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS causes HAEMOPHAGOCYTOSIS,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
759,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS causes HAEMOPHAGOCYTOSIS,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
760,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS causes HAEMOPHAGOCYTOSIS,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
761,HAEMOPHAGOCYTOSIS causes HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
762,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS causes HAEMOPHAGOCYTOSIS,causes,0.4472135954999579,Post mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such HAEMOPHAGOCYTOSIS could be a very prominent post mortem feature in H5N1 infection.,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
763,DEXTROSE contraindicates HYPOGLYCEMIA,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
764,DEXTROSE contraindicates HYPOGLYCEMIA,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
765,no_relation,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
766,no_relation,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
767,HYPOGLYCEMIA contraindicates DEXTROSE,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
768,HYPOGLYCEMIA contraindicates DEXTROSE,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
769,no_relation,contraindicates,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
770,no_relation,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
771,SKIN location BENIGN MUCOUS MEMBRANE PEMPHIGOID,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
772,SKIN location BENIGN MUCOUS MEMBRANE PEMPHIGOID,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
773,SKIN location BENIGN MUCOUS MEMBRANE PEMPHIGOID,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
774,SKIN location BENIGN MUCOUS MEMBRANE PEMPHIGOID,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
775,SKIN location BENIGN MUCOUS MEMBRANE PEMPHIGOID,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
776,SKIN location BENIGN MUCOUS MEMBRANE PEMPHIGOID,location,0.9878291611472622,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) is characterized by immunoglobulin deposits along the basal zone of the SKIN and mucous membranes, leading to blistering erosions of the involved regions.",SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID
777,CAFFEINE treats APNOEA,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
778,CAFFEINE treats APNOEA,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
779,no_relation,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
780,CAFFEINE treats APNOEA,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
781,APNOEA treats CAFFEINE,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
782,CAFFEINE treats APNOEA,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
783,CAFFEINE treats APNOEA,treats,0.9578262852211508,Episodes of prolonged APNOEA disappeared in all infants after administration of CAFFEINE and in 11 infants all pneumogram abnormalities resolved.,APNOEA,CAFFEINE
784,DIABETES diagnosis ISLET CELLS,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
785,DIABETES diagnosis ISLET CELLS,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
786,DIABETES diagnosis ISLET CELLS,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
787,no_relation,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
788,ISLET CELLS diagnosis DIABETES,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
789,DIABETES diagnosis ISLET CELLS,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
790,DIABETES diagnosis ISLET CELLS,diagnosis,0.7715167498104591,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of ISLET CELLS to D glucose in this experimental model of DIABETES may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",ISLET CELLS,DIABETES
791,ISLET CELLS location ISLET CELL TUMORS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
792,ISLET CELLS location ISLET CELL TUMORS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
793,ISLET CELLS location ISLET CELL TUMORS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
794,ISLET CELL TUMORS location ISLET CELLS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
795,ISLET CELL TUMORS location ISLET CELLS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
796,ISLET CELLS location ISLET CELL TUMORS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
797,ISLET CELL TUMORS location ISLET CELLS,location,0.964901281354015,"Neuron specific enolase was localized in nerve fibers, normal ISLET CELLS and islet cell tumors; its concentration was elevated only in the tissue of ISLET CELL TUMORS and in serum from patients with insulinoma.",ISLET CELLS,ISLET CELL TUMORS
798,no_relation,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
799,WALDENSTROM'S MACROGLOBULINEMIA causes HYPERVISCOSITY,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
800,WALDENSTROM'S MACROGLOBULINEMIA causes HYPERVISCOSITY,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
801,HYPERVISCOSITY causes WALDENSTROM'S MACROGLOBULINEMIA,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
802,no_relation,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
803,no_relation,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
804,WALDENSTROM'S MACROGLOBULINEMIA causes HYPERVISCOSITY,causes,0.788263422531435,"However, the HYPERVISCOSITY in WALDENSTROM'S MACROGLOBULINEMIA is an ideal representative of a venous stasis that is without associated vascular pathology.",HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA
805,no_relation,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
806,LIVER causes LIVER FAILURE,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
807,no_relation,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
808,no_relation,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
809,no_relation,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
810,LIVER causes LIVER FAILURE,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
811,no_relation,causes,0.312771621085612,"Protoporphyrins sometimes accumulate to toxic levels in the LIVER causing LIVER FAILURE; if this occurs, a liver transplant becomes necessary.",LIVER,LIVER FAILURE
812,PITUITARY ADENOMAS causes TUBERCULOUS INVOLVEMENT OF PITUITARY,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
813,TUBERCULOUS INVOLVEMENT OF PITUITARY causes PITUITARY ADENOMAS,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
814,PITUITARY ADENOMAS causes TUBERCULOUS INVOLVEMENT OF PITUITARY,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
815,no_relation,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
816,PITUITARY ADENOMAS causes TUBERCULOUS INVOLVEMENT OF PITUITARY,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
817,no_relation,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
818,no_relation,causes,0.34815531191139604,TUBERCULOUS INVOLVEMENT OF PITUITARY is extremely rare and is usually not suspected while dealing with PITUITARY ADENOMAS even in patients with history of systemic tuberculosis.,TUBERCULOUS INVOLVEMENT OF PITUITARY,PITUITARY ADENOMAS
819,PRIMARY HEADACHE CONDITIONS causes CLUSTER HEADACHE,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
820,no_relation,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
821,no_relation,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
822,CLUSTER HEADACHE causes PRIMARY HEADACHE CONDITIONS,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
823,CLUSTER HEADACHE causes PRIMARY HEADACHE CONDITIONS,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
824,no_relation,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
825,no_relation,causes,0.337526370277807,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
826,MPS II causes WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
827,MPS II causes WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
828,no_relation,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
829,no_relation,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
830,MPS II causes WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
831,no_relation,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
832,no_relation,causes,0.3779644730092271,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
833,EPILEPSY causes SEIZURES,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
834,no_relation,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
835,SEIZURES causes EPILEPSY,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
836,EPILEPSY causes SEIZURES,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
837,EPILEPSY causes SEIZURES,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
838,EPILEPSY causes SEIZURES,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
839,SEIZURES causes EPILEPSY,causes,0.520755643923296,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
840,CHRONIC NEUROGENIC BLADDERS treats PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
841,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
842,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
843,CHRONIC NEUROGENIC BLADDERS treats PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
844,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
845,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
846,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE treats CHRONIC NEUROGENIC BLADDERS,treats,0.304997140665209,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
847,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
848,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
849,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
850,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
851,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
852,EXTRACTION OF BOTH LENSES treats SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
853,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS treats EXTRACTION OF BOTH LENSES,treats,0.650944554904119,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
854,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
855,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
856,PAPAVERINE diagnosis ERECTILE DYSFUNCTION,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
857,no_relation,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
858,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
859,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
860,ERECTILE DYSFUNCTION diagnosis PAPAVERINE,diagnosis,0.43643578047198495,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
861,SKIN location ACUTE CONTACT DERMATITIS,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
862,SKIN location ACUTE CONTACT DERMATITIS,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
863,no_relation,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
864,SKIN location ACUTE CONTACT DERMATITIS,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
865,no_relation,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
866,SKIN location ACUTE CONTACT DERMATITIS,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
867,SKIN location ACUTE CONTACT DERMATITIS,location,0.855186110494136,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
868,no_relation,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
869,LYME DISEASE diagnosis BORRELIA BURGDORFERI,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
870,no_relation,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
871,no_relation,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
872,no_relation,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
873,LYME DISEASE diagnosis BORRELIA BURGDORFERI,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
874,LYME DISEASE diagnosis BORRELIA BURGDORFERI,diagnosis,0.557086014531156,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
875,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
876,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
877,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
878,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
879,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
880,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
881,no_relation,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
882,GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS causes CYCLOSPORINE,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
883,no_relation,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
884,no_relation,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
885,no_relation,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
886,no_relation,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
887,no_relation,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
888,CYCLOSPORINE causes GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,causes,0.371390676354104,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
889,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
890,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
891,OVERT CONGESTIVE HEART FAILURE treats FUROSEMIDE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
892,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
893,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
894,OVERT CONGESTIVE HEART FAILURE treats FUROSEMIDE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
895,FUROSEMIDE treats OVERT CONGESTIVE HEART FAILURE,treats,0.986393923832143,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
896,MPS II diagnosis WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
897,no_relation,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
898,MPS II diagnosis WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
899,WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis MPS II,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
900,WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis MPS II,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
901,no_relation,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
902,WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis MPS II,diagnosis,0.881917103688197,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
903,OSTEOID OSTEOMA diagnosis PAIN,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
904,no_relation,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
905,no_relation,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
906,OSTEOID OSTEOMA diagnosis PAIN,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
907,OSTEOID OSTEOMA diagnosis PAIN,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
908,PAIN diagnosis OSTEOID OSTEOMA,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
909,OSTEOID OSTEOMA diagnosis PAIN,diagnosis,0.474712663277541,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
910,no_relation,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
911,no_relation,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
912,LICHENOID ERUPTION diagnosis SKIN,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
913,SKIN diagnosis LICHENOID ERUPTION,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
914,SKIN diagnosis LICHENOID ERUPTION,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
915,no_relation,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
916,no_relation,diagnosis,0.5488212999484521,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
917,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
918,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
919,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
920,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
921,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
922,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
923,HYDROCORTISONE treats INFLAMMATION,treats,0.9838699100999068,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
924,no_relation,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
925,no_relation,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
926,no_relation,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
927,no_relation,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
928,no_relation,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
929,no_relation,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
930,AGENTS (ATROPINE diagnosis ARREST ARRHYTHMIA,diagnosis,0.338061701891407,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
931,no_relation,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
932,OSTEOID OSTEOMAS causes NOCTURNAL PAIN WHICH IS EXQUISITELY,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
933,OSTEOID OSTEOMAS causes NOCTURNAL PAIN WHICH IS EXQUISITELY,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
934,OSTEOID OSTEOMAS causes NOCTURNAL PAIN WHICH IS EXQUISITELY,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
935,OSTEOID OSTEOMAS causes NOCTURNAL PAIN WHICH IS EXQUISITELY,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
936,OSTEOID OSTEOMAS causes NOCTURNAL PAIN WHICH IS EXQUISITELY,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
937,OSTEOID OSTEOMAS causes NOCTURNAL PAIN WHICH IS EXQUISITELY,causes,0.979957887012223,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
938,no_relation,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
939,APL causes INTRAVASCULAR COAGULATION (DIC,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
940,INTRAVASCULAR COAGULATION (DIC causes APL,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
941,INTRAVASCULAR COAGULATION (DIC causes APL,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
942,APL causes INTRAVASCULAR COAGULATION (DIC,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
943,no_relation,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
944,no_relation,causes,0.468521285665818,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
945,SYPHILIS treats ERYTHROMYCIN,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
946,no_relation,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
947,ERYTHROMYCIN treats SYPHILIS,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
948,ERYTHROMYCIN treats SYPHILIS,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
949,ERYTHROMYCIN treats SYPHILIS,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
950,no_relation,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
951,no_relation,treats,0.963086824686154,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN
952,BCL 2 GENE location FOLLICULAR LYMPHOMAS,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
953,FOLLICULAR LYMPHOMAS location BCL 2 GENE,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
954,FOLLICULAR LYMPHOMAS location BCL 2 GENE,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
955,no_relation,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
956,BCL 2 GENE location FOLLICULAR LYMPHOMAS,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
957,BCL 2 GENE location FOLLICULAR LYMPHOMAS,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
958,FOLLICULAR LYMPHOMAS location BCL 2 GENE,location,0.617213399848368,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE
959,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
960,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
961,COMPLICATIONS OF PREGNANCY causes PREECLAMPSIA,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
962,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
963,no_relation,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
964,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
965,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,causes,0.722315118514615,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA
966,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
967,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
968,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
969,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
970,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
971,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
972,QUININE SULPHATE treats MUSCLE CRAMPS,treats,0.9918365981341758,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE
973,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
974,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
975,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
976,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
977,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
978,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
979,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA treats COLESTIPOL,treats,0.995893206467704,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL
980,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
981,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
982,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
983,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
984,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
985,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
986,ERYTHROMYCIN treats PERTUSSIS,treats,0.987878339907213,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN
987,BRAIN location STROKE,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
988,BRAIN location STROKE,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
989,BRAIN location STROKE,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
990,BRAIN location STROKE,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
991,BRAIN location STROKE,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
992,BRAIN location STROKE,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
993,STROKE location BRAIN,location,0.963086824686154,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE
994,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
995,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
996,ASTHMA treats MONTELUKAST,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
997,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
998,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
999,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
1000,MONTELUKAST treats ASTHMA,treats,0.9539980920057242,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST
1001,FLUORIDE treats CARIES,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1002,no_relation,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1003,no_relation,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1004,FLUORIDE treats CARIES,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1005,FLUORIDE treats CARIES,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1006,no_relation,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1007,no_relation,treats,0.9761870601839532,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE
1008,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1009,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1010,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1011,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1012,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1013,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1014,MYASTHENIA GRAVIS diagnosis NEOSTIGMINE,diagnosis,0.997054485501582,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE
1015,EXTRASKELETAL OSTEOCHONDROMA diagnosis CALCIUM DEPOSITS,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1016,EXTRASKELETAL OSTEOCHONDROMA diagnosis CALCIUM DEPOSITS,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1017,EXTRASKELETAL OSTEOCHONDROMA diagnosis CALCIUM DEPOSITS,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1018,CALCIUM DEPOSITS diagnosis EXTRASKELETAL OSTEOCHONDROMA,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1019,EXTRASKELETAL OSTEOCHONDROMA diagnosis CALCIUM DEPOSITS,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1020,EXTRASKELETAL OSTEOCHONDROMA diagnosis CALCIUM DEPOSITS,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1021,EXTRASKELETAL OSTEOCHONDROMA diagnosis CALCIUM DEPOSITS,diagnosis,0.617213399848368,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA
1022,HEPATOMA causes ASCITES,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1023,no_relation,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1024,ASCITES causes HEPATOMA,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1025,no_relation,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1026,ASCITES causes HEPATOMA,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1027,no_relation,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1028,ASCITES causes HEPATOMA,causes,0.4200840252084029,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA
1029,MOTION SICKNESS treats SCOPOLAMINE,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1030,no_relation,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1031,SCOPOLAMINE treats MOTION SICKNESS,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1032,SCOPOLAMINE treats MOTION SICKNESS,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1033,SCOPOLAMINE treats MOTION SICKNESS,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1034,SCOPOLAMINE treats MOTION SICKNESS,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1035,SCOPOLAMINE treats MOTION SICKNESS,treats,0.8660254037844392,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE
1036,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1037,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1038,UNSTABLE ANGINA treats LOW MOLECULAR WEIGHT HEPARIN,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1039,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1040,UNSTABLE ANGINA treats LOW MOLECULAR WEIGHT HEPARIN,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1041,UNSTABLE ANGINA treats LOW MOLECULAR WEIGHT HEPARIN,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1042,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,treats,0.9761870601839532,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN
1043,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1044,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1045,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1046,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1047,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1048,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1049,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,causes,0.938314863256836,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES
1050,no_relation,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1051,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1052,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1053,no_relation,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1054,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1055,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1056,VARICELLA ZOSTER VIRUS INFECTION causes VARICELLA ZOSTER VIRUS,causes,0.7715167498104591,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1057,PAROXETINE treats MAJOR DEPRESSION,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1058,PAROXETINE treats MAJOR DEPRESSION,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1059,PAROXETINE treats MAJOR DEPRESSION,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1060,PAROXETINE treats MAJOR DEPRESSION,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1061,PAROXETINE treats MAJOR DEPRESSION,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1062,no_relation,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1063,PAROXETINE treats MAJOR DEPRESSION,treats,0.997054485501582,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE
1064,BONE location OSTEOPOROSIS,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1065,OSTEOPOROSIS location BONE,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1066,OSTEOPOROSIS location BONE,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1067,BONE location OSTEOPOROSIS,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1068,BONE location OSTEOPOROSIS,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1069,BONE location OSTEOPOROSIS,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1070,BONE location OSTEOPOROSIS,location,0.9438798074485388,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS
1071,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1072,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1073,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1074,no_relation,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1075,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1076,HIGH GRADE CERVICAL DYSPLASIA causes LSIL,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1077,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,causes,0.721687836487032,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL
1078,RENAL LYMPHOMA causes PRIMARY LESION,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1079,RENAL LYMPHOMA causes PRIMARY LESION,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1080,RENAL LYMPHOMA causes PRIMARY LESION,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1081,RENAL LYMPHOMA causes PRIMARY LESION,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1082,no_relation,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1083,no_relation,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1084,RENAL LYMPHOMA causes PRIMARY LESION,causes,0.522232967867094,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA
1085,VARICELLA ZOSTER VIRUS diagnosis VARICELLA ZOSTER VIRUS INFECTION,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1086,VARICELLA ZOSTER VIRUS INFECTION diagnosis VARICELLA ZOSTER VIRUS,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1087,VARICELLA ZOSTER VIRUS diagnosis VARICELLA ZOSTER VIRUS INFECTION,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1088,VARICELLA ZOSTER VIRUS INFECTION diagnosis VARICELLA ZOSTER VIRUS,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1089,VARICELLA ZOSTER VIRUS INFECTION diagnosis VARICELLA ZOSTER VIRUS,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1090,VARICELLA ZOSTER VIRUS diagnosis VARICELLA ZOSTER VIRUS INFECTION,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1091,no_relation,diagnosis,0.617213399848368,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION
1092,no_relation,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1093,HEPATOMA causes ASCITES,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1094,ASCITES causes HEPATOMA,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1095,ASCITES causes HEPATOMA,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1096,HEPATOMA causes ASCITES,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1097,ASCITES causes HEPATOMA,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1098,HEPATOMA causes ASCITES,causes,0.312347523777212,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA
1099,SKIN location INTRADERMAL NEVUS,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1100,SKIN location INTRADERMAL NEVUS,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1101,SKIN location INTRADERMAL NEVUS,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1102,SKIN location INTRADERMAL NEVUS,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1103,INTRADERMAL NEVUS location SKIN,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1104,INTRADERMAL NEVUS location SKIN,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1105,INTRADERMAL NEVUS location SKIN,location,0.5669467095138411,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS
1106,no_relation,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1107,BCL 2 GENE location FOLLICULAR LYMPHOMA,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1108,BCL 2 GENE location FOLLICULAR LYMPHOMA,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1109,no_relation,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1110,BCL 2 GENE location FOLLICULAR LYMPHOMA,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1111,no_relation,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1112,BCL 2 GENE location FOLLICULAR LYMPHOMA,location,0.42426406871192895,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE
1113,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL LUNG CANCER (SCLC),causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1114,SMALL CELL LUNG CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1115,no_relation,causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1116,no_relation,causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1117,no_relation,causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1118,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL LUNG CANCER (SCLC),causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1119,SMALL CELL LUNG CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,causes,0.9615239476408228,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC)
1120,GANCICLOVIR treats CMV INFECTION,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1121,GANCICLOVIR treats CMV INFECTION,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1122,no_relation,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1123,GANCICLOVIR treats CMV INFECTION,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1124,GANCICLOVIR treats CMV INFECTION,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1125,CMV INFECTION treats GANCICLOVIR,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1126,GANCICLOVIR treats CMV INFECTION,treats,0.995893206467704,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR
1127,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1128,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1129,TUBERCULIN diagnosis TUBERCULOSIS,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1130,TUBERCULIN diagnosis TUBERCULOSIS,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1131,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1132,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1133,TUBERCULOSIS diagnosis TUBERCULIN,diagnosis,0.927172649945531,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN
1134,STATUS EPILEPTICUS diagnosis DIAZEPAM,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1135,no_relation,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1136,no_relation,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1137,no_relation,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1138,STATUS EPILEPTICUS diagnosis DIAZEPAM,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1139,no_relation,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1140,no_relation,diagnosis,0.351123441588392,The effect of nimodipine alone and in combination with DIAZEPAM or phenytoin was tested in the electroshock induced mouse model of STATUS EPILEPTICUS,STATUS EPILEPTICUS,DIAZEPAM
1141,SKIN location PETECHIAE,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1142,SKIN location PETECHIAE,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1143,SKIN location PETECHIAE,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1144,PETECHIAE location SKIN,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1145,no_relation,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1146,SKIN location PETECHIAE,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1147,PETECHIAE location SKIN,location,0.5962847939999439,"Note medications that can induce cytopenias Physical exam  Oral exam  Look for mucosal ulceration Physical exam  Eye exam  Look for presence of vascularization of the conjunctivae Physical exam  Cardiac exam  Look for presence of murmurs or tachycardia Physical exam  Abdominal exam  Look for the presence of organomegaly Physical exam  SKIN exam  Look for ecchymosis and PETECHIAE   Differential Diagnosis of Myelodysplastic Syndrome  Normal;           Differential Diagnosis of Myelodysplastic Syndrome Disease  Characteristics  Notes Vitamin B12 deficiency  Macrocytic anemia with megaloblastic bone marrow abnormalities  Usually pernicious anemia, patients with a history of gastrectomy, or diseases that affect the terminal ileum.",SKIN,PETECHIAE
1148,JOINTS location RHEUMATOID ARTHRITIS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1149,JOINTS location RHEUMATOID ARTHRITIS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1150,JOINTS location RHEUMATOID ARTHRITIS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1151,JOINTS location RHEUMATOID ARTHRITIS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1152,JOINTS location RHEUMATOID ARTHRITIS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1153,RHEUMATOID ARTHRITIS location JOINTS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1154,JOINTS location RHEUMATOID ARTHRITIS,location,0.948683298050514,Intra articular application of Placenta in the arthritis JOINTS of patients with RHEUMATOID ARTHRITIS results in a significant improvement as compared with placebo.,JOINTS,RHEUMATOID ARTHRITIS
1155,IRON treats IRON DEFICIENCY ANEMIA,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1156,no_relation,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1157,IRON treats IRON DEFICIENCY ANEMIA,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1158,IRON treats IRON DEFICIENCY ANEMIA,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1159,IRON treats IRON DEFICIENCY ANEMIA,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1160,IRON treats IRON DEFICIENCY ANEMIA,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1161,IRON treats IRON DEFICIENCY ANEMIA,treats,0.848874687627165,"? Adherence to a gluten free diet in patients with celiac disease can lead to the correction of IRON DEFICIENCY ANEMIA and the replacement of iron stores, and it can prevent the recurrence of IRON deficiency.",IRON DEFICIENCY ANEMIA,IRON
1162,HEPATOMA causes ASCITES,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1163,HEPATOMA causes ASCITES,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1164,no_relation,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1165,HEPATOMA causes ASCITES,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1166,ASCITES causes HEPATOMA,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1167,no_relation,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1168,no_relation,causes,0.787838597158335,Two early postoperative complications were noticed: transient ASCITES and pancreatic pseudocyst and a late development of a hepatic nodule (probably HEPATOMA,ASCITES,HEPATOMA
1169,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1170,no_relation,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1171,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1172,no_relation,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1173,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1174,no_relation,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1175,no_relation,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
1176,PROPRANOLOL treats ANGINA PECTORIS,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1177,PROPRANOLOL treats ANGINA PECTORIS,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1178,no_relation,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1179,PROPRANOLOL treats ANGINA PECTORIS,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1180,no_relation,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1181,PROPRANOLOL treats ANGINA PECTORIS,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1182,PROPRANOLOL treats ANGINA PECTORIS,treats,1.0,3 These results indicate that oxyfedrine is a safe and well tolerated drug with an efficacy comparable with that of PROPRANOLOL in the treatment of patients with ANGINA PECTORIS,ANGINA PECTORIS,PROPRANOLOL
1183,PREGNANCY contraindicates WARFARIN,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1184,WARFARIN contraindicates PREGNANCY,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1185,PREGNANCY contraindicates WARFARIN,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1186,PREGNANCY contraindicates WARFARIN,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1187,no_relation,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1188,no_relation,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1189,no_relation,contraindicates,0.3665083330689161,Fetal warfarin syndrome (FWS) or warfarin (coumadin) embryopathy is a rare condition as a result of fetal exposure to maternal ingestion of WARFARIN during PREGNANCY,WARFARIN,PREGNANCY
1190,LAMELAR BONE causes BONE PAIN,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1191,no_relation,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1192,LAMELAR BONE causes BONE PAIN,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1193,no_relation,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1194,no_relation,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1195,BONE PAIN causes LAMELAR BONE,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1196,LAMELAR BONE causes BONE PAIN,causes,0.589767824619588,"The patient was compatible with HCAO, characterized by high bone mass, bone thickening and BONE PAIN with normal LAMELAR BONE",LAMELAR BONE,BONE PAIN
1197,TUBERCULIN diagnosis TUBERCULOSIS INFECTION,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1198,TUBERCULIN diagnosis TUBERCULOSIS INFECTION,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1199,TUBERCULOSIS INFECTION diagnosis TUBERCULIN,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1200,TUBERCULIN diagnosis TUBERCULOSIS INFECTION,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1201,TUBERCULOSIS INFECTION diagnosis TUBERCULIN,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1202,TUBERCULOSIS INFECTION diagnosis TUBERCULIN,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1203,TUBERCULOSIS INFECTION diagnosis TUBERCULIN,diagnosis,0.979957887012223,A new test that measures interferon gamma (IFN gamma) release in whole blood following stimulation with TUBERCULIN has the potential to detect TUBERCULOSIS INFECTION using a single blood draw.,TUBERCULOSIS INFECTION,TUBERCULIN
1204,WARFARIN ANTICOAGULATION treats ATRIAL FIBRILLATION,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1205,WARFARIN ANTICOAGULATION treats ATRIAL FIBRILLATION,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1206,WARFARIN ANTICOAGULATION treats ATRIAL FIBRILLATION,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1207,no_relation,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1208,WARFARIN ANTICOAGULATION treats ATRIAL FIBRILLATION,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1209,WARFARIN ANTICOAGULATION treats ATRIAL FIBRILLATION,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1210,WARFARIN ANTICOAGULATION treats ATRIAL FIBRILLATION,treats,0.966736489045664,Thromboembolism did not occur in patients who were in ATRIAL FIBRILLATION and receiving WARFARIN ANTICOAGULATION.,ATRIAL FIBRILLATION,WARFARIN ANTICOAGULATION
1211,no_relation,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1212,X LINKED HYDROCEPHALUS causes MASA SYNDROME,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1213,no_relation,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1214,MASA SYNDROME causes X LINKED HYDROCEPHALUS,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1215,no_relation,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1216,no_relation,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1217,MASA SYNDROME causes X LINKED HYDROCEPHALUS,causes,0.320256307610174,"X LINKED HYDROCEPHALUS MASA SYNDROME X linked complicated Spastic Paraplegia Type I and X linked partial agenesis of the corpus callosum are the four rare diseases usually referred to L1 syndrome, caused by mutations in the L1CAM gene.",X LINKED HYDROCEPHALUS,MASA SYNDROME
1218,no_relation,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1219,PRO (B29) HUMAN INSULIN causes IDDM,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1220,no_relation,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1221,PRO (B29) HUMAN INSULIN causes IDDM,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1222,IDDM causes PRO (B29) HUMAN INSULIN,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1223,no_relation,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1224,no_relation,causes,0.400891862868637,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1225,RIGHT PARIETAL PARASAGITTAL MENINGIOMA causes SEIZURES,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1226,RIGHT PARIETAL PARASAGITTAL MENINGIOMA causes SEIZURES,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1227,SEIZURES causes RIGHT PARIETAL PARASAGITTAL MENINGIOMA,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1228,RIGHT PARIETAL PARASAGITTAL MENINGIOMA causes SEIZURES,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1229,RIGHT PARIETAL PARASAGITTAL MENINGIOMA causes SEIZURES,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1230,RIGHT PARIETAL PARASAGITTAL MENINGIOMA causes SEIZURES,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1231,SEIZURES causes RIGHT PARIETAL PARASAGITTAL MENINGIOMA,causes,0.997054485501582,The authors describe the case of a 58 year old man with an history of SEIZURES because of RIGHT PARIETAL PARASAGITTAL MENINGIOMA,SEIZURES,RIGHT PARIETAL PARASAGITTAL MENINGIOMA
1232,PROGERIA SYNDROME (HGPS) causes PREMATURE AGING,causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1233,PREMATURE AGING causes PROGERIA SYNDROME (HGPS),causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1234,no_relation,causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1235,no_relation,causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1236,PROGERIA SYNDROME (HGPS) causes PREMATURE AGING,causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1237,no_relation,causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1238,PREMATURE AGING causes PROGERIA SYNDROME (HGPS),causes,0.5393598899705939,The most recently discovered diseases associated with LMNA mutations are the PREMATURE AGING disorders Hutchinson Gilford PROGERIA SYNDROME (HGPS) and atypical Werner's syndrome.,PREMATURE AGING,PROGERIA SYNDROME (HGPS)
1239,PRO (B29) HUMAN INSULIN treats IDDM,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1240,PRO (B29) HUMAN INSULIN treats IDDM,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1241,IDDM treats PRO (B29) HUMAN INSULIN,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1242,PRO (B29) HUMAN INSULIN treats IDDM,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1243,no_relation,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1244,PRO (B29) HUMAN INSULIN treats IDDM,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1245,PRO (B29) HUMAN INSULIN treats IDDM,treats,0.801783725737273,"Fineberg NS, Fineberg SE, Anderson JH et al. Immunologic effects of insulin lispro [Lys (B28), PRO (B29 HUMAN INSULIN] in IDDM and NIDDM patients previously treated with insulin.",IDDM,PRO (B29) HUMAN INSULIN
1246,no_relation,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1247,INSULIN DEPENDENT DIABETES causes DIABETIC KETOACIDOSIS,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1248,no_relation,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1249,INSULIN DEPENDENT DIABETES causes DIABETIC KETOACIDOSIS,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1250,INSULIN DEPENDENT DIABETES causes DIABETIC KETOACIDOSIS,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1251,INSULIN DEPENDENT DIABETES causes DIABETIC KETOACIDOSIS,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1252,INSULIN DEPENDENT DIABETES causes DIABETIC KETOACIDOSIS,causes,0.7022468831767831,Analysis of the mortality of children with INSULIN DEPENDENT DIABETES in Moscow in the eighties revealed a very high specific incidence of DIABETIC KETOACIDOSIS the principal cause of lethal outcomes occurring in the period of the disease manifestation in more than a half of the analyzed cases.,DIABETIC KETOACIDOSIS,INSULIN DEPENDENT DIABETES
1253,EPILEPTIC SEIZURES causes SEIZURES,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1254,EPILEPTIC SEIZURES causes SEIZURES,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1255,EPILEPTIC SEIZURES causes SEIZURES,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1256,no_relation,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1257,EPILEPTIC SEIZURES causes SEIZURES,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1258,no_relation,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1259,SEIZURES causes EPILEPTIC SEIZURES,causes,0.583459965991578,The examined parameters included: the prevalence and the age of onset of the SEIZURES the clinical subgroup of cerebral palsy and subtype of EPILEPTIC SEIZURES,SEIZURES,EPILEPTIC SEIZURES
1260,TUBERCULIN RESPONSE diagnosis TUBERCULOSIS,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1261,TUBERCULOSIS diagnosis TUBERCULIN RESPONSE,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1262,TUBERCULOSIS diagnosis TUBERCULIN RESPONSE,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1263,TUBERCULOSIS diagnosis TUBERCULIN RESPONSE,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1264,TUBERCULOSIS diagnosis TUBERCULIN RESPONSE,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1265,TUBERCULOSIS diagnosis TUBERCULIN RESPONSE,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1266,no_relation,diagnosis,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1267,MEDULLARY CARCINOMA causes COLD NODULES,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1268,no_relation,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1269,no_relation,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1270,no_relation,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1271,COLD NODULES causes MEDULLARY CARCINOMA,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1272,no_relation,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1273,no_relation,causes,0.304997140665209,"Affinity labelling with a 125I labelled photoactive derivative of TSH (HSAB TSH) was used to analyse TSH receptor size in the following specimens of human thyroid tissue: (1) COLD NODULES; (2) autonomous nodules; (3) papillary carcinoma; (4) MEDULLARY CARCINOMA; (5) metastasis of papillary carcinoma to lymph node; (6) anaplastic carcinoma, and (7) Graves' thyroid.",COLD NODULES,MEDULLARY CARCINOMA
1274,no_relation,location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1275,UPPER AIRWAY location OBSTRUCTIVE SLEEP APNOEA (OSA),location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1276,UPPER AIRWAY location OBSTRUCTIVE SLEEP APNOEA (OSA),location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1277,UPPER AIRWAY location OBSTRUCTIVE SLEEP APNOEA (OSA),location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1278,UPPER AIRWAY location OBSTRUCTIVE SLEEP APNOEA (OSA),location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1279,UPPER AIRWAY location OBSTRUCTIVE SLEEP APNOEA (OSA),location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1280,no_relation,location,0.8908708063747479,OBSTRUCTIVE SLEEP APNOEA (OSA) is characterised by repetitive collapse of the upper airway during sleep owing to a sleep related decrement in UPPER AIRWAY muscle activity with consequent failure of the pharyngeal dilator muscles to oppose the collapsing pressure that is generated by the diaphragm and accessory muscles during inspiration.,UPPER AIRWAY,OBSTRUCTIVE SLEEP APNOEA (OSA)
1281,no_relation,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1282,no_relation,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1283,no_relation,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1284,no_relation,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1285,no_relation,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1286,no_relation,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1287,TUBERCULIN RESPONSE treats TUBERCULOSIS,treats,0.442325868464691,"The TUBERCULIN RESPONSE which is a delayed hypersensitivity reaction, indicates the status of cellular immunity against TUBERCULOSIS",TUBERCULOSIS,TUBERCULIN RESPONSE
1288,no_relation,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1289,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1290,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1291,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1292,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1293,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1294,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341758,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
1295,INTRACTABLE EPILEPSY causes SEIZURES,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1296,INTRACTABLE EPILEPSY causes SEIZURES,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1297,INTRACTABLE EPILEPSY causes SEIZURES,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1298,no_relation,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1299,INTRACTABLE EPILEPSY causes SEIZURES,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1300,no_relation,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1301,SEIZURES causes INTRACTABLE EPILEPSY,causes,0.8,Twenty to 30% of patients with epilepsy develop chronic or INTRACTABLE EPILEPSY i.e. the SEIZURES persist despite accurate diagnosis and carefully monitored treatment with antiepileptic drugs.,SEIZURES,INTRACTABLE EPILEPSY
1302,ALLERGY causes HYPERSENSITIVITY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1303,HYPERSENSITIVITY causes ALLERGY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1304,ALLERGY causes HYPERSENSITIVITY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1305,ALLERGY causes HYPERSENSITIVITY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1306,ALLERGY causes HYPERSENSITIVITY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1307,ALLERGY causes HYPERSENSITIVITY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1308,HYPERSENSITIVITY causes ALLERGY,causes,0.99654575824488,"The HYPERSENSITIVITY proved to be due to an ALLERGY to a reaction product, and the simultaneous presence of the preservatives 1,3,5 trihydroxyethylhexahydrotriazine and thymol was found to be necessary for the occurrence of a positive patch test reaction.",HYPERSENSITIVITY,ALLERGY
1309,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1310,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1311,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1312,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1313,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1314,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1315,QUININE SULFATE treats NOCTURNAL CRAMPS,treats,0.99654575824488,QUININE SULFATE is a widely prescribed drug for NOCTURNAL CRAMPS,NOCTURNAL CRAMPS,QUININE SULFATE
1316,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1317,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1318,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1319,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1320,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1321,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1322,DUODENAL SOMATOSTATINOMAS diagnosis PSAMMOMA BODIES,diagnosis,0.8834522085987719,The histological finding of PSAMMOMA BODIES is important in the diagnosis of DUODENAL SOMATOSTATINOMAS,PSAMMOMA BODIES,DUODENAL SOMATOSTATINOMAS
1323,PATHOLOGIC FRACTURES location BONE METASTASES,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1324,BONE METASTASES location PATHOLOGIC FRACTURES,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1325,no_relation,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1326,PATHOLOGIC FRACTURES location BONE METASTASES,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1327,no_relation,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1328,BONE METASTASES location PATHOLOGIC FRACTURES,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1329,BONE METASTASES location PATHOLOGIC FRACTURES,location,0.50709255283711,"Outcomes:  Skeletal events (new BONE METASTASES PATHOLOGIC FRACTURES spinal cord compression, irradiation of or surgery on bone, development or progression of bone pain [and, in some studies, hypercalcemia]), quality of life, and survival.",PATHOLOGIC FRACTURES,BONE METASTASES
1330,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1331,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1332,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1333,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1334,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1335,no_relation,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1336,STAPHYLOCOCCI treats STAPHYLOCOCCAL INFECTIONS,treats,0.304997140665209,"1   If staphylococci resistant to penicillinase resistant penicillins (oxacillin resistant [methicillin resistant] STAPHYLOCOCCI are prevalent in the hospital or community, empiric therapy of suspected STAPHYLOCOCCAL INFECTIONS should include another appropriate anti infective (e.g., vancomycin.",STAPHYLOCOCCI,STAPHYLOCOCCAL INFECTIONS
1337,no_relation,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1338,THROMBOSED VEINS location VENOUS THROMBOSIS,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1339,THROMBOSED VEINS location VENOUS THROMBOSIS,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1340,THROMBOSED VEINS location VENOUS THROMBOSIS,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1341,THROMBOSED VEINS location VENOUS THROMBOSIS,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1342,THROMBOSED VEINS location VENOUS THROMBOSIS,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1343,THROMBOSED VEINS location VENOUS THROMBOSIS,location,0.721687836487032,"In three patients THROMBOSED VEINS were documented by venography and in all five cases, the presence of VENOUS THROMBOSIS was substantiated by the clinical findings.",THROMBOSED VEINS,VENOUS THROMBOSIS
1344,no_relation,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1345,no_relation,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1346,no_relation,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1347,MONOCLONAL GAMMOPATHY causes WALDENSTROM'S MACROGLOBULINEMIA,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1348,MONOCLONAL GAMMOPATHY causes WALDENSTROM'S MACROGLOBULINEMIA,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1349,no_relation,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1350,no_relation,causes,0.34815531191139604,"Plasmapheresis and paraproteinemia: cryoprotein induced diseases, MONOCLONAL GAMMOPATHY WALDENSTROM'S MACROGLOBULINEMIA hyperviscosity syndrome, multiple myeloma, light chain disease, and amyloidosis.",MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA
1351,ABNORMALITIES OF BONE TURNOVER STRUCTURE causes PAGET'S DISEASE,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1352,no_relation,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1353,PAGET'S DISEASE causes ABNORMALITIES OF BONE TURNOVER STRUCTURE,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1354,PAGET'S DISEASE causes ABNORMALITIES OF BONE TURNOVER STRUCTURE,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1355,no_relation,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1356,no_relation,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1357,PAGET'S DISEASE causes ABNORMALITIES OF BONE TURNOVER STRUCTURE,causes,0.997054485501582,PAGET'S DISEASE is a metabolic bone disease characterized by ABNORMALITIES OF BONE TURNOVER STRUCTURE AND architecture.,ABNORMALITIES OF BONE TURNOVER STRUCTURE,PAGET'S DISEASE
1358,no_relation,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1359,SKIN SPECIFIC PEMPHIGUS VULGARIS causes ANTIGENIC PROPERTIES OF SKIN,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1360,SKIN SPECIFIC PEMPHIGUS VULGARIS causes ANTIGENIC PROPERTIES OF SKIN,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1361,no_relation,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1362,ANTIGENIC PROPERTIES OF SKIN causes SKIN SPECIFIC PEMPHIGUS VULGARIS,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1363,ANTIGENIC PROPERTIES OF SKIN causes SKIN SPECIFIC PEMPHIGUS VULGARIS,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1364,no_relation,causes,0.516397779494322,The possibility that the distribution of skin lesions in some cutaneous diseases is due to variations in the ANTIGENIC PROPERTIES OF SKIN was investigated by mapping the expression of the SKIN SPECIFIC PEMPHIGUS VULGARIS and bullous pemphigoid antigens in different regions of the body.,ANTIGENIC PROPERTIES OF SKIN,SKIN SPECIFIC PEMPHIGUS VULGARIS
1365,BOWEL PERFORATION causes MECONIUM PERITONITIS,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1366,BOWEL PERFORATION causes MECONIUM PERITONITIS,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1367,MECONIUM PERITONITIS causes BOWEL PERFORATION,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1368,BOWEL PERFORATION causes MECONIUM PERITONITIS,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1369,BOWEL PERFORATION causes MECONIUM PERITONITIS,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1370,MECONIUM PERITONITIS causes BOWEL PERFORATION,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1371,MECONIUM PERITONITIS causes BOWEL PERFORATION,causes,0.9722718241315028,MECONIUM PERITONITIS is a chemical peritonitis which occurs following BOWEL PERFORATION during fetal life.,MECONIUM PERITONITIS,BOWEL PERFORATION
1372,RENAL ARTERIES location FIBROMUSCULAR DYSPLASIA,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1373,RENAL ARTERIES location FIBROMUSCULAR DYSPLASIA,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1374,RENAL ARTERIES location FIBROMUSCULAR DYSPLASIA,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1375,no_relation,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1376,RENAL ARTERIES location FIBROMUSCULAR DYSPLASIA,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1377,no_relation,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1378,no_relation,location,0.986393923832143,Imaging revealed FIBROMUSCULAR DYSPLASIA of the RENAL ARTERIES and the superior mesentery artery.,RENAL ARTERIES,FIBROMUSCULAR DYSPLASIA
1379,GLUCAGON diagnosis INSULIN INDUCED HYPOGLYCEMIA,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1380,no_relation,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1381,INSULIN INDUCED HYPOGLYCEMIA diagnosis GLUCAGON,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1382,no_relation,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1383,no_relation,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1384,INSULIN INDUCED HYPOGLYCEMIA diagnosis GLUCAGON,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1385,INSULIN INDUCED HYPOGLYCEMIA diagnosis GLUCAGON,diagnosis,0.3779644730092271,"The GLUCAGON and norepinephrine responses to INSULIN INDUCED HYPOGLYCEMIA are blunted in late pregnancy in the dog, impacting on the magnitude of the metabolic responses to the fall in glucose.",INSULIN INDUCED HYPOGLYCEMIA,GLUCAGON
1386,ANXIETY causes OBSESSIVE COMPULSIVE NEUROSIS,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1387,OBSESSIVE COMPULSIVE NEUROSIS causes ANXIETY,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1388,OBSESSIVE COMPULSIVE NEUROSIS causes ANXIETY,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1389,ANXIETY causes OBSESSIVE COMPULSIVE NEUROSIS,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1390,no_relation,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1391,no_relation,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1392,OBSESSIVE COMPULSIVE NEUROSIS causes ANXIETY,causes,0.78086880944303,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1393,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1394,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1395,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1396,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1397,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1398,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1399,NEOSTIGMINE treats MYASTHENIA GRAVIS,treats,1.0,A 52 year old man with MYASTHENIA GRAVIS and normal liver function was treated with NEOSTIGMINE prednisolone and azathioprine.,MYASTHENIA GRAVIS,NEOSTIGMINE
1400,EMESIS diagnosis ONDANSETRON,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1401,EMESIS diagnosis ONDANSETRON,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1402,EMESIS diagnosis ONDANSETRON,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1403,EMESIS diagnosis ONDANSETRON,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1404,no_relation,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1405,no_relation,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1406,no_relation,diagnosis,0.881917103688197,The lower incidence of EMESIS recorded by the ONDANSETRON groups compared with the droperidol group was not statistically significant.,EMESIS,ONDANSETRON
1407,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1408,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1409,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1410,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1411,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1412,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1413,AMOXICILLIN treats ACUTE MAXILLARY SINUSITIS,treats,1.0,Multicenter comparison of clarithromycin and AMOXICILLIN in the treatment of ACUTE MAXILLARY SINUSITIS,ACUTE MAXILLARY SINUSITIS,AMOXICILLIN
1414,COLON CANCER causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1415,no_relation,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1416,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1417,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1418,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1419,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CANCER,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1420,no_relation,causes,0.5892556509887901,The risk of colon cancer is extreme in the rare COLON CANCER syndromes of FAMILIAL ADENOMATOUS POLYPOSIS and hereditary nonpolyposis colon cancer.,COLON CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
1421,LYME DISEASE causes SPIROCHETE BORRELIA BURGDORFERI,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1422,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1423,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1424,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1425,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1426,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1427,SPIROCHETE BORRELIA BURGDORFERI causes LYME DISEASE,causes,1.0,The SPIROCHETE BORRELIA BURGDORFERI is the causative agent of LYME DISEASE the leading vector borne illness in the United States.,SPIROCHETE BORRELIA BURGDORFERI,LYME DISEASE
1428,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY causes PRION PROTEIN,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1429,no_relation,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1430,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1431,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1432,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1433,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1434,PRION PROTEIN causes TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,causes,0.924500327042048,The former is consistent with the concept of an agent with an independent genome while the latter is consistent with the concept that 'strain of agent' is another expression of the involvement of PRION PROTEIN in the pathogenesis of TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY,PRION PROTEIN,TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY
1435,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1436,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1437,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1438,no_relation,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1439,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1440,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1441,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,1.0,PHEOCHROMOCYTOMA is a catecholamine producing tumor and a rare cause of HYPERTENSION,HYPERTENSION,PHEOCHROMOCYTOMA
1442,no_relation,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1443,no_relation,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1444,no_relation,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1445,PANCREATIC ISLETS location INSULIN DEPENDENT DIABETES MELLITUS,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1446,PANCREATIC ISLETS location INSULIN DEPENDENT DIABETES MELLITUS,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1447,no_relation,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1448,PANCREATIC ISLETS location INSULIN DEPENDENT DIABETES MELLITUS,location,0.549442255794756,Cytokines produced by immune cells infiltrating PANCREATIC ISLETS are important mediators of beta cell destruction in INSULIN DEPENDENT DIABETES MELLITUS,PANCREATIC ISLETS,INSULIN DEPENDENT DIABETES MELLITUS
1449,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1450,no_relation,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1451,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1452,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1453,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1454,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1455,NAPROXEN treats OSTEOARTHRITIS OF THE HIP,treats,0.997054485501582,"In a double blind study, the efficacy and tolerability of S adenosylmethionine (SAMe) were evaluated in comparison with those of placebo and NAPROXEN in the treatment of OSTEOARTHRITIS OF THE HIP knee, spine, and hand.",OSTEOARTHRITIS OF THE HIP,NAPROXEN
1456,no_relation,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1457,OBSESSIVE COMPULSIVE NEUROSIS diagnosis ANXIETY,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1458,no_relation,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1459,no_relation,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1460,ANXIETY diagnosis OBSESSIVE COMPULSIVE NEUROSIS,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1461,no_relation,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1462,OBSESSIVE COMPULSIVE NEUROSIS diagnosis ANXIETY,diagnosis,0.312347523777212,"Whereas anxiety responds independently to exposure therapy, and hence that the ANXIETY reduction model of OBSESSIVE COMPULSIVE NEUROSIS is inadequate.",ANXIETY,OBSESSIVE COMPULSIVE NEUROSIS
1463,no_relation,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1464,TUBEROUS SCLEROSIS causes TONGUE BASE HAMARTOMA,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1465,no_relation,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1466,no_relation,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1467,no_relation,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1468,no_relation,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1469,no_relation,causes,0.6741998624632421,"To the best of our knowledge, this is the first reported case of a TONGUE BASE HAMARTOMA in a patient with TUBEROUS SCLEROSIS",TUBEROUS SCLEROSIS,TONGUE BASE HAMARTOMA
1470,LYMPH NODE METASTASIS causes METASTATIC LESIONS,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1471,LYMPH NODE METASTASIS causes METASTATIC LESIONS,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1472,LYMPH NODE METASTASIS causes METASTATIC LESIONS,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1473,no_relation,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1474,METASTATIC LESIONS causes LYMPH NODE METASTASIS,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1475,METASTATIC LESIONS causes LYMPH NODE METASTASIS,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1476,no_relation,causes,0.6454972243679029,"When TM expression was compared between the primary and metastatic lesions in the 39 patients who had LYMPH NODE METASTASIS 26 (67%) showed decreased TM expression, 13 (33%) showed no change, and none (0%) showed an increase in the METASTATIC LESIONS.",METASTATIC LESIONS,LYMPH NODE METASTASIS
1477,no_relation,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1478,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1479,SALMONELLA ISOLATES treats AMPICILLIN,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1480,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1481,no_relation,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1482,no_relation,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1483,AMPICILLIN treats SALMONELLA ISOLATES,treats,0.843274042711568,"SALMONELLA ISOLATES were found to be susceptible to chloramphenicol, kanamycin, AMPICILLIN and tetracycline.",SALMONELLA ISOLATES,AMPICILLIN
1484,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1485,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1486,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1487,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1488,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1489,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1490,LEVODOPA treats PARKINSON'S DISEASE,treats,0.997054485501582,Eighty eight patients with PARKINSON'S DISEASE were treated with LEVODOPA,PARKINSON'S DISEASE,LEVODOPA
1491,RELATED GENE (HERG) causes TORSADES DE POINTES,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1492,RELATED GENE (HERG) causes TORSADES DE POINTES,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1493,RELATED GENE (HERG) causes TORSADES DE POINTES,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1494,RELATED GENE (HERG) causes TORSADES DE POINTES,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1495,RELATED GENE (HERG) causes TORSADES DE POINTES,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1496,no_relation,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1497,RELATED GENE (HERG) causes TORSADES DE POINTES,causes,0.9838699100999068,Unintended inhibition of the cardiac potassium channel human ether a go go RELATED GENE (HERG) is considered the main culprit in drug induced arrhythmias known as TORSADES DE POINTES,TORSADES DE POINTES,RELATED GENE (HERG)
1498,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1499,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1500,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1501,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1502,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1503,AMANTADINE treats PARKINSON'S DISEASE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1504,PARKINSON'S DISEASE treats AMANTADINE,treats,1.0,AMANTADINE in the treatment of PARKINSON'S DISEASE,PARKINSON'S DISEASE,AMANTADINE
1505,PHEOCHROMOCYTOMA diagnosis PHENTOLAMINE,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1506,PHEOCHROMOCYTOMA diagnosis PHENTOLAMINE,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1507,PHENTOLAMINE diagnosis PHEOCHROMOCYTOMA,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1508,PHEOCHROMOCYTOMA diagnosis PHENTOLAMINE,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1509,no_relation,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1510,PHENTOLAMINE diagnosis PHEOCHROMOCYTOMA,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1511,PHEOCHROMOCYTOMA diagnosis PHENTOLAMINE,diagnosis,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1512,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1513,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1514,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1515,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1516,HYDROXYUREA treats POLYCYTHEMIA VERA,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1517,POLYCYTHEMIA VERA treats HYDROXYUREA,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1518,no_relation,treats,0.986393923832143,HYDROXYUREA in the treatment of POLYCYTHEMIA VERA: a prospective study of 100 patients over a 20 year period.,POLYCYTHEMIA VERA,HYDROXYUREA
1519,VIREMIA causes VIRUS EXPOSURE,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1520,VIREMIA causes VIRUS EXPOSURE,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1521,VIRUS EXPOSURE causes VIREMIA,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1522,VIRUS EXPOSURE causes VIREMIA,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1523,VIRUS EXPOSURE causes VIREMIA,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1524,VIRUS EXPOSURE causes VIREMIA,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1525,no_relation,causes,0.966736489045664,Efficacious FeLV vaccines prevent persistent VIREMIA and development of FeLV related disease after VIRUS EXPOSURE but not minimal viral replication and a provirus positive state as recently demonstrated using sensitive real time PCR assays.,VIRUS EXPOSURE,VIREMIA
1526,ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1527,ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1528,ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1529,no_relation,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1530,HYPERSENSITIVITY REACTION causes ALLERGY,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1531,ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1532,ALLERGY causes HYPERSENSITIVITY REACTION,causes,0.7875615306482171,SEE:   ALLERGY ;  anaphylaxis  ETIOLOGY: The condition is the result of a type I allergic or HYPERSENSITIVITY REACTION during which the allergen is absorbed into the blood directly or through the mucosa.,HYPERSENSITIVITY REACTION,ALLERGY
1533,VARIOLA VIRUS causes SMALLPOX,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1534,VARIOLA VIRUS causes SMALLPOX,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1535,VARIOLA VIRUS causes SMALLPOX,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1536,SMALLPOX causes VARIOLA VIRUS,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1537,VARIOLA VIRUS causes SMALLPOX,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1538,VARIOLA VIRUS causes SMALLPOX,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1539,VARIOLA VIRUS causes SMALLPOX,causes,0.9830783046228492,Each comparison gave the same conclusion: CMPV is the closest known virus to VARIOLA VIRUS the cause of SMALLPOX,VARIOLA VIRUS,SMALLPOX
1540,PARTIAL EPILEPSY causes SEIZURES,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1541,PARTIAL EPILEPSY causes SEIZURES,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1542,SEIZURES causes PARTIAL EPILEPSY,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1543,PARTIAL EPILEPSY causes SEIZURES,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1544,PARTIAL EPILEPSY causes SEIZURES,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1545,PARTIAL EPILEPSY causes SEIZURES,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1546,no_relation,causes,0.985329278164293,During therapy of 40 patients (8 57 year olds) with PARTIAL EPILEPSY the severity of the SEIZURES as well as emotional and cognitive functions of the patients were evaluated.,SEIZURES,PARTIAL EPILEPSY
1547,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1548,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1549,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1550,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1551,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1552,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1553,TOPICAL MINOXIDIL treats MALE PATTERN BALDNESS,treats,0.99654575824488,"Olsen EA, DeLong ER, Weiner MS. Long term follow up of men with MALE PATTERN BALDNESS treated with TOPICAL MINOXIDIL",MALE PATTERN BALDNESS,TOPICAL MINOXIDIL
1554,HODGKIN'S DISEASE treats VINCRISTINE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1555,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1556,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1557,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1558,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1559,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1560,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
1561,no_relation,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1562,MECONIUM location MECONIUM PERITONITIS,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1563,no_relation,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1564,no_relation,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1565,MECONIUM PERITONITIS location MECONIUM,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1566,no_relation,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1567,no_relation,location,0.7504787743864558,MECONIUM PERITONITIS occasionally occurs as a localized collection of MECONIUM contained in a cyst made of fibrous granulation tissue.,MECONIUM,MECONIUM PERITONITIS
1568,ATOPIC DERMATITIS diagnosis ATOPIC WINTER FEET,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1569,ATOPIC DERMATITIS diagnosis ATOPIC WINTER FEET,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1570,no_relation,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1571,no_relation,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1572,no_relation,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1573,no_relation,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1574,no_relation,diagnosis,0.363803437554499,When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17 valerate cream in a double blind study on 49 patients with ATOPIC DERMATITIS or ATOPIC WINTER FEET betamethasone cream was found to be the most potent.,ATOPIC DERMATITIS,ATOPIC WINTER FEET
1575,no_relation,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1576,PHENTOLAMINE causes PHEOCHROMOCYTOMA,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1577,no_relation,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1578,no_relation,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1579,no_relation,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1580,no_relation,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1581,PHENTOLAMINE causes PHEOCHROMOCYTOMA,causes,0.6154574548966639,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1582,PHENTOLAMINE treats PHEOCHROMOCYTOMA,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1583,no_relation,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1584,PHENTOLAMINE treats PHEOCHROMOCYTOMA,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1585,no_relation,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1586,PHENTOLAMINE treats PHEOCHROMOCYTOMA,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1587,PHENTOLAMINE treats PHEOCHROMOCYTOMA,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1588,PHENTOLAMINE treats PHEOCHROMOCYTOMA,treats,0.492365963917331,"177 ,   a  Sudden and marked reduction in BP following parenteral administration of PHENTOLAMINE suggests PHEOCHROMOCYTOMA;  a   however, false negative and false positive responses are frequent.",PHEOCHROMOCYTOMA,PHENTOLAMINE
1589,FLAT ADENOMAS causes HIGH GRADE DYSPLASIA,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1590,no_relation,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1591,FLAT ADENOMAS causes HIGH GRADE DYSPLASIA,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1592,FLAT ADENOMAS causes HIGH GRADE DYSPLASIA,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1593,FLAT ADENOMAS causes HIGH GRADE DYSPLASIA,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1594,HIGH GRADE DYSPLASIA causes FLAT ADENOMAS,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1595,FLAT ADENOMAS causes HIGH GRADE DYSPLASIA,causes,0.97439119569462,"Compared with polypoid adenomas of similar size, FLAT ADENOMAS show a higher frequency of HIGH GRADE DYSPLASIA and rapid submucosal invasion.",HIGH GRADE DYSPLASIA,FLAT ADENOMAS
1596,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1597,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1598,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1599,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1600,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1601,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1602,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1603,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1604,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1605,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1606,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1607,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1608,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1609,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1610,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1611,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1612,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1613,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1614,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1615,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1616,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1617,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1618,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1619,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1620,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1621,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1622,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1623,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1624,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1625,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1626,SEIZURE causes PETIT MAL,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1627,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1628,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1629,no_relation,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1630,PETIT MAL causes SEIZURE,causes,0.316227766,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
1631,PAIN causes POLYMYALGIA RHEUMATICA,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1632,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1633,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1634,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1635,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1636,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1637,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1638,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1639,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1640,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1641,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1642,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1643,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1644,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1645,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1646,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1647,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1648,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1649,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1650,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1651,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1652,PAIN causes POLYMYALGIA RHEUMATICA,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1653,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1654,PAIN causes POLYMYALGIA RHEUMATICA,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1655,PAIN causes POLYMYALGIA RHEUMATICA,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1656,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1657,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1658,PAIN causes POLYMYALGIA RHEUMATICA,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1659,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1660,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1661,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1662,POLYMYALGIA RHEUMATICA causes PAIN,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1663,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1664,no_relation,causes,0.4886777774,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
1665,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1666,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1667,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1668,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1669,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1670,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1671,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1672,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1673,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1674,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1675,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1676,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1677,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1678,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1679,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1680,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1681,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1682,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1683,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1684,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1685,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1686,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1687,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1688,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1689,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1690,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1691,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1692,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1693,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1694,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1695,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1696,SEIZURE causes TEMPORAL LOBE EPILEPSY,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1697,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1698,TEMPORAL LOBE EPILEPSY causes SEIZURE,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1699,no_relation,causes,0.9649012814,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
1700,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1701,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1702,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1703,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1704,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1705,VARICELLA causes ZOSTER,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1706,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1707,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1708,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1709,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1710,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1711,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1712,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1713,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1714,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1715,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1716,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1717,VARICELLA causes ZOSTER,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1718,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1719,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1720,VARICELLA causes ZOSTER,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1721,VARICELLA causes ZOSTER,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1722,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1723,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1724,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1725,ZOSTER causes VARICELLA,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1726,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1727,VARICELLA causes ZOSTER,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1728,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1729,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1730,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1731,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1732,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1733,no_relation,causes,0.5388159061,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
1734,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1735,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1736,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1737,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1738,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1739,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1740,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1741,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1742,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1743,ITCH causes PRURITUS,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1744,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1745,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1746,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1747,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1748,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1749,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1750,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1751,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1752,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1753,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1754,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1755,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1756,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1757,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1758,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1759,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1760,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1761,ITCH causes PRURITUS,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1762,ITCH causes PRURITUS,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1763,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1764,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1765,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1766,PRURITUS causes ITCH,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1767,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1768,no_relation,causes,0.9918365981,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
1769,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1770,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1771,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1772,no_relation,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1773,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1774,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1775,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1776,no_relation,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1777,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1778,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1779,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1780,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1781,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1782,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1783,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1784,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1785,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1786,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1787,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1788,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1789,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1790,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1791,no_relation,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1792,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1793,PAIN causes PRIMARY DYSMENORRHEA,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1794,PAIN causes PRIMARY DYSMENORRHEA,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1795,PAIN causes PRIMARY DYSMENORRHEA,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1796,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1797,PAIN causes PRIMARY DYSMENORRHEA,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1798,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1799,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1800,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1801,no_relation,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1802,PRIMARY DYSMENORRHEA causes PAIN,causes,0.9931270663,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
1803,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1804,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1805,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1806,no_relation,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1807,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1808,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1809,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1810,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1811,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1812,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1813,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1814,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1815,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1816,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1817,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1818,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1819,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1820,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1821,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1822,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1823,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1824,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1825,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1826,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1827,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1828,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1829,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1830,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1831,FEVER causes MULTICENTRIC CASTLEMAN'S DISEASE,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1832,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1833,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1834,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1835,MULTICENTRIC CASTLEMAN'S DISEASE causes FEVER,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1836,no_relation,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1837,no_relation,causes,0.979957887,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
1838,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1839,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1840,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1841,no_relation,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1842,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1843,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1844,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1845,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1846,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1847,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1848,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1849,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1850,no_relation,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1851,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1852,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1853,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1854,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1855,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1856,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1857,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1858,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1859,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1860,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1861,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1862,no_relation,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1863,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1864,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1865,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1866,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1867,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1868,no_relation,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1869,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1870,ESSENTIAL THROMBOCYTHEMIA causes THROMBOCYTOSIS,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1871,no_relation,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1872,THROMBOCYTOSIS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9819805061,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
1873,DIABETIC NEUROPATHY causes DIABETES MELLITUS,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1874,DIABETES MELLITUS causes DIABETIC NEUROPATHY,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1875,DIABETES MELLITUS causes DIABETIC NEUROPATHY,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1876,no_relation,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1877,DIABETES MELLITUS causes DIABETIC NEUROPATHY,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1878,DIABETIC NEUROPATHY causes DIABETES MELLITUS,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1879,DIABETES MELLITUS causes DIABETIC NEUROPATHY,causes,0.90913729009699,"Diabetic neuropathy is common in patients with DIABETES MELLITUS, and 7.5% of diabetics experience pain from DIABETIC NEUROPATHY",DIABETIC NEUROPATHY,DIABETES MELLITUS
1880,DKA causes DIABETES MELLITUS,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1881,DIABETES MELLITUS causes DKA,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1882,DIABETES MELLITUS causes DKA,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1883,DKA causes DIABETES MELLITUS,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1884,DIABETES MELLITUS causes DKA,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1885,DKA causes DIABETES MELLITUS,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1886,DIABETES MELLITUS causes DKA,causes,0.936382183834624,Rationale: ? Patients with DIABETES MELLITUS may present initially with DKA,DKA,DIABETES MELLITUS
1887,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1888,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1889,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1890,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1891,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1892,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1893,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
1894,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1895,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1896,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1897,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1898,no_relation,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1899,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1900,FAMILIAL ADENOMATOUS POLYPOSIS causes DYSPLASIA,causes,0.768221279597376,"We report a patient with FAMILIAL ADENOMATOUS POLYPOSIS who developed DYSPLASIA in a large exophytic hyperplastic gastric tumor that appeared to arise on a background of diffuse fundic gland polyposis and presented with anemia, hypoalbuminemia, and a protein-losing enteropathy",DYSPLASIA,FAMILIAL ADENOMATOUS POLYPOSIS
1901,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1902,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1903,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1904,no_relation,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1905,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1906,HIGH PLATELET COUNTS causes ESSENTIAL THROMBOCYTHEMIA,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1907,ESSENTIAL THROMBOCYTHEMIA causes HIGH PLATELET COUNTS,causes,0.9539980920057242,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
1908,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1909,no_relation,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1910,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1911,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1912,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1913,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1914,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,0.953462589245592,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
1915,WEIGHT LOSS causes PANCREATIC ADENOCARCINOMA,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1916,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1917,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1918,no_relation,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1919,no_relation,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1920,no_relation,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1921,PANCREATIC ADENOCARCINOMA causes WEIGHT LOSS,causes,0.975900072948533,"Because duodenal and/or pancreatic cancer was suspected due to WEIGHT LOSS, the pancreatic and bile duct obstruction, and the increased risk of small intestine and PANCREATIC ADENOCARCINOMA in patients with PSJ, a pancreatoduodenectomy was performed",WEIGHT LOSS,PANCREATIC ADENOCARCINOMA
1922,no_relation,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1923,TOXEMIA causes COMPLICATED PREGNANCIES,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1924,no_relation,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1925,TOXEMIA causes COMPLICATED PREGNANCIES,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1926,no_relation,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1927,TOXEMIA causes COMPLICATED PREGNANCIES,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1928,TOXEMIA causes COMPLICATED PREGNANCIES,causes,0.358568582800318,"In COMPLICATED PREGNANCIES (e.g., TOXEMIA, diabetes mellitus) the L/S ratio may result in erroneous clinical interpretation and premature intervention",COMPLICATED PREGNANCIES,TOXEMIA
1929,no_relation,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1930,HYPERSENSITIVITY REACTION causes STEVENS-JOHNSON SYNDROME,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1931,STEVENS-JOHNSON SYNDROME causes HYPERSENSITIVITY REACTION,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1932,HYPERSENSITIVITY REACTION causes STEVENS-JOHNSON SYNDROME,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1933,HYPERSENSITIVITY REACTION causes STEVENS-JOHNSON SYNDROME,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1934,HYPERSENSITIVITY REACTION causes STEVENS-JOHNSON SYNDROME,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1935,STEVENS-JOHNSON SYNDROME causes HYPERSENSITIVITY REACTION,causes,0.9258200997725508,A patient presented with a HYPERSENSITIVITY REACTION to the aromatic anticonvulsants which evolved into STEVENS-JOHNSON SYNDROME and was complicated by the presence of adult respiratory distress syndrome,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY REACTION
1936,no_relation,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1937,no_relation,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1938,HYPERSENSITIVITY SYMPTOMS causes ALLERGIC REACTION,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1939,no_relation,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1940,no_relation,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1941,HYPERSENSITIVITY SYMPTOMS causes ALLERGIC REACTION,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1942,no_relation,causes,0.848528137423857,"Although many foods have been described to cause an ALLERGIC REACTION, only a few are responsible for the majority of HYPERSENSITIVITY SYMPTOMS",ALLERGIC REACTION,HYPERSENSITIVITY SYMPTOMS
1943,no_relation,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1944,no_relation,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1945,no_relation,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1946,no_relation,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1947,no_relation,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1948,SEVERE DYSPLASIA causes CIN III,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1949,no_relation,causes,0.328797974610715,"Of the patients undergoing cryosurgical treatment, 83 had cervical intraepithelial neoplasia (CIN) I (mild dysplasia), 172 had CIN II (moderate dysplasia), and 60 had CIN III (SEVERE DYSPLASIA and carcinoma in situ",SEVERE DYSPLASIA,CIN III
1950,no_relation,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1951,HYPERTENSIVE ENCEPHALOPATHY causes HYPERTENSION,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1952,HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1953,HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1954,HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1955,HYPERTENSION causes HYPERTENSIVE ENCEPHALOPATHY,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1956,no_relation,causes,0.896258159530272,Prevention of the occurrence of neurological deficits in children with acute glomerulonephritis and HYPERTENSIVE ENCEPHALOPATHY requires careful evaluation and appropriate management of HYPERTENSION,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
1957,no_relation,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1958,ALLERGIC ASTHMA causes ALLERGIC REACTIONS,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1959,no_relation,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1960,ALLERGIC REACTIONS causes ALLERGIC ASTHMA,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1961,ALLERGIC ASTHMA causes ALLERGIC REACTIONS,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1962,no_relation,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1963,no_relation,causes,0.549442255794756,"Allergen specific immunotherapy has been shown to be effective in rigorous double-blind placebo-controlled clinical trials in both children and adults A recent WHO position paper stated that immunotherapy is an effective treatment for patients with allergic rhinitis/conjunctivitis, ALLERGIC ASTHMA and ALLERGIC REACTIONS from stinging insects and is thought to be more effective in children than in adults",ALLERGIC ASTHMA,ALLERGIC REACTIONS
1964,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1965,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1966,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1967,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1968,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1969,INVASIVE DUCTAL CARCINOMA causes SOLID PATTERN,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1970,no_relation,causes,0.975900072948533,"The INVASIVE DUCTAL CARCINOMA showed a SOLID PATTERN, high nuclear and structural atypia and frequent mitotic figures, while the tubular adenoma consisted of a proliferation of small ducts lined by single layers of epithelial and myoepithelial cells with bland nuclei and inconspicuous nucleoli",SOLID PATTERN,INVASIVE DUCTAL CARCINOMA
1971,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1972,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1973,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1974,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1975,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1976,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1977,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1978,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1979,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1980,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1981,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1982,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1983,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1984,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1985,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1986,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1987,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1988,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1989,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1990,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1991,CHRONIC EOSINOPHILIC LEUKAEMIA diagnosis BONE MARROW,diagnosis,0.538815906080325,"A diagnosis of CHRONIC EOSINOPHILIC LEUKAEMIA was made on the basis of myeloproliferative involvement of both peripheral blood and BONE MARROW, associated with eosinophilic differentiation and a t(5;12)(q33;p13) translocation",BONE MARROW,CHRONIC EOSINOPHILIC LEUKAEMIA
1992,SPLENOMEGALY causes HAIRY CELL LEUKAEMIA,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1993,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1994,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1995,SPLENOMEGALY causes HAIRY CELL LEUKAEMIA,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1996,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1997,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1998,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
1999,SPLENOMEGALY causes HAIRY CELL LEUKAEMIA,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2000,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2001,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2002,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2003,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2004,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2005,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2006,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2007,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2008,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2009,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2010,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2011,no_relation,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2012,HAIRY CELL LEUKAEMIA causes SPLENOMEGALY,causes,0.917662935482247,The material investigated consisted of two spleens resected at gastrectomy and one resected because of SPLENOMEGALY in a case of HAIRY CELL LEUKAEMIA,SPLENOMEGALY,HAIRY CELL LEUKAEMIA
2013,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2014,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2015,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2016,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2017,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2018,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2019,HAIR FOLLICLES diagnosis BENIGN FOLLICULAR TUMORS,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2020,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2021,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2022,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2023,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2024,HAIR FOLLICLES diagnosis BENIGN FOLLICULAR TUMORS,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2025,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2026,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2027,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2028,HAIR FOLLICLES diagnosis BENIGN FOLLICULAR TUMORS,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2029,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2030,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2031,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2032,no_relation,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2033,BENIGN FOLLICULAR TUMORS diagnosis HAIR FOLLICLES,diagnosis,0.4574957109978139,"However, the deeper portions of HAIR FOLLICLES were also found to be unlabeled, and further study of BENIGN FOLLICULAR TUMORS which may histologically mimic basal cell carcinomas is suggested",HAIR FOLLICLES,BENIGN FOLLICULAR TUMORS
2034,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2035,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2036,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2037,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2038,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2039,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2040,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2041,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2042,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2043,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2044,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2045,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2046,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2047,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2048,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2049,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2050,ACUTE MYELOFIBROSIS causes BONE MARROW FIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2051,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2052,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2053,no_relation,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2054,BONE MARROW FIBROSIS causes ACUTE MYELOFIBROSIS,causes,0.832050294337844,ACUTE MYELOFIBROSIS (AM) or malignant myelosclerosis is a myeloprofilerative syndrome in which BONE MARROW FIBROSIS is associated with a proliferation of immature myeloid cells,BONE MARROW FIBROSIS,ACUTE MYELOFIBROSIS
2055,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2056,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2057,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2058,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2059,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2060,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2061,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2062,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2063,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2064,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2065,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2066,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2067,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2068,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2069,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2070,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2071,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2072,RESPIRATORY ALKALOSIS causes HYPERVENTILATION,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2073,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2074,no_relation,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2075,HYPERVENTILATION causes RESPIRATORY ALKALOSIS,causes,0.301511344577764,Hyperactivity may quickly turn to lethargy; HYPERVENTILATION (with RESPIRATORY ALKALOSIS) changes to hypoventilation (with mixed respiratory and metabolic acidosis) and respiratory failure,RESPIRATORY ALKALOSIS,HYPERVENTILATION
2076,GAMMA HEAVY CHAIN DISEASE diagnosis SPLENOMEGALY,diagnosis,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
2077,GAMMA HEAVY CHAIN DISEASE diagnosis SPLENOMEGALY,diagnosis,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
2078,GAMMA HEAVY CHAIN DISEASE diagnosis SPLENOMEGALY,diagnosis,0.50709255283711,A patient with GAMMA HEAVY CHAIN DISEASE (Franklin's disease) was discovered during evaluation for pancytopenia and SPLENOMEGALY,SPLENOMEGALY,GAMMA HEAVY CHAIN DISEASE
2079,SEIZURES causes EPILEPSY,causes,0.975900072948533,The treatment of EPILEPSY after the first epileptic seizure decreases effectively the number of SEIZURES within the first three years,SEIZURES,EPILEPSY
2080,EPILEPSY causes SEIZURES,causes,0.975900072948533,The treatment of EPILEPSY after the first epileptic seizure decreases effectively the number of SEIZURES within the first three years,SEIZURES,EPILEPSY
2081,EPILEPSY causes SEIZURES,causes,0.975900072948533,The treatment of EPILEPSY after the first epileptic seizure decreases effectively the number of SEIZURES within the first three years,SEIZURES,EPILEPSY
2082,NEUROMYELITIS OPTICA location SPINAL CORD,location,0.753778361444409,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
2083,SPINAL CORD location NEUROMYELITIS OPTICA,location,0.753778361444409,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
2084,SPINAL CORD location NEUROMYELITIS OPTICA,location,0.753778361444409,"Recognizing that the patient's disease was localized only to the SPINAL CORD led to an eventual serological diagnosis of NEUROMYELITIS OPTICA (Devic's disease), a demyelinating syndrome that is now considered distinct from multiple sclerosis and that primarily affects the spinal cord and optic nerves",SPINAL CORD,NEUROMYELITIS OPTICA
2085,PANCREATITIS causes PANCREAS,causes,0.486664263392288,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
2086,no_relation,causes,0.486664263392288,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
2087,PANCREAS causes PANCREATITIS,causes,0.486664263392288,"The changes in ductal vascularity correlated with the severity of the histological changes to the PANCREAS and may, thus, in part explain the progress of PANCREATITIS",PANCREAS,PANCREATITIS
2088,no_relation,causes,0.6488856845230501,"We review the role of platelets in inflammation, how they assist in the recruitment of leukocytes into lung tissue in ASTHMA, and evidence of their dysfunction in CYSTIC FIBROSIS (CF",ASTHMA,CYSTIC FIBROSIS
2089,CYSTIC FIBROSIS causes ASTHMA,causes,0.6488856845230501,"We review the role of platelets in inflammation, how they assist in the recruitment of leukocytes into lung tissue in ASTHMA, and evidence of their dysfunction in CYSTIC FIBROSIS (CF",ASTHMA,CYSTIC FIBROSIS
2090,no_relation,causes,0.6488856845230501,"We review the role of platelets in inflammation, how they assist in the recruitment of leukocytes into lung tissue in ASTHMA, and evidence of their dysfunction in CYSTIC FIBROSIS (CF",ASTHMA,CYSTIC FIBROSIS
2091,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
2092,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
2093,no_relation,treats,0.911684611677103,"b ,   c  Class:  beta-Adrenergic Blocking Agents 24:24; CV100 (VA)  Synonyms:  HYDROCHLOROTHIAZIDE and Propranolol Hydrochloride  Uses  Hypertension  Management of HYPERTENSION, alone or in combination with other antihypertensive agents",HYPERTENSION,HYDROCHLOROTHIAZIDE
2094,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
2095,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
2096,ORLISTAT treats OBESITY,treats,1.0,"Evaluation of the safety and efficacy of sibutramine, ORLISTAT and metformin in the treatment of OBESITY",OBESITY,ORLISTAT
2097,no_relation,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2098,no_relation,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2099,MICROCALCIFICATION causes DCIS,causes,0.762000762001143,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2100,no_relation,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
2101,AMPHOTERICIN B diagnosis NEUTROPENIA,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
2102,no_relation,diagnosis,0.42426406871192895,"Ayestaran A, Lopez R, Montoro JB et al. Pharmacokinetics of conventional formulation versus fat emulsion formulation of AMPHOTERICIN B in a group of patients with NEUTROPENIA",NEUTROPENIA,AMPHOTERICIN B
2103,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2104,no_relation,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2105,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2106,THYROID DISORDERS diagnosis TRIIODOTHYRONINE,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2107,THYROID DISORDERS diagnosis TRIIODOTHYRONINE,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2108,TRIIODOTHYRONINE diagnosis THYROID DISORDERS,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2109,no_relation,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
2110,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
2111,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.9797958971132712,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
2112,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2113,no_relation,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2114,DEXAMETHASONE treats HYPERCORTISOLISM,treats,0.78086880944303,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2115,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2116,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2117,ISOTRETINOIN treats ACNE,treats,0.9838699100999068,Association of suicide attempts with ACNE and treatment with ISOTRETINOIN: retrospective Swedish cohort study,ACNE,ISOTRETINOIN
2118,ERGONOVINE diagnosis VASOSPASTIC ANGINA,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
2119,VASOSPASTIC ANGINA diagnosis ERGONOVINE,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
2120,VASOSPASTIC ANGINA diagnosis ERGONOVINE,diagnosis,0.975900072948533,"These results suggest that the two provocative tests for coronary spasm that involve acetylcholine and ERGONOVINE are clinically useful in the diagnosis of VASOSPASTIC ANGINA, but testing with intracoronary ergonovine is needed when a spontaneous focal coronary spasm is relieved by the intracoronary injection of acetylcholine",VASOSPASTIC ANGINA,ERGONOVINE
2121,THYROXINE treats THYROID DEFICIENCY,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
2122,THYROXINE treats THYROID DEFICIENCY,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
2123,THYROXINE treats THYROID DEFICIENCY,treats,0.635000635000953,"In developing PTU-treated rats, the abnormalities completely disappeared after therapy with increasing physiological doses of THYROXINE; consequently they were directly related to THYROID DEFICIENCY and not to toxic effects of PTU",THYROID DEFICIENCY,THYROXINE
2124,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
2125,PNEUMOCYSTIS PNEUMONIA treats PENTAMIDINE ISETHIONATE,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
2126,PENTAMIDINE ISETHIONATE treats PNEUMOCYSTIS PNEUMONIA,treats,0.953462589245592,"In 1984, three patients died of severe hypoglycemia after receiving PENTAMIDINE ISETHIONATE to treat PNEUMOCYSTIS PNEUMONIA",PNEUMOCYSTIS PNEUMONIA,PENTAMIDINE ISETHIONATE
2127,no_relation,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
2128,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
2129,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
2130,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
2131,CHLORAMBUCIL treats CHRONIC LYMPHOCYTIC LEUKEMIA,treats,0.956182887467515,Effects of CHLORAMBUCIL and therapeutic decision in initial forms of CHRONIC LYMPHOCYTIC LEUKEMIA (stage A): results of a randomized clinical trial on 612 patients,CHRONIC LYMPHOCYTIC LEUKEMIA,CHLORAMBUCIL
2132,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2133,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2134,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2135,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2136,METHYLPREDNISOLONE treats GVHD,treats,0.577350269189626,Prophylaxis for GVHD consisted of cyclosporine and METHYLPREDNISOLONE,GVHD,METHYLPREDNISOLONE
2137,no_relation,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
2138,no_relation,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
2139,ENDOMETRIAL CARCINOMA contraindicates POSTMENOPAUSAL BLEEDING,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
2140,POSTMENOPAUSAL BLEEDING contraindicates ENDOMETRIAL CARCINOMA,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
2141,no_relation,contraindicates,0.308606699924184,"With POSTMENOPAUSAL BLEEDING, ENDOMETRIAL CARCINOMA must always be ruled out",POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CARCINOMA
2142,no_relation,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
2143,no_relation,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
2144,no_relation,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
2145,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
2146,GLIBENCLAMIDE treats MATURITY ONSET DIABETES,treats,0.811107105653813,A clinical comparison between glipizide (Glibenese ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申��LIBENCLAMIDEnclamide (Daonil ����渇�膩��臂�申�鰹申鐃順����鐃初���申���紮�申羝�申鐃緒申�渇�膩������括�鐃順�����鰹申鐃� tMATURITY ONSET DIABETESy onset diabetes: a controlled double-blind cross-over study,MATURITY ONSET DIABETES,GLIBENCLAMIDE
2147,no_relation,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2148,THYROID DISORDERS diagnosis TRIIODOTHYRONINE,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2149,no_relation,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2150,THYROID DISORDERS diagnosis TRIIODOTHYRONINE,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2151,no_relation,diagnosis,0.940720868383597,"The commonly used laboratory investigations for the diagnosis and management of THYROID DISORDERS are the thyroid hormones, thyroxine and TRIIODOTHYRONINE and the pituitary hormone, thyrotrophin (TSH",THYROID DISORDERS,TRIIODOTHYRONINE
2152,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2153,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2154,DEXAMETHASONE causes HYPERCORTISOLISM,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2155,no_relation,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2156,HYPERCORTISOLISM causes DEXAMETHASONE,causes,0.312347523777212,"Very high plasma androgen levels or evidence of HYPERCORTISOLISM, which is not normally suppressible by DEXAMETHASONE, should lead to the search for a tumor or Cushing's syndrome",HYPERCORTISOLISM,DEXAMETHASONE
2157,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
2158,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
2159,no_relation,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
2160,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
2161,INSULIN treats HYPERGLYCEMIA,treats,0.98058067569092,"Beta cells are nonetheless destroyed (by unknown means), and the patient develops HYPERGLYCEMIA or ketoacidosis unless he or she receives INSULIN",HYPERGLYCEMIA,INSULIN
2162,ERGOMETRINE treats VARIANT ANGINA,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
2163,no_relation,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
2164,ERGOMETRINE treats VARIANT ANGINA,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
2165,ERGOMETRINE treats VARIANT ANGINA,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
2166,no_relation,treats,0.964901281354015,"Studies were performed on isolated canine coronary artery segments to characterize the mechanism of the constrictor response of ERGOMETRINE (ergonovine), an agent used to induce coronary vasospasm in patients with VARIANT ANGINA",VARIANT ANGINA,ERGOMETRINE
2167,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2168,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2169,no_relation,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2170,MICROCALCIFICATION diagnosis DCIS,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2171,DCIS diagnosis MICROCALCIFICATION,diagnosis,0.635000635000953,Many cases of DCIS are detected because of MICROCALCIFICATION on mammograms; 20% of screen-detected cancers are of this type,MICROCALCIFICATION,DCIS
2172,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2173,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2174,WOLFRAM SYNDROME causes DIABETES INSIPIDUS,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2175,no_relation,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2176,no_relation,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2177,WOLFRAM SYNDROME causes DIABETES INSIPIDUS,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2178,DIABETES INSIPIDUS causes WOLFRAM SYNDROME,causes,0.9950371902,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
2179,MYXEDEMA treats INTRAVENOUS L THYROXINE,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2180,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2181,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2182,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2183,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2184,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2185,INTRAVENOUS L THYROXINE treats MYXEDEMA,treats,0.9525793444,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
2186,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2187,no_relation,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2188,no_relation,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2189,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2190,TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY treats CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2191,no_relation,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2192,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN treats TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,treats,0.8111071056999999,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
2193,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2194,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2195,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2196,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2197,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2198,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2199,METHOTREXATE treats OSTEOSARCOMA,treats,0.9759000729,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
2200,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2201,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2202,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2203,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2204,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2205,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2206,VARIOLA MAJOR VIRUS causes SMALLPOX,causes,1.0,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
2207,no_relation,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2208,CHRONIC RELAPSING ATOPIC DERMATITIS causes A MODEL OF ATOPIC DISEASE,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2209,CHRONIC RELAPSING ATOPIC DERMATITIS causes A MODEL OF ATOPIC DISEASE,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2210,no_relation,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2211,A MODEL OF ATOPIC DISEASE causes CHRONIC RELAPSING ATOPIC DERMATITIS,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2212,A MODEL OF ATOPIC DISEASE causes CHRONIC RELAPSING ATOPIC DERMATITIS,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2213,no_relation,causes,0.8980265101,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
2214,TETRACYCLINE contraindicates PREGNANCY,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2215,no_relation,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2216,no_relation,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2217,PREGNANCY contraindicates TETRACYCLINE,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2218,no_relation,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2219,PREGNANCY contraindicates TETRACYCLINE,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2220,no_relation,contraindicates,0.8219949365000001,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
2221,SYSTEMIC HYPERTENSION treats SUBLINGUAL NIFEDIPINE,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2222,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2223,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2224,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2225,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2226,SUBLINGUAL NIFEDIPINE treats SYSTEMIC HYPERTENSION,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2227,no_relation,treats,0.9878783399,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
2228,NOCARDIA causes NOCARDIOSIS,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2229,NOCARDIA causes NOCARDIOSIS,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2230,NOCARDIA causes NOCARDIOSIS,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2231,NOCARDIOSIS causes NOCARDIA,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2232,NOCARDIA causes NOCARDIOSIS,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2233,no_relation,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2234,NOCARDIA causes NOCARDIOSIS,causes,0.995893206467704,"c ,   116  Nocardiosis  Tetracyclines are alternative to co trimoxazole for treatment of NOCARDIOSIS   +    caused by  NOCARDIA",NOCARDIOSIS,NOCARDIA
2235,no_relation,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2236,no_relation,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2237,ERYTHEMATOSUS (SLE causes RHEUMATOID ARTHRITIS,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2238,no_relation,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2239,no_relation,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2240,ERYTHEMATOSUS (SLE causes RHEUMATOID ARTHRITIS,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2241,ERYTHEMATOSUS (SLE causes RHEUMATOID ARTHRITIS,causes,0.870388279778489,"134 ,   e  Warnings/Precautions  Warnings  Systemic Lupus ERYTHEMATOSUS (SLE  May cause SLE (e.g., glomerulonephritis) or RHEUMATOID ARTHRITIS  134 ,   d ,   e   particularly in patients receiving >200 mg daily dosage for prolonged periods, in slow acetylators of hydralazine, or in those with decreased renal function.",RHEUMATOID ARTHRITIS,ERYTHEMATOSUS (SLE
2242,no_relation,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2243,GLAUCOMATOUS PAINFUL BLIND EYE causes GLAUCOMA,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2244,no_relation,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2245,no_relation,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2246,no_relation,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2247,no_relation,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2248,no_relation,causes,0.6154574548966639,"And for GLAUCOMATOUS PAINFUL BLIND EYE and some cases of GLAUCOMA Cyclocryotherapy for ciliary body ablation could be considered to be performed.[28] [edit] Veterinary implant  TR BioSurgical has commercialized a new implant specifically for veterinary medicine, called TR ClarifEYE.",GLAUCOMATOUS PAINFUL BLIND EYE,GLAUCOMA
2249,no_relation,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2250,MARCH HEMOGLOBINURIA causes MICROANGIOPATHIC HEMOLYSIS,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2251,no_relation,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2252,MARCH HEMOGLOBINURIA causes MICROANGIOPATHIC HEMOLYSIS,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2253,no_relation,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2254,no_relation,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2255,no_relation,causes,0.312347523777212,March Hemoglobinuria  MARCH HEMOGLOBINURIA a disorder that somewhat resembles MICROANGIOPATHIC HEMOLYSIS usually occurs in young persons after prolonged marching or running or playing on bongo drums.,MICROANGIOPATHIC HEMOLYSIS,MARCH HEMOGLOBINURIA
2256,LEWY BODY DEMENTIA causes WELL FORMED VISUAL HALLUCINATIONS,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2257,WELL FORMED VISUAL HALLUCINATIONS causes LEWY BODY DEMENTIA,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2258,no_relation,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2259,LEWY BODY DEMENTIA causes WELL FORMED VISUAL HALLUCINATIONS,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2260,LEWY BODY DEMENTIA causes WELL FORMED VISUAL HALLUCINATIONS,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2261,LEWY BODY DEMENTIA causes WELL FORMED VISUAL HALLUCINATIONS,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2262,no_relation,causes,0.975900072948533,"Fluctuations in cognition, parkinsonian symptoms, WELL FORMED VISUAL HALLUCINATIONS and relative preservation of short term memory suggest LEWY BODY DEMENTIA rather than Alzheimer's disease (see  Table 213 5.",WELL FORMED VISUAL HALLUCINATIONS,LEWY BODY DEMENTIA
2263,no_relation,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2264,MULTIFOCAL ATRIAL TACHYCARDIA causes NARROW QRS COMPLEX TACHYARRHYTHMIAS,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2265,no_relation,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2266,no_relation,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2267,MULTIFOCAL ATRIAL TACHYCARDIA causes NARROW QRS COMPLEX TACHYARRHYTHMIAS,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2268,NARROW QRS COMPLEX TACHYARRHYTHMIAS causes MULTIFOCAL ATRIAL TACHYCARDIA,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2269,no_relation,causes,0.327326835353989,"Irregular, NARROW QRS COMPLEX TACHYARRHYTHMIAS include atrial fibrillation (AF), atrial flutter or true atrial tachycardia with variable AV conduction, and MULTIFOCAL ATRIAL TACHYCARDIA",MULTIFOCAL ATRIAL TACHYCARDIA,NARROW QRS COMPLEX TACHYARRHYTHMIAS
2270,no_relation,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2271,NEURALGIA causes NEUROPATHIC PAIN,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2272,no_relation,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2273,no_relation,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2274,no_relation,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2275,no_relation,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2276,no_relation,causes,0.650944554904119,"Nerve injury and reduced sensory input more often cause NEUROPATHIC PAIN than cure it, and augmenting sensory input often lessens NEURALGIA",NEUROPATHIC PAIN,NEURALGIA
2277,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2278,POSTOPERATIVE HYPERTENSION causes PHEOCHROMOCYTOMA RESECTION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2279,POSTOPERATIVE HYPERTENSION causes PHEOCHROMOCYTOMA RESECTION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2280,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2281,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2282,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2283,PHEOCHROMOCYTOMA RESECTION causes POSTOPERATIVE HYPERTENSION,causes,0.8660254037844392,"• According to an expert review, POSTOPERATIVE HYPERTENSION occurs in up to 50% of patients after PHEOCHROMOCYTOMA RESECTION ( 29.",POSTOPERATIVE HYPERTENSION,PHEOCHROMOCYTOMA RESECTION
2284,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE causes GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2285,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE causes GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2286,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY causes LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2287,no_relation,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2288,no_relation,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2289,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE causes GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2290,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE causes GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,causes,0.847998304005088,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE acetate therapy in four cases.,GONADOTROPHIN INDEPENDENT FAMILIAL SEXUAL PRECOCITY,LUTEINIZING HORMONE RELEASING FACTOR AGONIST AND MEDROXYPROGESTERONE
2291,no_relation,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2292,no_relation,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2293,no_relation,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2294,PREGNANCY causes CALCITRIOL,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2295,no_relation,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2296,no_relation,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2297,no_relation,causes,0.452267016866645,"b ,    e  Specific Populations  PREGNANCY  Category C.  b ,   c ,   d ,   e  Lactation  CALCITRIOL may be distributed into human milk.",PREGNANCY,CALCITRIOL
2298,L MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2299,L MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2300,L MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2301,LISTERIA INFECTIONS causes L MONOCYTOGENES,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2302,no_relation,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2303,no_relation,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2304,L MONOCYTOGENES causes LISTERIA INFECTIONS,causes,0.9878291611472622,"LISTERIA INFECTIONS  Treatment of infections caused by  L MONOCYTOGENES  (e.g., infections during pregnancy, granulomatosis infantiseptica, sepsis, meningitis, endocarditis, foodborne infections.",LISTERIA INFECTIONS,L MONOCYTOGENES
2305,no_relation,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2306,no_relation,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2307,ANTICOAGULANTS (HEPARIN WARFARIN causes GI BLEEDING,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2308,ANTICOAGULANTS (HEPARIN WARFARIN causes GI BLEEDING,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2309,ANTICOAGULANTS (HEPARIN WARFARIN causes GI BLEEDING,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2310,GI BLEEDING causes ANTICOAGULANTS (HEPARIN WARFARIN,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2311,no_relation,causes,0.4472135954999579,"Drugs associated with GI BLEEDING include ANTICOAGULANTS (HEPARIN WARFARIN those affecting platelet function (eg, aspirin and certain other NSAIDs, clopidogrel, SSRIs), and those affecting mucosal defenses (eg, NSAIDs.",GI BLEEDING,ANTICOAGULANTS (HEPARIN WARFARIN
2312,TRIGEMINAL NEURALGIA causes PAIN,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2313,TRIGEMINAL NEURALGIA causes PAIN,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2314,TRIGEMINAL NEURALGIA causes PAIN,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2315,no_relation,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2316,TRIGEMINAL NEURALGIA causes PAIN,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2317,TRIGEMINAL NEURALGIA causes PAIN,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2318,TRIGEMINAL NEURALGIA causes PAIN,causes,0.9761870601839532,"Rationale: • TRIGEMINAL NEURALGIA is unpredictable, and expected attacks of PAIN are possible at any time.",PAIN,TRIGEMINAL NEURALGIA
2319,PMR causes PAIN,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2320,PMR causes PAIN,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2321,PMR causes PAIN,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2322,PMR causes PAIN,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2323,no_relation,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2324,no_relation,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2325,PAIN causes PMR,causes,0.995893206467704,"PMR is differentiated from polymyositis by normal muscle enzymes, electromyography, and muscle biopsy and by the prominence of PAIN over weakness.",PAIN,PMR
2326,MYOCLONUS causes CJD,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2327,no_relation,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2328,CJD causes MYOCLONUS,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2329,no_relation,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2330,no_relation,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2331,no_relation,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2332,CJD causes MYOCLONUS,causes,0.848528137423857,"MYOCLONUS (a jerky reaction, particularly prominent after a startle) is an important physical finding, but its absence does not rule out CJD",MYOCLONUS,CJD
2333,DKC causes CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2334,no_relation,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2335,DKC causes CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2336,CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE causes DKC,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2337,no_relation,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2338,no_relation,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2339,DKC causes CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,causes,0.9901475429766742,"Characteristics  DKC can be characterized by CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE nails, leukoplakia of the oral mucosa, continuous lacrimation due to atresia of the lacrimal ducts, often thrombocytopenia, anemia, testicular atrophy in the male carriers, and predisposition to cancer.",CUTANEOUS PIGMENTATION PREMATURE GRAYING DYSTROPHY OF THE,DKC
2340,LAURENCE MOON SYNDROME causes MENTAL RETARDATION,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2341,LAURENCE MOON SYNDROME causes MENTAL RETARDATION,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2342,LAURENCE MOON SYNDROME causes MENTAL RETARDATION,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2343,LAURENCE MOON SYNDROME causes MENTAL RETARDATION,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2344,LAURENCE MOON SYNDROME causes MENTAL RETARDATION,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2345,no_relation,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2346,no_relation,causes,0.939793423488437,"LAURENCE MOON SYNDROME  is characterized by obesity, MENTAL RETARDATION retinitis pigmentosa, and polydactyly.",MENTAL RETARDATION,LAURENCE MOON SYNDROME
2347,NEISSERIA MENINGITIDIS causes MENINGOCOCCAL INFECTION,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2348,NEISSERIA MENINGITIDIS causes MENINGOCOCCAL INFECTION,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2349,NEISSERIA MENINGITIDIS causes MENINGOCOCCAL INFECTION,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2350,NEISSERIA MENINGITIDIS causes MENINGOCOCCAL INFECTION,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2351,NEISSERIA MENINGITIDIS causes MENINGOCOCCAL INFECTION,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2352,MENINGOCOCCAL INFECTION causes NEISSERIA MENINGITIDIS,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2353,MENINGOCOCCAL INFECTION causes NEISSERIA MENINGITIDIS,causes,1.0,"1 ,   4 ,   106 ,   108  MENINGOCOCCAL INFECTION is an acute, life threatening illness caused by  NEISSERIA MENINGITIDIS  and is transmitted person to person by the respiratory route.",MENINGOCOCCAL INFECTION,NEISSERIA MENINGITIDIS
2354,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2355,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2356,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2357,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2358,LYMPHADENOPATHY causes INFECTIOUS MONONUCLEOSIS,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2359,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2360,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,1.0,"Painless LYMPHADENOPATHY can also result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2361,ENDOMETRIOSIS causes PAIN,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2362,PAIN causes ENDOMETRIOSIS,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2363,ENDOMETRIOSIS causes PAIN,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2364,no_relation,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2365,ENDOMETRIOSIS causes PAIN,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2366,ENDOMETRIOSIS causes PAIN,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2367,ENDOMETRIOSIS causes PAIN,causes,0.34188172937891403,7.4 Consider the LNG IUS to reduce PAIN associated with ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS
2368,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2369,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2370,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2371,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2372,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2373,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2374,PLASMODIUM FALCIPARUM causes MALARIA,causes,0.99654575824488,MALARIA caused by  PLASMODIUM FALCIPARUM.,MALARIA,PLASMODIUM FALCIPARUM
2375,DRUG causes OVERDOSE,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2376,DRUG causes OVERDOSE,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2377,DRUG causes OVERDOSE,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2378,DRUG causes OVERDOSE,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2379,OVERDOSE causes DRUG,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2380,DRUG causes OVERDOSE,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2381,DRUG causes OVERDOSE,causes,0.975900072948533,"OVERDOSE can result from inhalation, injection, or absorption of the DRUG from the gastrointestinal tract ('body packing')",OVERDOSE,DRUG
2382,FM causes PAIN,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2383,FM causes PAIN,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2384,FM causes PAIN,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2385,FM causes PAIN,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2386,no_relation,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2387,FM causes PAIN,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2388,FM causes PAIN,causes,0.9237604307034007,"25   At a clinical level, however, individuals who attribute their FM to trauma have more perceived disability, self reported PAIN life interference, and affective distress than patients with idiopathic onset.",PAIN,FM
2389,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2390,no_relation,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2391,PAPILLEDEMA causes INCREASED INTRACRANIAL PRESSURE,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2392,no_relation,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2393,no_relation,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2394,PAPILLEDEMA causes INCREASED INTRACRANIAL PRESSURE,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2395,no_relation,causes,0.9918365981341758,"PAPILLEDEMA indicates INCREASED INTRACRANIAL PRESSURE which may be due to idiopathic intracranial hypertension, accelerated hypertension, a mass lesion, or sagittal sinus thrombosis.",PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
2396,IOSCA causes ATAXIA,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2397,no_relation,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2398,IOSCA causes ATAXIA,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2399,no_relation,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2400,ATAXIA causes IOSCA,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2401,IOSCA causes ATAXIA,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2402,IOSCA causes ATAXIA,causes,0.9237604307034007,"Children with IOSCA present with ATAXIA peripheral neuropathy, areflexia, athetosis, and Babinski signs early in the first decade of life.",ATAXIA,IOSCA
2403,no_relation,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2404,ONCHOCERCIASIS causes ONCHOCERCA VOLVULUS,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2405,ONCHOCERCIASIS causes ONCHOCERCA VOLVULUS,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2406,no_relation,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2407,no_relation,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2408,ONCHOCERCIASIS causes ONCHOCERCA VOLVULUS,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2409,no_relation,causes,0.95257934441568,ONCHOCERCIASIS  (River Blindness)  ONCHOCERCIASIS is infection with the filarial nematode  ONCHOCERCA VOLVULUS,ONCHOCERCIASIS,ONCHOCERCA VOLVULUS
2410,DRUGS causes OVERDOSE,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2411,DRUGS causes OVERDOSE,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2412,no_relation,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2413,DRUGS causes OVERDOSE,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2414,DRUGS causes OVERDOSE,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2415,DRUGS causes OVERDOSE,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2416,DRUGS causes OVERDOSE,causes,0.971285862357264,"Although effective, these DRUGS are now rarely used because OVERDOSE causes toxicity and they have more adverse effects.",OVERDOSE,DRUGS
2417,SEVERE HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2418,PHEOCHROMOCYTOMA causes SEVERE HYPERTENSION,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2419,SEVERE HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2420,SEVERE HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2421,SEVERE HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2422,SEVERE HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2423,PHEOCHROMOCYTOMA causes SEVERE HYPERTENSION,causes,0.99124070716193,"HYPERTENSION  Although mild or moderate hypertension does not usually cause headache, SEVERE HYPERTENSION from the following conditions can cause headache: acute pressor response to exogenous agents, PHEOCHROMOCYTOMA malignant hypertension, and preeclampsia and eclampsia.",SEVERE HYPERTENSION,PHEOCHROMOCYTOMA
2424,BACTERIUM causes BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2425,BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS causes BACTERIUM,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2426,BACTERIUM causes BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2427,BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS causes BACTERIUM,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2428,BACTERIUM causes BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2429,BACTERIUM causes BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2430,BACTERIUM causes BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,causes,1.0,"Among young children, up to 50% of BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS cases may be caused by this BACTERIUM",BACTERIOLOGICALLY PROVEN SEPTIC ARTHRITIS,BACTERIUM
2431,MEDICATION causes TOLERANCE,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2432,no_relation,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2433,MEDICATION causes TOLERANCE,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2434,MEDICATION causes TOLERANCE,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2435,MEDICATION causes TOLERANCE,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2436,MEDICATION causes TOLERANCE,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2437,MEDICATION causes TOLERANCE,causes,0.9494253265550828,He usually took the MEDICATION within the prescribed limits but developed rapid TOLERANCE and found himself taking 'a few more here and there',TOLERANCE,MEDICATION
2438,no_relation,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2439,FIBROMYALGIA causes PAIN,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2440,no_relation,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2441,FIBROMYALGIA causes PAIN,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2442,no_relation,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2443,no_relation,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2444,FIBROMYALGIA causes PAIN,causes,0.9113223768657672,"MAIN RESULTS  Pregabalin, ≥ 300 mg/d, reduced pain in patients with postherpetic neuralgia, PAINful diabetic neuropathy, and FIBROMYALGIA; 600 mg/d reduced pain in patients with central neuropathic pain (Table.",PAIN,FIBROMYALGIA
2445,no_relation,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2446,GILBERT SYNDROME causes NORMAL LIVER FUNCTION TEST,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2447,no_relation,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2448,GILBERT SYNDROME causes NORMAL LIVER FUNCTION TEST,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2449,no_relation,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2450,GILBERT SYNDROME causes NORMAL LIVER FUNCTION TEST,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2451,no_relation,causes,0.375,"GILBERT SYNDROME is differentiated from hepatitis by fractionation that shows predominantly unconjugated bilirubin, otherwise NORMAL LIVER FUNCTION TEST results, and absence of urinary bilirubin.",NORMAL LIVER FUNCTION TEST,GILBERT SYNDROME
2452,no_relation,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2453,HEMOLYSIS causes HEMOLYTIC ANEMIA,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2454,HEMOLYTIC ANEMIA causes HEMOLYSIS,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2455,no_relation,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2456,no_relation,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2457,no_relation,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2458,no_relation,causes,0.312347523777212,"In all of these pathway defects, HEMOLYTIC ANEMIA occurs only in homozygotes, and the exact mechanism of HEMOLYSIS is unknown.",HEMOLYSIS,HEMOLYTIC ANEMIA
2459,no_relation,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2460,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2461,no_relation,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2462,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2463,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2464,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2465,HYPERTENSION causes PHEOCHROMOCYTOMA,causes,0.964763821237732,"In elderly patients, severe weight loss with persistent HYPERTENSION is suggestive of PHEOCHROMOCYTOMA",HYPERTENSION,PHEOCHROMOCYTOMA
2466,no_relation,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2467,AL AMYLOIDOSIS OF THE LIVER causes HEPATOMEGALY,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2468,HEPATOMEGALY causes AL AMYLOIDOSIS OF THE LIVER,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2469,HEPATOMEGALY causes AL AMYLOIDOSIS OF THE LIVER,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2470,no_relation,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2471,no_relation,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2472,no_relation,causes,0.986393923832143,Nuclear Liver Spleen Scan  Nuclear liver spleen scan showing marked HEPATOMEGALY in a patient with AL AMYLOIDOSIS OF THE LIVER and spleen.,HEPATOMEGALY,AL AMYLOIDOSIS OF THE LIVER
2473,no_relation,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2474,no_relation,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2475,no_relation,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2476,IMMOTILE CILIA SYNDROME causes BRONCHIECTASIS,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2477,no_relation,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2478,no_relation,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2479,no_relation,causes,0.606339062590832,"Thus, the term IMMOTILE CILIA SYNDROME was coined to include all patients with chronic sinusitis and BRONCHIECTASIS resulting from ultrastructural abnormalities of cilia.",BRONCHIECTASIS,IMMOTILE CILIA SYNDROME
2480,no_relation,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2481,GORLIN SYNDROME causes METASTATIC BASAL CELL CARCINOMA,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2482,GORLIN SYNDROME causes METASTATIC BASAL CELL CARCINOMA,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2483,no_relation,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2484,GORLIN SYNDROME causes METASTATIC BASAL CELL CARCINOMA,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2485,no_relation,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2486,no_relation,causes,0.938314863256836,METASTATIC BASAL CELL CARCINOMA to the bone in GORLIN SYNDROME,METASTATIC BASAL CELL CARCINOMA,GORLIN SYNDROME
2487,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2488,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2489,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2490,no_relation,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2491,TRICHURIS TRICHIURA causes TRICHURIASIS,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2492,no_relation,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2493,no_relation,causes,0.938314863256836,TRICHURIASIS  (Whipworm Infection; Trichocephaliasis)  TRICHURIASIS is infection with  TRICHURIS TRICHIURA,TRICHURIASIS,TRICHURIS TRICHIURA
2494,HYPOPHOSPHATEMIA causes FANCONI SYNDROME,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2495,no_relation,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2496,no_relation,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2497,FANCONI SYNDROME causes HYPOPHOSPHATEMIA,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2498,no_relation,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2499,FANCONI SYNDROME causes HYPOPHOSPHATEMIA,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2500,FANCONI SYNDROME causes HYPOPHOSPHATEMIA,causes,0.787838597158335,"In acquired FANCONI SYNDROME adults present with the laboratory abnormalities of renal tubular acidosis (proximal type II), HYPOPHOSPHATEMIA and hypokalemia.",HYPOPHOSPHATEMIA,FANCONI SYNDROME
2501,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2502,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2503,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2504,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2505,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2506,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2507,no_relation,causes,0.768221279597376,"Aortic valve stenosis, PREGNANCY obesity, and the use of certain drugs (e.g., COCAINE amphetamines, steroids, or erythropoietin) also may lead to hypertension.",PREGNANCY,COCAINE
2508,no_relation,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2509,BIRT HOGG DUBE SYNDROME causes PNEUMOTHORAX,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2510,PNEUMOTHORAX causes BIRT HOGG DUBE SYNDROME,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2511,BIRT HOGG DUBE SYNDROME causes PNEUMOTHORAX,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2512,BIRT HOGG DUBE SYNDROME causes PNEUMOTHORAX,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2513,BIRT HOGG DUBE SYNDROME causes PNEUMOTHORAX,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2514,PNEUMOTHORAX causes BIRT HOGG DUBE SYNDROME,causes,0.9760921603577252,"14  BIRT HOGG DUBE SYNDROME  BIRT HOGG DUBE SYNDROME (BHDS) is an autosomal dominant multisystem disorder characterized by the cutaneous triad of fibrofolliculomas, trichodiscomas, and acrochordons; the development of spontaneous PNEUMOTHORAX in association with lung cysts; and a predisposition to renal neoplasms.",PNEUMOTHORAX,BIRT HOGG DUBE SYNDROME
2515,DUBIN JOHNSON SYNDROME causes CONJUGATED HYPERBILIRUBINEMIA,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2516,no_relation,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2517,DUBIN JOHNSON SYNDROME causes CONJUGATED HYPERBILIRUBINEMIA,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2518,DUBIN JOHNSON SYNDROME causes CONJUGATED HYPERBILIRUBINEMIA,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2519,DUBIN JOHNSON SYNDROME causes CONJUGATED HYPERBILIRUBINEMIA,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2520,DUBIN JOHNSON SYNDROME causes CONJUGATED HYPERBILIRUBINEMIA,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2521,DUBIN JOHNSON SYNDROME causes CONJUGATED HYPERBILIRUBINEMIA,causes,0.995893206467704,CONJUGATED HYPERBILIRUBINEMIA due to impaired excretion can result from DUBIN JOHNSON SYNDROME,CONJUGATED HYPERBILIRUBINEMIA,DUBIN JOHNSON SYNDROME
2522,no_relation,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2523,WERNICKE ENCEPHALOPATHY causes FLUCTUATING CONFUSIONAL STATES,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2524,WERNICKE ENCEPHALOPATHY causes FLUCTUATING CONFUSIONAL STATES,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2525,FLUCTUATING CONFUSIONAL STATES causes WERNICKE ENCEPHALOPATHY,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2526,no_relation,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2527,no_relation,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2528,no_relation,causes,0.8908708063747479,"Thiamine (vitamin B 1 ) deficiency is responsible for the hallmark features of WERNICKE ENCEPHALOPATHY which include ophthalmoplegia (i.e., nystagmus, extraocular palsies, gaze palsies, and, in rare cases, internuclear ophthalmoplegia), gait ataxia, and FLUCTUATING CONFUSIONAL STATES",FLUCTUATING CONFUSIONAL STATES,WERNICKE ENCEPHALOPATHY
2529,no_relation,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2530,FAMILIAL ADENOMATOUS POLYPOSIS causes PAPILLARY THYROID CANCER,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2531,FAMILIAL ADENOMATOUS POLYPOSIS causes PAPILLARY THYROID CANCER,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2532,FAMILIAL ADENOMATOUS POLYPOSIS causes PAPILLARY THYROID CANCER,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2533,FAMILIAL ADENOMATOUS POLYPOSIS causes PAPILLARY THYROID CANCER,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2534,PAPILLARY THYROID CANCER causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2535,no_relation,causes,0.441726104299386,"• PAPILLARY THYROID CANCER occurs in approximately 2% of patients with FAMILIAL ADENOMATOUS POLYPOSIS most often in female carriers, who manifest the disease at about age 28.",PAPILLARY THYROID CANCER,FAMILIAL ADENOMATOUS POLYPOSIS
2536,ACUTE PORPHYRIA causes FLACCID PARALYSIS,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2537,FLACCID PARALYSIS causes ACUTE PORPHYRIA,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2538,ACUTE PORPHYRIA causes FLACCID PARALYSIS,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2539,FLACCID PARALYSIS causes ACUTE PORPHYRIA,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2540,no_relation,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2541,no_relation,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2542,no_relation,causes,0.975900072948533,porphyric p.     Polyneuropathy resulting from ACUTE PORPHYRIA characterized by pains and paresthesias in the extremities and by FLACCID PARALYSIS,FLACCID PARALYSIS,ACUTE PORPHYRIA
2543,BACTERIA causes BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2544,BACTERIA causes BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2545,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS causes BACTERIA,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2546,BACTERIA causes BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2547,BACTERIA causes BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2548,BACTERIA causes BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2549,BACTERIA causes BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,causes,0.855186110494136,Causes [edit] Infectious parotitis  Acute bacterial parotitis: is most often caused by a BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS but may be caused by any commensal BACTERIA[1]  Parotitis as Extrapulmonary Tuberculosis: The mycobacterium that cause tuberculosis can also cause parotid infection.,BACTERIAL INFECTION OF STAPHYLOCOCCUS AUREUS,BACTERIA
2550,no_relation,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2551,PNEUMONIA causes LUNG,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2552,LUNG causes PNEUMONIA,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2553,no_relation,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2554,no_relation,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2555,LUNG causes PNEUMONIA,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2556,LUNG causes PNEUMONIA,causes,0.471404520791032,• Other causes of lung abscess do not result from aspiration of oral anaerobic bacteria and are not preventable except by decreasing the risk for PNEUMONIA by immunizations or by quickly treating extrapulmonary sites of infections that can seed the LUNG,LUNG,PNEUMONIA
2557,no_relation,causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2558,SYSTEM ATROPHY (MSA) causes DEMENTIA ASSOCIATED WITH PARKINSONISM,causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2559,DEMENTIA ASSOCIATED WITH PARKINSONISM causes SYSTEM ATROPHY (MSA),causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2560,DEMENTIA ASSOCIATED WITH PARKINSONISM causes SYSTEM ATROPHY (MSA),causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2561,no_relation,causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2562,no_relation,causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2563,no_relation,causes,0.481543412343077,"Other parkinsonian syndromes include progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), multiple SYSTEM ATROPHY (MSA) vascular parkinsonism, normal pressure hydrocephalus (NPH), drug induced parkinsonism (DIP), and DEMENTIA ASSOCIATED WITH PARKINSONISM",DEMENTIA ASSOCIATED WITH PARKINSONISM,SYSTEM ATROPHY (MSA)
2564,SECRETION (PHEOCHROMOCYTOMAS) causes HYPERTENSION,causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2565,no_relation,causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2566,SECRETION (PHEOCHROMOCYTOMAS) causes HYPERTENSION,causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2567,SECRETION (PHEOCHROMOCYTOMAS) causes HYPERTENSION,causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2568,HYPERTENSION causes SECRETION (PHEOCHROMOCYTOMAS),causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2569,SECRETION (PHEOCHROMOCYTOMAS) causes HYPERTENSION,causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2570,SECRETION (PHEOCHROMOCYTOMAS) causes HYPERTENSION,causes,0.9931270663228408,HYPERTENSION may result from abnormal epinephrine and norepinephrine SECRETION (PHEOCHROMOCYTOMAS) or from cortisol excess (ACTH secreting tumors.,HYPERTENSION,SECRETION (PHEOCHROMOCYTOMAS)
2571,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2572,no_relation,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2573,no_relation,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2574,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2575,no_relation,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2576,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2577,DIABETES MELLITUS causes DIABETIC KETOACIDOSIS,causes,0.9494253265550828,"185  Hyperglycemic Effects  Hyperglycemia, new onset DIABETES MELLITUS or exacerbation of preexisting diabetes mellitus reported with use of HIV protease inhibitors (PIs); DIABETIC KETOACIDOSIS has occurred.",DIABETIC KETOACIDOSIS,DIABETES MELLITUS
2578,HERPES ZOSTER causes CYTOMEGALOVIRUS [CMV] INFECTIONS,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2579,no_relation,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2580,no_relation,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2581,no_relation,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2582,no_relation,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2583,no_relation,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2584,no_relation,causes,0.40824829046386296,"1   Viral infections (e.g., CYTOMEGALOVIRUS [CMV] INFECTIONS herpes simplex, HERPES ZOSTER reported more frequently in cardiac transplant recipients receiving mycophenolate than in those receiving azathioprine.",CYTOMEGALOVIRUS [CMV] INFECTIONS,HERPES ZOSTER
2585,FEBRILE SEIZURES causes EPILEPSY,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2586,FEBRILE SEIZURES causes EPILEPSY,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2587,EPILEPSY causes FEBRILE SEIZURES,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2588,no_relation,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2589,no_relation,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2590,no_relation,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2591,FEBRILE SEIZURES causes EPILEPSY,causes,0.889000889001333,Predictors of EPILEPSY in children who have experienced FEBRILE SEIZURES,FEBRILE SEIZURES,EPILEPSY
2592,TRICHOSTRONGYLIASIS causes TRICHOSTRONGYLUS,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2593,TRICHOSTRONGYLIASIS causes TRICHOSTRONGYLUS,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2594,no_relation,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2595,TRICHOSTRONGYLUS causes TRICHOSTRONGYLIASIS,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2596,TRICHOSTRONGYLUS causes TRICHOSTRONGYLIASIS,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2597,TRICHOSTRONGYLUS causes TRICHOSTRONGYLIASIS,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2598,TRICHOSTRONGYLUS causes TRICHOSTRONGYLIASIS,causes,0.8944271909999159,13  Trichostrongyliasis  Treatment of TRICHOSTRONGYLIASIS   +    caused by  TRICHOSTRONGYLUS,TRICHOSTRONGYLIASIS,TRICHOSTRONGYLUS
2599,HIT WITH THROMBOSIS causes THROMBOCYTOPENIA,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2600,THROMBOCYTOPENIA causes HIT WITH THROMBOSIS,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2601,no_relation,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2602,no_relation,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2603,HIT WITH THROMBOSIS causes THROMBOCYTOPENIA,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2604,HIT WITH THROMBOSIS causes THROMBOCYTOPENIA,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2605,no_relation,causes,0.9045340337332908,471   Evaluate patients who develop THROMBOCYTOPENIA or thrombosis after treatment discontinuance for HIT and HIT WITH THROMBOSIS.,THROMBOCYTOPENIA,HIT WITH THROMBOSIS
2606,ENDOMETRIOSIS causes PAIN,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2607,ENDOMETRIOSIS causes PAIN,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2608,ENDOMETRIOSIS causes PAIN,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2609,no_relation,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2610,no_relation,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2611,no_relation,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2612,ENDOMETRIOSIS causes PAIN,causes,0.975900072948533,C]  Specific recommendation: • Encourage patients to differentiate the pain of ENDOMETRIOSIS from other types of PAIN and its relation to their menstrual cycle and intercourse and to keep a diary of their symptoms.,PAIN,ENDOMETRIOSIS
2613,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2614,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2615,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2616,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2617,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2618,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2619,JC VIRUS causes PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,causes,0.997054485501582,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY and other disorders caused by JC VIRUS: clinical features and pathogenesis.,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS
2620,no_relation,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2621,no_relation,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2622,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2623,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2624,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2625,ANESTHETIC AGENTS causes MALIGNANT HYPERTHERMIA,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2626,no_relation,causes,0.7548294124240691,"If MALIGNANT HYPERTHERMIA occurs, discontinue all ANESTHETIC AGENTS and initiate IV dantrolene therapy  a   in conjunction with supportive measures (e.g., administering oxygen, treating metabolic acidosis, instituting cooling procedures); maintain urinary output and monitor serum electrolytes.",MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
2627,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2628,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2629,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2630,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2631,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2632,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2633,INFECTIOUS MONONUCLEOSIS causes LYMPHADENOPATHY,causes,0.994134846772434,"Similar LYMPHADENOPATHY can result from INFECTIOUS MONONUCLEOSIS toxoplasmosis, cytomegalovirus, non Hodgkin lymphoma, or leukemia.",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
2634,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELERS' DIARRHEA,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2635,TRAVELERS' DIARRHEA causes ENTEROTOXIGENIC  ESCHERICHIA COLI,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2636,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELERS' DIARRHEA,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2637,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELERS' DIARRHEA,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2638,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELERS' DIARRHEA,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2639,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELERS' DIARRHEA,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2640,ENTEROTOXIGENIC  ESCHERICHIA COLI causes TRAVELERS' DIARRHEA,causes,0.936382183834624,"302 ,   321  Data are limited regarding safety of repeated use of co trimoxazole in pediatric patients   186 ,   a  GI Infections  Treatment of TRAVELERS' DIARRHEA caused by susceptible ENTEROTOXIGENIC  ESCHERICHIA COLI",TRAVELERS' DIARRHEA,ENTEROTOXIGENIC  ESCHERICHIA COLI
2641,no_relation,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2642,NEUROPATHIC PAIN causes FM,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2643,FM causes NEUROPATHIC PAIN,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2644,no_relation,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2645,FM causes NEUROPATHIC PAIN,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2646,no_relation,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2647,no_relation,causes,0.9918365981341758,"In inflammatory pain attributable to synovitis or bursitis, NEUROPATHIC PAIN caused by direct nerve injury, and the central pain augmentation of FM and other CSSs, pain amplification is associated with lower pain threshold.",NEUROPATHIC PAIN,FM
2648,no_relation,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2649,EMPHYSEMA causes LUNG,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2650,EMPHYSEMA causes LUNG,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2651,no_relation,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2652,no_relation,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2653,no_relation,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2654,no_relation,causes,0.363803437554499,"Conditions that affect the LUNG diffusely, such as EMPHYSEMA and pulmonary fibrosis, decrease both DLCO and alveolar ventilation (V A.",LUNG,EMPHYSEMA
2655,TRIGEMINAL NEURALGIA causes PAIN,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2656,TRIGEMINAL NEURALGIA causes PAIN,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2657,TRIGEMINAL NEURALGIA causes PAIN,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2658,TRIGEMINAL NEURALGIA causes PAIN,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2659,no_relation,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2660,no_relation,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2661,no_relation,causes,0.801783725737273,"Intermittent unilateral facial numbness or PAIN (resembling TRIGEMINAL NEURALGIA palsy, or spasm may occur.",PAIN,TRIGEMINAL NEURALGIA
2662,ECLAMPSIA causes GENERALIZED SEIZURES,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2663,ECLAMPSIA causes GENERALIZED SEIZURES,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2664,ECLAMPSIA causes GENERALIZED SEIZURES,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2665,GENERALIZED SEIZURES causes ECLAMPSIA,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2666,no_relation,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2667,no_relation,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2668,ECLAMPSIA causes GENERALIZED SEIZURES,causes,0.964901281354015,• ECLAMPSIA defined by GENERALIZED SEIZURES may first occur following delivery simulating TTP ( 71.,GENERALIZED SEIZURES,ECLAMPSIA
2669,BWS[ causes NEONATAL HYPOGLYCEMIA,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2670,BWS[ causes NEONATAL HYPOGLYCEMIA,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2671,BWS[ causes NEONATAL HYPOGLYCEMIA,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2672,BWS[ causes NEONATAL HYPOGLYCEMIA,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2673,BWS[ causes NEONATAL HYPOGLYCEMIA,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2674,no_relation,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2675,BWS[ causes NEONATAL HYPOGLYCEMIA,causes,0.847998304005088,"NEONATAL HYPOGLYCEMIA low blood glucose in the first month of life, occurs in about half of children with BWS[9] Most of these hypoglycemic newborns are asymptomatic and have a normal blood glucose level within days.",NEONATAL HYPOGLYCEMIA,BWS[
2676,no_relation,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2677,RUBELLA VIRUS causes CONGENITAL INFECTIONS,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2678,RUBELLA VIRUS causes CONGENITAL INFECTIONS,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2679,RUBELLA VIRUS causes CONGENITAL INFECTIONS,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2680,CONGENITAL INFECTIONS causes RUBELLA VIRUS,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2681,no_relation,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2682,RUBELLA VIRUS causes CONGENITAL INFECTIONS,causes,0.913811548620257,"CONGENITAL INFECTIONS that can cause MR include RUBELLA VIRUS cytomegalovirus,  Toxoplasma gondii ,  Treponema pallidum , and HIV.",CONGENITAL INFECTIONS,RUBELLA VIRUS
2683,PROCAINAMIDE causes SYSTEMIC LUPUS ERYTHEMATOSUS,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2684,no_relation,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2685,no_relation,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2686,no_relation,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2687,PROCAINAMIDE causes SYSTEMIC LUPUS ERYTHEMATOSUS,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2688,no_relation,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2689,no_relation,causes,0.50709255283711,"ETIOLOGY: Many diseases and conditions can inflame the membranous covering of the heart, including infections (bacterial, tubercular, viral, fungal); collagen vascular diseases (e.g., rheumatic fever, rheumatoid arthritis, or SYSTEMIC LUPUS ERYTHEMATOSUS; drugs (hydralazine, PROCAINAMIDE isoniazid, minoxidil); myocardial infarction; cancer; renal failure; cardiac surgery; or trauma.",SYSTEMIC LUPUS ERYTHEMATOSUS,PROCAINAMIDE
2690,no_relation,causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2691,COMMON COLD causes RESPIRATORY SYNCYTIAL VIRUS [RSV],causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2692,no_relation,causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2693,COMMON COLD causes RESPIRATORY SYNCYTIAL VIRUS [RSV],causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2694,no_relation,causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2695,RESPIRATORY SYNCYTIAL VIRUS [RSV] causes COMMON COLD,causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2696,no_relation,causes,0.8090398349558909,"Although specific pathogens commonly produce characteristic clinical manifestations (eg, rhinovirus and the COMMON COLD or RESPIRATORY SYNCYTIAL VIRUS [RSV] and bronchiolitis), each is capable of causing any of the viral respiratory syndromes.",COMMON COLD,RESPIRATORY SYNCYTIAL VIRUS [RSV]
2697,URINARY TRACT FIBROSIS causes URINARY TRACT INFECTIONS,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2698,URINARY TRACT FIBROSIS causes URINARY TRACT INFECTIONS,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2699,no_relation,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2700,URINARY TRACT FIBROSIS causes URINARY TRACT INFECTIONS,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2701,URINARY TRACT FIBROSIS causes URINARY TRACT INFECTIONS,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2702,no_relation,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2703,URINARY TRACT FIBROSIS causes URINARY TRACT INFECTIONS,causes,0.964901281354015,"◊ Reproductive assistance for infertility in women ◊ Dialysis for renal failure  Rationale: • Immune mediated inflammatory granulomas leading to widespread fibrosis of affected organs can cause complications such as portal hypertension and URINARY TRACT FIBROSIS which, in turn, can progress to varix formation, ascites, pedal edema, splenomegaly, hydronephrosis, repeated URINARY TRACT INFECTIONS and liver and renal failure.",URINARY TRACT FIBROSIS,URINARY TRACT INFECTIONS
2704,no_relation,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2705,no_relation,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2706,AGE RELATED MACULAR DEGENERATION causes RETINA,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2707,no_relation,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2708,no_relation,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2709,AGE RELATED MACULAR DEGENERATION causes RETINA,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2710,no_relation,causes,0.493196961916072,"retinotomy    (                  audio )  Surgical incision of the RETINA e.g., to remove proliferating blood vessels in AGE RELATED MACULAR DEGENERATION",RETINA,AGE RELATED MACULAR DEGENERATION
2711,no_relation,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2712,no_relation,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2713,no_relation,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2714,no_relation,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2715,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS causes LEUKOENCEPHALOPATHY,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2716,no_relation,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2717,no_relation,causes,0.412081691846067,"These disorders include inflammatory arteriopathies such as collagen vascular diseases, Takayasu disease, and neurovascular syphilis, as well as noninflammatory arteriopathies such as arterial dissection, fibromuscular dysplasia, moyamoya disease, CADASIL (CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS) and LEUKOENCEPHALOPATHY radiation vasculopathy, and vasospasm after SAH.",LEUKOENCEPHALOPATHY,CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS
2718,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2719,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2720,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2721,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2722,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2723,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2724,AVIRULENT BACTERIA causes SBE,causes,0.99654575824488,SBE is usually caused by relatively AVIRULENT BACTERIA the most common species being streptococci from the normal oral or gastrointestinal (GI) flora.,SBE,AVIRULENT BACTERIA
2725,no_relation,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2726,AIN IS causes RIGEMINAL NEURALGIA T,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2727,AIN IS causes RIGEMINAL NEURALGIA T,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2728,RIGEMINAL NEURALGIA T causes AIN IS,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2729,no_relation,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2730,RIGEMINAL NEURALGIA T causes AIN IS,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2731,RIGEMINAL NEURALGIA T causes AIN IS,causes,0.964901281354015,"Rationale:  It is characteristic for tRIGEMINAL NEURALGIA To have periods of weeks, months, or even years during which there is no pain and then varying intervals where pAIN IS frequent.",AIN IS,RIGEMINAL NEURALGIA T
2732,SALMONELLA TYPHI causes TYPHOID FEVER,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2733,SALMONELLA TYPHI causes TYPHOID FEVER,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2734,SALMONELLA TYPHI causes TYPHOID FEVER,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2735,SALMONELLA TYPHI causes TYPHOID FEVER,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2736,no_relation,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2737,SALMONELLA TYPHI causes TYPHOID FEVER,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2738,SALMONELLA TYPHI causes TYPHOID FEVER,causes,0.98058067569092,Typhoid Fever and other Salmonella Infections  Alternative for treatment of TYPHOID FEVER   +    (enteric fever) caused by susceptible  SALMONELLA TYPHI,TYPHOID FEVER,SALMONELLA TYPHI
2739,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2740,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2741,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2742,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2743,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2744,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2745,B RECURRENTIS causes LOUSE BORNE RELAPSING FEVER,causes,0.997054485501582,EPIDEMIOLOGY  LOUSE BORNE RELAPSING FEVER (LBRF) is caused by infection with  B RECURRENTIS,LOUSE BORNE RELAPSING FEVER,B RECURRENTIS
2746,DIPHENHYDRAMINE causes MOTION SICKNESS,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2747,no_relation,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2748,no_relation,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2749,DIPHENHYDRAMINE causes MOTION SICKNESS,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2750,no_relation,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2751,no_relation,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2752,no_relation,causes,0.4200840252084029,"Infants are at risk for toxicity from drugs used by adults; toxicity can occur prenatally when they are exposed via placental transfer or postnatally through breast milk (numerous agents—see  Drugs  and  Table 266 4 ) or skin contact with caregivers who have recently applied certain topical drugs (eg, scopolamine for MOTION SICKNESS malathion for lice, DIPHENHYDRAMINE for poison ivy.",MOTION SICKNESS,DIPHENHYDRAMINE
2753,no_relation,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2754,no_relation,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2755,MULLIEZ EA causes PERSISTENT HYPERTENSION,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2756,no_relation,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2757,MULLIEZ EA causes PERSISTENT HYPERTENSION,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2758,PERSISTENT HYPERTENSION causes MULLIEZ EA,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2759,PERSISTENT HYPERTENSION causes MULLIEZ EA,causes,0.37210420376762493,"2]  Proye CA, MULLIEZ EA Carnaille BM, Lecomte Houcke M, Decoulx M, Wemeau JL, et al. Essential hypertension: first reason for PERSISTENT HYPERTENSION after unilateral adrenalectomy for primary aldosteronism.",PERSISTENT HYPERTENSION,MULLIEZ EA
2760,no_relation,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2761,no_relation,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2762,no_relation,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2763,NONHEPATITIS VIRUSES causes ACUTE VIRAL HEPATITIS,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2764,no_relation,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2765,no_relation,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2766,no_relation,causes,0.7293249574894731,"Liver infections caused by NONHEPATITIS VIRUSES (eg, Epstein Barr, yellow fever, cytomegalovirus) generally are not termed ACUTE VIRAL HEPATITIS",ACUTE VIRAL HEPATITIS,NONHEPATITIS VIRUSES
2767,VIRAL INFECTIONS causes EPSTEIN BARR VIRUS,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2768,VIRAL INFECTIONS causes EPSTEIN BARR VIRUS,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2769,no_relation,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2770,VIRAL INFECTIONS causes EPSTEIN BARR VIRUS,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2771,EPSTEIN BARR VIRUS causes VIRAL INFECTIONS,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2772,VIRAL INFECTIONS causes EPSTEIN BARR VIRUS,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2773,VIRAL INFECTIONS causes EPSTEIN BARR VIRUS,causes,0.988371697650617,"compromise  Treat VIRAL INFECTIONS that may cause vasculitis (HIV, hepatitis, cytomegalovirus, parvovirus B19, herpes zoster, EPSTEIN BARR VIRUS with antiviral agents, if possible.",VIRAL INFECTIONS,EPSTEIN BARR VIRUS
2774,no_relation,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2775,BENZATHINE PENICILLIN G causes RHEUMATIC FEVER,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2776,no_relation,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2777,no_relation,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2778,BENZATHINE PENICILLIN G causes RHEUMATIC FEVER,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2779,no_relation,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2780,no_relation,causes,0.34874291623145803,Three  versus four week administration of BENZATHINE PENICILLIN G: effects on incidence of streptococcal infections and recurrences of RHEUMATIC FEVER,RHEUMATIC FEVER,BENZATHINE PENICILLIN G
2781,PSEUDOHYPOPARATHYROIDISM causes HYPOCALCEMIA,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2782,no_relation,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2783,PSEUDOHYPOPARATHYROIDISM causes HYPOCALCEMIA,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2784,no_relation,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2785,PSEUDOHYPOPARATHYROIDISM causes HYPOCALCEMIA,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2786,HYPOCALCEMIA causes PSEUDOHYPOPARATHYROIDISM,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2787,PSEUDOHYPOPARATHYROIDISM causes HYPOCALCEMIA,causes,1.0,"PSEUDOHYPOPARATHYROIDISM is caused by inherited PTH resistance, which results in HYPOCALCEMIA and secondary marked elevations of PTH levels.",HYPOCALCEMIA,PSEUDOHYPOPARATHYROIDISM
2788,no_relation,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2789,MEDICATIONS causes TOLERANCE TO H 2,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2790,MEDICATIONS causes TOLERANCE TO H 2,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2791,MEDICATIONS causes TOLERANCE TO H 2,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2792,MEDICATIONS causes TOLERANCE TO H 2,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2793,MEDICATIONS causes TOLERANCE TO H 2,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2794,MEDICATIONS causes TOLERANCE TO H 2,causes,0.923380516876639,"• TOLERANCE TO H 2 RAs may develop relatively quickly in patients taking these MEDICATIONS on a regular basis, limiting their efficacy.",TOLERANCE TO H 2,MEDICATIONS
2795,CENTRAL NERVOUS SYSTEM (CNS causes COMA,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2796,no_relation,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2797,CENTRAL NERVOUS SYSTEM (CNS causes COMA,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2798,CENTRAL NERVOUS SYSTEM (CNS causes COMA,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2799,COMA causes CENTRAL NERVOUS SYSTEM (CNS,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2800,CENTRAL NERVOUS SYSTEM (CNS causes COMA,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2801,no_relation,causes,0.964901281354015,"47  During a later phase, in up to 80% of cases, CENTRAL NERVOUS SYSTEM (CNS manifestations such as delirium that interrupts stupor, COMA and seizures, as well as hearing loss, can occur.",CENTRAL NERVOUS SYSTEM (CNS,COMA
2802,PERNICIOUS ANEMIA causes FOOD COBALAMIN MALABSORPTION,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2803,FOOD COBALAMIN MALABSORPTION causes PERNICIOUS ANEMIA,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2804,FOOD COBALAMIN MALABSORPTION causes PERNICIOUS ANEMIA,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2805,PERNICIOUS ANEMIA causes FOOD COBALAMIN MALABSORPTION,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2806,PERNICIOUS ANEMIA causes FOOD COBALAMIN MALABSORPTION,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2807,FOOD COBALAMIN MALABSORPTION causes PERNICIOUS ANEMIA,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2808,no_relation,causes,0.824957911384306,"Whereas FOOD COBALAMIN MALABSORPTION is common among patients with subclinical deficiency, those with clinical manifestations of cobalamin deficiency are more likely to have PERNICIOUS ANEMIA",PERNICIOUS ANEMIA,FOOD COBALAMIN MALABSORPTION
2809,CLOSTRIDIUM causes CLOSTRIDIUM INFECTIONS,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2810,CLOSTRIDIUM causes CLOSTRIDIUM INFECTIONS,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2811,no_relation,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2812,CLOSTRIDIUM causes CLOSTRIDIUM INFECTIONS,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2813,CLOSTRIDIUM causes CLOSTRIDIUM INFECTIONS,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2814,CLOSTRIDIUM INFECTIONS causes CLOSTRIDIUM,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2815,CLOSTRIDIUM causes CLOSTRIDIUM INFECTIONS,causes,0.913811548620257,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
2816,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2817,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2818,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2819,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2820,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2821,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2822,TAPEWORM LARVAE causes COENUROSIS,causes,1.0,COENUROSIS caused by TAPEWORM LARVAE usually produces grapelike cysts that may obstruct CSF outflow in the 4th ventricle.,COENUROSIS,TAPEWORM LARVAE
2823,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2824,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2825,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2826,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2827,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2828,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2829,no_relation,causes,0.488677777425221,"exanthema , eruption] Any eruption or RASH that appears on the SKIN as opposed to one that appears on the mucous membranes (enanthem.",SKIN,RASH
2830,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2831,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2832,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2833,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2834,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2835,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2836,no_relation,causes,0.640512615220348,"OSTEOARTHRITIS other degenerative changes, trauma or fractures, osteomyelitis, and PAGET'S DISEASE can all result in increased uptake on bone scans.",OSTEOARTHRITIS,PAGET'S DISEASE
2837,CLOSTRIDIA causes EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2838,CLOSTRIDIA causes EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2839,CLOSTRIDIA causes EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2840,CLOSTRIDIA causes EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2841,CLOSTRIDIA causes EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2842,no_relation,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2843,CLOSTRIDIA causes EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,causes,0.929981109950554,"CLOSTRIDIA are often the primary agents in EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS (previously common with septic abortion), certain other female genital tract infections (tubo ovarian, pelvic, and uterine abscesses), and infection after perforation of colon carcinoma.",EMPHYSEMATOUS CHOLECYSTITIS GAS GANGRENE OF THE UTERUS,CLOSTRIDIA
2844,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2845,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2846,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2847,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2848,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2849,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2850,no_relation,causes,0.464990554975277,"• In evaluating women for CUSHING'S SYNDROME vs. polycystic ovary syndrome, 1 MG DEXAMETHASONE SUPPRESSION or midnight cortisol was found to have better discriminatory ability than UFC ( 51.",CUSHING'S SYNDROME,1 MG DEXAMETHASONE SUPPRESSION
2851,PV causes THROMBOSIS,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2852,no_relation,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2853,THROMBOSIS causes PV,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2854,no_relation,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2855,PV causes THROMBOSIS,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2856,no_relation,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2857,no_relation,causes,0.696310623822791,"• Management in PV should be individualized by age, the presence or absence of risk factors for THROMBOSIS and childbearing potential.",THROMBOSIS,PV
2858,BOTULINUM TOXIN causes BOTULISM,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2859,BOTULINUM TOXIN causes BOTULISM,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2860,BOTULISM causes BOTULINUM TOXIN,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2861,BOTULINUM TOXIN causes BOTULISM,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2862,BOTULINUM TOXIN causes BOTULISM,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2863,BOTULINUM TOXIN causes BOTULISM,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2864,BOTULINUM TOXIN causes BOTULISM,causes,1.0,BOTULISM caused by production of BOTULINUM TOXIN in the colon following ingestion of spores of  Clostridium botulinum.,BOTULISM,BOTULINUM TOXIN
2865,RABIES VIRUS causes PARALYTIC RABIES,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2866,no_relation,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2867,RABIES VIRUS causes PARALYTIC RABIES,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2868,RABIES VIRUS causes PARALYTIC RABIES,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2869,PARALYTIC RABIES causes RABIES VIRUS,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2870,no_relation,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2871,RABIES VIRUS causes PARALYTIC RABIES,causes,0.9878291611472622,"2]  Hemachudha T, Wacharapluesadee S, Lumlertdaecha B, Orciari L A, Rupprecht CE, La Ongpant M, et al. Sequence analysis of RABIES VIRUS in humans exhibiting encephalitic or PARALYTIC RABIES",PARALYTIC RABIES,RABIES VIRUS
2872,ESSENTIAL THROMBOCYTHEMIA causes HEMORRHAGE,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2873,ESSENTIAL THROMBOCYTHEMIA causes HEMORRHAGE,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2874,no_relation,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2875,no_relation,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2876,ESSENTIAL THROMBOCYTHEMIA causes HEMORRHAGE,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2877,ESSENTIAL THROMBOCYTHEMIA causes HEMORRHAGE,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2878,no_relation,causes,0.668153104781061,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2879,no_relation,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2880,PUUMALA VIRUS causes HFRS,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2881,PUUMALA VIRUS causes HFRS,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2882,PUUMALA VIRUS causes HFRS,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2883,no_relation,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2884,PUUMALA VIRUS causes HFRS,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2885,HFRS causes PUUMALA VIRUS,causes,0.948683298050514,"Hemorrhagic fever with renal syndrome   Along with Hantaan virus, other hantaviruses causing HFRS are Seoul virus, PUUMALA VIRUS and Dobrava/Belgrade virus.",HFRS,PUUMALA VIRUS
2886,no_relation,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2887,no_relation,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2888,HYPERSENSITIVITY REACTIONS causes STEVENS JOHNSON SYNDROME,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2889,no_relation,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2890,no_relation,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2891,no_relation,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2892,no_relation,causes,0.9045340337332908,"Sensitivity Reactions  HYPERSENSITIVITY REACTIONS  Serious cutaneous reactions, including STEVENS JOHNSON SYNDROME  1 ,   2 ,   93 ,   99   erythema multiforme.",STEVENS JOHNSON SYNDROME,HYPERSENSITIVITY REACTIONS
2893,no_relation,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2894,no_relation,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2895,KERATOUVEITIS causes CORNEA,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2896,no_relation,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2897,no_relation,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2898,no_relation,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2899,no_relation,causes,0.538815906080325,"KERATOUVEITIS    Inflammation of both the cornea and the uveal tract (i.e., of both the CORNEA and the iris, ciliary body, and choroid.",CORNEA,KERATOUVEITIS
2900,no_relation,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2901,no_relation,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2902,no_relation,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2903,no_relation,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2904,no_relation,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2905,no_relation,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2906,ESSENTIAL THROMBOCYTHEMIA causes HEMORRHAGE,causes,0.717137165600636,"In a patient with ESSENTIAL THROMBOCYTHEMIA who has clinically significant HEMORRHAGE or thrombosis, good control of the platelet count can be achieved with oral hydroxyurea (15 mg/kg/day), with adjustments in the dosage as needed to lower the platelet count.",HEMORRHAGE,ESSENTIAL THROMBOCYTHEMIA
2907,no_relation,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2908,TOXIC SHOCK SYNDROME causes TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2909,no_relation,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2910,TOXIC SHOCK SYNDROME causes TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2911,no_relation,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2912,no_relation,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2913,TOXIC SHOCK SYNDROME causes TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS,causes,0.929981109950554,Prevalence of TOXIC SHOCK SYNDROME TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS and the presence of antibodies to this superantigen in menstruating women.,TOXIC SHOCK SYNDROME,TOXIN 1 PRODUCING STAPHYLOCOCCUS AUREUS
2914,VULVODYNIA causes NEUROPATHIC PAIN,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2915,no_relation,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2916,no_relation,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2917,no_relation,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2918,no_relation,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2919,no_relation,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2920,VULVODYNIA causes NEUROPATHIC PAIN,causes,0.4850712500726661,• NEUROPATHIC PAIN can be generalized to the entire vulva (generalized VULVODYNIA and is coupled with a normal physical exam.,NEUROPATHIC PAIN,VULVODYNIA
2921,no_relation,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2922,no_relation,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2923,no_relation,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2924,no_relation,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2925,PREGNANCY causes NICOTINE REPLACEMENT THERAPY,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2926,no_relation,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2927,no_relation,causes,0.320256307610174,NICOTINE REPLACEMENT THERAPY during PREGNANCY,PREGNANCY,NICOTINE REPLACEMENT THERAPY
2928,no_relation,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2929,PREGNANCY causes MEPROBAMATE,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2930,no_relation,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2931,no_relation,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2932,no_relation,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2933,no_relation,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2934,no_relation,causes,0.474712663277541,"a ,   b ,   c  Fetal/Neonatal Morbidity  Retrospective studies suggest increased risk of congenital malformations in infants of mothers who received anxiolytics (chlordiazepoxide, diazepam, MEPROBAMATE during the first trimester of PREGNANCY",PREGNANCY,MEPROBAMATE
2935,no_relation,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2936,no_relation,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2937,no_relation,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2938,no_relation,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2939,no_relation,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2940,no_relation,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2941,PANTOPRAZOLE causes GASTRO OESOPHAGEAL REFLUX DISEASE,causes,0.368229847159329,"upper gastrointestinal symptoms: a randomized placebo controlled trial  Meta analysis: the relationship between Helicobacter pylori infection and gastro oesophageal reflux disease  Once daily PANTOPRAZOLE 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD related symptoms  Is there any association between myocardial infarction, GASTRO OESOPHAGEAL REFLUX DISEASE and acid suppressing drugs.",GASTRO OESOPHAGEAL REFLUX DISEASE,PANTOPRAZOLE
2942,no_relation,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2943,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2944,SEVERE ALLERGIC REACTION causes NEOMYCIN,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2945,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2946,no_relation,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2947,NEOMYCIN causes SEVERE ALLERGIC REACTION,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2948,no_relation,causes,0.606091526731326,"1  Fixed combination Vaccine Containing DTaP and IPV (DTaP IPV; Kinrix ® ,  •  SEVERE ALLERGIC REACTION (e.g., anaphylaxis) to any ingredient in the vaccine (e.g., NEOMYCIN polymyxin B) or after previous dose of any vaccine containing diphtheria, tetanus, pertussis, or poliovirus antigens.",SEVERE ALLERGIC REACTION,NEOMYCIN
2949,MITES causes NORMAL SCABIES,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2950,no_relation,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2951,no_relation,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2952,MITES causes NORMAL SCABIES,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2953,MITES causes NORMAL SCABIES,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2954,MITES causes NORMAL SCABIES,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2955,no_relation,causes,0.589767824619588,"• Investigations of the prevalence of mites in the personal environment of 37 cases of NORMAL SCABIES revealed live MITES from dust samples taken from bedroom floors, overstuffed chairs, and couches in all 37 cases ( 11.",NORMAL SCABIES,MITES
2956,EPILEPSY causes SEIZURES,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2957,EPILEPSY causes SEIZURES,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2958,EPILEPSY causes SEIZURES,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2959,EPILEPSY causes SEIZURES,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2960,no_relation,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2961,EPILEPSY causes SEIZURES,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2962,EPILEPSY causes SEIZURES,causes,0.341743063086704,">     Other Seizure Etiologies  IM or IV:  For SEIZURES associated with EPILEPSY glomerulonephritis, or hypothyroidism: Usually, 1 g.",SEIZURES,EPILEPSY
2963,no_relation,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2964,no_relation,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2965,no_relation,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2966,no_relation,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2967,BONE causes PAGET'S DISEASE,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2968,PAGET'S DISEASE causes BONE,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2969,no_relation,causes,0.818181818181818,"Evidence: • BONE affected by PAGET'S DISEASE can enlarge, and this enlargement of deformity is a presenting symptom in 20% of patients.",BONE,PAGET'S DISEASE
2970,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2971,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2972,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2973,HTLV 1 causes TROPICAL SPASTIC PARAPARESIS,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2974,no_relation,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2975,no_relation,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2976,TROPICAL SPASTIC PARAPARESIS causes HTLV 1,causes,0.970142500145332,"HTLV 1 causes adult T lymphocyte (ATL)leukemia/lymphoma, T cell non Hodgkin lymphoma, and an unusual neurodegenerative syndrome designated TROPICAL SPASTIC PARAPARESIS or HTLV 1 associated myelopathy (TSP/HAM.",TROPICAL SPASTIC PARAPARESIS,HTLV 1
2977,no_relation,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2978,PHEOCHROMOCYTOMAS causes HYPERTENSION,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2979,PHEOCHROMOCYTOMAS causes HYPERTENSION,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2980,HYPERTENSION causes PHEOCHROMOCYTOMAS,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2981,PHEOCHROMOCYTOMAS causes HYPERTENSION,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2982,PHEOCHROMOCYTOMAS causes HYPERTENSION,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2983,HYPERTENSION causes PHEOCHROMOCYTOMAS,causes,0.997054485501582,"• PHEOCHROMOCYTOMAS pose a risk to health and life, and HYPERTENSION may be the initial clue to their presence.",HYPERTENSION,PHEOCHROMOCYTOMAS
2984,no_relation,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2985,HYPERCORTISOLISM causes MCCUNE ALBRIGHT SYNDROME,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2986,MCCUNE ALBRIGHT SYNDROME causes HYPERCORTISOLISM,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2987,HYPERCORTISOLISM causes MCCUNE ALBRIGHT SYNDROME,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2988,no_relation,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2989,HYPERCORTISOLISM causes MCCUNE ALBRIGHT SYNDROME,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2990,HYPERCORTISOLISM causes MCCUNE ALBRIGHT SYNDROME,causes,0.8728715609439692,"Evidence: • A unilateral mass (adenoma or carcinoma) with contralateral atrophy, bilateral masses (MCCUNE ALBRIGHT SYNDROME massive macronodular adrenal disease), or small and/or nodular glands (exogenous glucocorticoids, primary pigmented nodular adrenal disease) are seen in patients with HYPERCORTISOLISM of adrenal origin ( 95 ;  96.",HYPERCORTISOLISM,MCCUNE ALBRIGHT SYNDROME
2991,no_relation,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2992,TIC DOULOUREUX causes PAROXYSMAL PAIN,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2993,TIC DOULOUREUX causes PAROXYSMAL PAIN,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2994,TIC DOULOUREUX causes PAROXYSMAL PAIN,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2995,TIC DOULOUREUX causes PAROXYSMAL PAIN,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2996,TIC DOULOUREUX causes PAROXYSMAL PAIN,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2997,TIC DOULOUREUX causes PAROXYSMAL PAIN,causes,0.9918365981341758,"Trigeminal Neuralgia (Tic Douloureux)  Trigeminal neuralgia, or TIC DOULOUREUX is a distinctive facial pain syndrome of middle aged and elderly persons in which intense, PAROXYSMAL PAIN occurs several times to dozens of times daily.",PAROXYSMAL PAIN,TIC DOULOUREUX
2998,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
2999,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
3000,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
3001,no_relation,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
3002,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
3003,no_relation,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
3004,GRAVES' DISEASE causes THYROTOXICOSIS,causes,0.985329278164293,"Hyperthyroidism during childhood and adolescence:  GRAVES' DISEASE is the usual cause; it is characterized by diffuse goiter, THYROTOXICOSIS and, rarely, infiltrative ophthalmopathy.",GRAVES' DISEASE,THYROTOXICOSIS
3005,WHOOPING COUGH causes BORDETELLA PERTUSSIS,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3006,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3007,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3008,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3009,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3010,BORDETELLA PERTUSSIS causes WHOOPING COUGH,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3011,no_relation,causes,1.0,"2]  He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. WHOOPING COUGH caused by  BORDETELLA PERTUSSIS  and  Bordetella parapertussis  in an immunized population.",WHOOPING COUGH,BORDETELLA PERTUSSIS
3012,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3013,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3014,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3015,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3016,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3017,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3018,TTP causes FEVER,causes,0.9166984970282108,"• FEVER and neurologic impairment are found in TTP which is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure.",FEVER,TTP
3019,SEIZURE causes SE,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3020,no_relation,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3021,SE causes SEIZURE,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3022,SE causes SEIZURE,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3023,no_relation,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3024,no_relation,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3025,no_relation,causes,0.95257934441568,"Do SEIZURE type, cause, and duration of SE affect long term mortality.",SEIZURE,SE
3026,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3027,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3028,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3029,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3030,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3031,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3032,no_relation,causes,0.398014876083996,"As hypomagnesia is a common cause of VT, stat dose MAGNESIUM SULPHATE can be given for TORSADES or if hypomagnesemia is found/suspected.",TORSADES,MAGNESIUM SULPHATE
3033,LUNG DISEASES causes INTERSTITIUM OF THE LUNG,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3034,no_relation,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3035,LUNG DISEASES causes INTERSTITIUM OF THE LUNG,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3036,no_relation,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3037,LUNG DISEASES causes INTERSTITIUM OF THE LUNG,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3038,no_relation,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3039,no_relation,causes,0.480384461415261,"Because airway disease and other lung diseases also may affect the INTERSTITIUM OF THE LUNG and interstitial LUNG DISEASES can affect the airways, the term  diffuse parenchymal lung disease  (DPLD) is often preferred.",INTERSTITIUM OF THE LUNG,LUNG DISEASES
3040,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3041,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3042,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3043,no_relation,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3044,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3045,BRUCELLOSIS causes BRUCELLA MELITENSIS,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3046,BRUCELLA MELITENSIS causes BRUCELLOSIS,causes,0.994134846772434,"538 ,   667 ,   729 ,   730 ,   731 ,   732 ,   733  Brucellosis  Treatment of BRUCELLOSIS   +    caused by  BRUCELLA MELITENSIS.",BRUCELLOSIS,BRUCELLA MELITENSIS
3047,RICKETTSIA AKARI causes SELF LIMITED DISEASE,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3048,RICKETTSIA AKARI causes SELF LIMITED DISEASE,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3049,RICKETTSIA AKARI causes SELF LIMITED DISEASE,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3050,RICKETTSIA AKARI causes SELF LIMITED DISEASE,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3051,SELF LIMITED DISEASE causes RICKETTSIA AKARI,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3052,RICKETTSIA AKARI causes SELF LIMITED DISEASE,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3053,RICKETTSIA AKARI causes SELF LIMITED DISEASE,causes,1.0,"rickettsialpox    (                      audio )  An acute, febrile, SELF LIMITED DISEASE caused by  RICKETTSIA AKARI.",SELF LIMITED DISEASE,RICKETTSIA AKARI
3054,SWEET SYNDROME causes NEUTROPHILIA,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3055,NEUTROPHILIA causes SWEET SYNDROME,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3056,SWEET SYNDROME causes NEUTROPHILIA,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3057,SWEET SYNDROME causes NEUTROPHILIA,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3058,no_relation,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3059,no_relation,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3060,NEUTROPHILIA causes SWEET SYNDROME,causes,0.6154574548966639,One such uncommon idiopathic condition is SWEET SYNDROME which is an acute febrile illness with painful cutaneous plaques and associated NEUTROPHILIA of any cause.,NEUTROPHILIA,SWEET SYNDROME
3061,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3062,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3063,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3064,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3065,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3066,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3067,FRUCTOSE INTOLERANCE causes POSTPRANDIAL HYPOGLYCEMIA,causes,0.993883734673619,FRUCTOSE INTOLERANCE most often causes POSTPRANDIAL HYPOGLYCEMIA that usually manifests in infancy and occasionally later in life ( 23.,POSTPRANDIAL HYPOGLYCEMIA,FRUCTOSE INTOLERANCE
3068,no_relation,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3069,EMPHYSEMA causes LUNG,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3070,no_relation,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3071,no_relation,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3072,no_relation,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3073,no_relation,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3074,no_relation,causes,0.3396831102433789,"Asymmetrical pulmonary edema can occur as a result of the patient's lying on the involved side as the edema develops, or it may result from vascular obstruction (thromboembolism) or attenuation (EMPHYSEMA) in the more radiolucent regions of the LUNG",LUNG,EMPHYSEMA
3075,no_relation,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3076,no_relation,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3077,MEN II causes MEDULLARY THYROID CANCER,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3078,no_relation,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3079,no_relation,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3080,MEN II causes MEDULLARY THYROID CANCER,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3081,MEN II causes MEDULLARY THYROID CANCER,causes,0.8576900278702358,"If MEN II is suspected, MEDULLARY THYROID CANCER should be considered, and pheochromocytoma must be excluded before the patient goes to surgery.",MEDULLARY THYROID CANCER,MEN II
3082,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3083,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3084,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3085,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3086,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3087,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3088,PHEOCHROMOCYTOMA causes HYPERTENSION,causes,0.997054485501582,"a ,   b  Considered drug of choice for medical management of pheochromocytoma until surgery is performed and for prolonged treatment of HYPERTENSION caused by PHEOCHROMOCYTOMA  not  amenable to surgery.",HYPERTENSION,PHEOCHROMOCYTOMA
3089,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CARCINOMA,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3090,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CARCINOMA,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3091,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CARCINOMA,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3092,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CARCINOMA,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3093,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CARCINOMA,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3094,FAMILIAL ADENOMATOUS POLYPOSIS causes COLON CARCINOMA,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3095,COLON CARCINOMA causes FAMILIAL ADENOMATOUS POLYPOSIS,causes,1.0,FAMILIAL ADENOMATOUS POLYPOSIS  FAMILIAL ADENOMATOUS POLYPOSIS is a hereditary disorder causing numerous colonic polyps and resulting in COLON CARCINOMA by age 40.,COLON CARCINOMA,FAMILIAL ADENOMATOUS POLYPOSIS
3096,DRUGS causes DRUG INDUCED PHOTOSENSITIVITY,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3097,DRUG INDUCED PHOTOSENSITIVITY causes DRUGS,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3098,DRUGS causes DRUG INDUCED PHOTOSENSITIVITY,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3099,DRUGS causes DRUG INDUCED PHOTOSENSITIVITY,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3100,DRUGS causes DRUG INDUCED PHOTOSENSITIVITY,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3101,DRUGS causes DRUG INDUCED PHOTOSENSITIVITY,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3102,DRUGS causes DRUG INDUCED PHOTOSENSITIVITY,causes,0.953462589245592,DRUG INDUCED PHOTOSENSITIVITY: Individuals using certain DRUGS or other chemicals may develop dermatitis or sunburn after exposure to light of an intensity or duration that normally would not have affected them.,DRUG INDUCED PHOTOSENSITIVITY,DRUGS
3103,no_relation,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3104,INFECTIOUS DIARRHEA causes DIARRHEA,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3105,INFECTIOUS DIARRHEA causes DIARRHEA,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3106,no_relation,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3107,no_relation,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3108,no_relation,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3109,INFECTIOUS DIARRHEA causes DIARRHEA,causes,0.824957911384306,"C]  Specific recommendation: • Obtain consultation with a gastroenterologist for colonoscopy and biopsies in patients with: ◊ Diarrhea, tenesmus, and bloody stools after INFECTIOUS DIARRHEA has been excluded with appropriate stool cultures ◊ Persistent DIARRHEA or tenesmus without a clear cause ◊ Extraintestinal rheumatologic or dermatologic manifestations.",DIARRHEA,INFECTIOUS DIARRHEA
3110,BRONCHOGENIC CARCINOMA causes CHRONIC COUGH,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3111,BRONCHOGENIC CARCINOMA causes CHRONIC COUGH,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3112,no_relation,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3113,BRONCHOGENIC CARCINOMA causes CHRONIC COUGH,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3114,no_relation,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3115,no_relation,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3116,BRONCHOGENIC CARCINOMA causes CHRONIC COUGH,causes,0.963863194682999,"62   BRONCHOGENIC CARCINOMA is not a common cause of CHRONIC COUGH but should be included in the differential diagnosis when the chest roentgenogram is abnormal, especially when the film shows centrally located lesions.",CHRONIC COUGH,BRONCHOGENIC CARCINOMA
3117,INGESTED SUBSTANCES causes ALLERGIC REACTIONS,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3118,INGESTED SUBSTANCES causes ALLERGIC REACTIONS,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3119,INGESTED SUBSTANCES causes ALLERGIC REACTIONS,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3120,ALLERGIC REACTIONS causes INGESTED SUBSTANCES,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3121,INGESTED SUBSTANCES causes ALLERGIC REACTIONS,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3122,INGESTED SUBSTANCES causes ALLERGIC REACTIONS,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3123,no_relation,causes,0.9897433186107868,The list of INGESTED SUBSTANCES said to cause ALLERGIC REACTIONS is seemingly endless.,ALLERGIC REACTIONS,INGESTED SUBSTANCES
3124,CORYNEBACTERIUM DIPHTHERIAE causes NASOPHARYNX (RESPIRATORY DIPHTHERIA),causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3125,no_relation,causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3126,CORYNEBACTERIUM DIPHTHERIAE causes NASOPHARYNX (RESPIRATORY DIPHTHERIA),causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3127,no_relation,causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3128,CORYNEBACTERIUM DIPHTHERIAE causes NASOPHARYNX (RESPIRATORY DIPHTHERIA),causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3129,CORYNEBACTERIUM DIPHTHERIAE causes NASOPHARYNX (RESPIRATORY DIPHTHERIA),causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3130,CORYNEBACTERIUM DIPHTHERIAE causes NASOPHARYNX (RESPIRATORY DIPHTHERIA),causes,0.911684611677103,CORYNEBACTERIUM DIPHTHERIAE  usually infects the NASOPHARYNX (RESPIRATORY DIPHTHERIA) or skin.,NASOPHARYNX (RESPIRATORY DIPHTHERIA),CORYNEBACTERIUM DIPHTHERIAE
3131,INTRAARTICULAR HYALURONATE INJECTION causes PAIN,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3132,no_relation,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3133,no_relation,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3134,INTRAARTICULAR HYALURONATE INJECTION causes PAIN,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3135,no_relation,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3136,no_relation,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3137,no_relation,causes,0.721687836487032,Reduced PAIN of INTRAARTICULAR HYALURONATE INJECTION with the reciprocating procedure device.,PAIN,INTRAARTICULAR HYALURONATE INJECTION
3138,LESCH NYHAN SYNDROME causes HYPERURICEMIA,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3139,LESCH NYHAN SYNDROME causes HYPERURICEMIA,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3140,no_relation,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3141,HYPERURICEMIA causes LESCH NYHAN SYNDROME,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3142,no_relation,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3143,LESCH NYHAN SYNDROME causes HYPERURICEMIA,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3144,no_relation,causes,0.9918365981341758,"Athetosis, self mutilation, and HYPERURICEMIA in boys indicate Lesch Nyhan syndrome (see  LESCH NYHAN SYNDROME.",HYPERURICEMIA,LESCH NYHAN SYNDROME
3145,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3146,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3147,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3148,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3149,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3150,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3151,no_relation,causes,0.790569415042095,"In adults with TYPE 2 DIABETES children, and women with gestational diabetes, insulin analogues and regular HUMAN INSULIN do not differ in effect.",TYPE 2 DIABETES,HUMAN INSULIN
3152,M LEPRAE causes LEPROSY,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3153,M LEPRAE causes LEPROSY,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3154,M LEPRAE causes LEPROSY,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3155,no_relation,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3156,no_relation,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3157,M LEPRAE causes LEPROSY,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3158,M LEPRAE causes LEPROSY,causes,0.950255268139496,"The manifestations of LEPROSY depend on the infected person's immune response to the causative agent,  M LEPRAE",LEPROSY,M LEPRAE
3159,HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION causes WAGR SYNDROME,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3160,no_relation,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3161,no_relation,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3162,HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION causes WAGR SYNDROME,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3163,no_relation,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3164,HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION causes WAGR SYNDROME,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3165,no_relation,causes,0.622171016838255,"WAGR SYNDROME is the combination of Wilms' tumor (with  WT1  deletion), aniridia, GU malformations (eg, renal hypoplasia, cystic disease, HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION",HYPOSPADIAS CRYPTORCHIDISM AND MENTAL RETARDATION,WAGR SYNDROME
3166,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3167,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3168,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3169,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3170,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3171,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3172,SODIUM BICARBONATE causes METABOLIC ALKALOSIS,causes,1.0,b  SODIUM BICARBONATE: May cause METABOLIC ALKALOSIS in patients with renal insufficiency.,METABOLIC ALKALOSIS,SODIUM BICARBONATE
3173,no_relation,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3174,no_relation,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3175,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3176,no_relation,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3177,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3178,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3179,INCREASED INTRACRANIAL PRESSURE causes PAPILLEDEMA,causes,0.979911869877732,PAPILLEDEMA is a late sign of INCREASED INTRACRANIAL PRESSURE; initial absence is not reassuring.,PAPILLEDEMA,INCREASED INTRACRANIAL PRESSURE
3180,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3181,no_relation,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3182,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3183,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3184,PELVIC PAIN causes ENDOMETRIOSIS,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3185,ENDOMETRIOSIS causes PELVIC PAIN,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3186,no_relation,causes,0.99124070716193,"menorrhalgia    (                  audio )  [&dblprime; +  rhoia , flow, +  algia , pain] Painful menstruation or PELVIC PAIN accompanying menstruation, sometimes a symptom of ENDOMETRIOSIS",PELVIC PAIN,ENDOMETRIOSIS
3187,no_relation,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3188,VIRUS causes 'MINOR' VIREMIA,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3189,'MINOR' VIREMIA causes VIRUS,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3190,no_relation,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3191,no_relation,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3192,VIRUS causes 'MINOR' VIREMIA,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3193,'MINOR' VIREMIA causes VIRUS,causes,0.8626621856275071,"The VIRUS then spreads to the regional lymph nodes, enters the bloodstream ('MINOR' VIREMIA) and reaches the reticuloendothelial system (i.e., deep lymph nodes, bone marrow, spleen, and liver)",'MINOR' VIREMIA,VIRUS
3194,ENCAINIDE causes VENTRICULAR ARRHYTHMIA SUPPRESSION,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3195,no_relation,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3196,no_relation,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3197,no_relation,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3198,VENTRICULAR ARRHYTHMIA SUPPRESSION causes ENCAINIDE,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3199,ENCAINIDE causes VENTRICULAR ARRHYTHMIA SUPPRESSION,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3200,no_relation,causes,0.4574957109978139,"Mortality following VENTRICULAR ARRHYTHMIA SUPPRESSION by ENCAINIDE flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST.",VENTRICULAR ARRHYTHMIA SUPPRESSION,ENCAINIDE
3201,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3202,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3203,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3204,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3205,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3206,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3207,PASTEURELLA causes PASTEURELLOSIS,causes,0.9950371902099888,PASTEURELLOSIS    (                    audio )  A disease caused by infection with bacteria of the genus  PASTEURELLA,PASTEURELLOSIS,PASTEURELLA
3208,CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS causes LEISHMANIA PARASITES,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3209,LEISHMANIA PARASITES causes CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3210,LEISHMANIA PARASITES causes CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3211,LEISHMANIA PARASITES causes CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3212,LEISHMANIA PARASITES causes CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3213,LEISHMANIA PARASITES causes CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3214,LEISHMANIA PARASITES causes CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,causes,1.0,"Commonly presents with abdominal pain, weight loss, hematochezia, or melena  Colonoscopy with tissue biopsy is necessary to differentiate colorectal cancer from CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS  Caused by LEISHMANIA PARASITES transmitted by sand fly bites.",CHRONIC INTESTINAL SCHISTOSOMIASIS VISCERAL LEISHMANIASIS,LEISHMANIA PARASITES
3215,OBSTRUCTIVE JAUNDICE causes HEPATOCELLULAR CARCINOMA,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3216,no_relation,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3217,HEPATOCELLULAR CARCINOMA causes OBSTRUCTIVE JAUNDICE,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3218,HEPATOCELLULAR CARCINOMA causes OBSTRUCTIVE JAUNDICE,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3219,no_relation,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3220,no_relation,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3221,OBSTRUCTIVE JAUNDICE causes HEPATOCELLULAR CARCINOMA,causes,0.369274472937998,"They may also occur as complications of HEPATOCELLULAR CARCINOMA  90   chronic granulomatous disease,  91 , 92   or percutaneous transhepatic biliary drainage procedures in patients with cancer and OBSTRUCTIVE JAUNDICE",OBSTRUCTIVE JAUNDICE,HEPATOCELLULAR CARCINOMA
3222,MEN1 causes MULTIPLE FACIAL ANGIOFIBROMAS,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3223,no_relation,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3224,MEN1 causes MULTIPLE FACIAL ANGIOFIBROMAS,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3225,MEN1 causes MULTIPLE FACIAL ANGIOFIBROMAS,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3226,no_relation,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3227,MEN1 causes MULTIPLE FACIAL ANGIOFIBROMAS,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3228,MEN1 causes MULTIPLE FACIAL ANGIOFIBROMAS,causes,0.963086824686154,• A survey study of a consecutive sample of patients with MEN1 found MULTIPLE FACIAL ANGIOFIBROMAS and collagenomas to be cutaneous manifestations of the disease ( 22.,MULTIPLE FACIAL ANGIOFIBROMAS,MEN1
3229,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3230,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3231,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3232,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3233,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3234,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3235,no_relation,causes,0.416025147168922,"Ballenger JC, Davidson JR, Lecrubier Y et al. Consensus statement update on POSTTRAUMATIC STRESS DISORDER from the international consensus group on DEPRESSION AND ANXIETY",DEPRESSION AND ANXIETY,POSTTRAUMATIC STRESS DISORDER
3236,CHRONIC PAIN SYNDROME causes CHRONIC PAIN,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3237,no_relation,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3238,no_relation,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3239,no_relation,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3240,no_relation,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3241,no_relation,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3242,no_relation,causes,0.606339062590832,"Vulvar vestibulitis (localized vulvar dysesthesia) is probably a form of CHRONIC PAIN SYNDROME (see  CHRONIC PAIN ) of the vulva, in which the nervous system, from peripheral receptors to the cerebral cortex, is sensitized and remodeled for unknown reasons.",CHRONIC PAIN,CHRONIC PAIN SYNDROME
3243,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3244,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3245,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3246,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3247,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3248,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3249,no_relation,causes,0.474712663277541,"Mumps and other PARAINFLUENZA VIRUS INFECTIONS as well as INFLUENZA VIRUS INFECTION most often present in the winter, although they may occur at any time of year.",INFLUENZA VIRUS INFECTION,PARAINFLUENZA VIRUS INFECTIONS
3250,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3251,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3252,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3253,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3254,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3255,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3256,VARICELLA ZOSTER VIRUS causes SHINGLES,causes,0.995893206467704,46  Focal and Regional Neuropathic Pain Syndromes  SHINGLES and postherpetic neuralgia (PHN)   are caused by reactivation of VARICELLA ZOSTER VIRUS (VZV) in a sensory ganglion.,SHINGLES,VARICELLA ZOSTER VIRUS
3257,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3258,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3259,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3260,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3261,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3262,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3263,CANDIDA causes VULVOVAGINAL CANDIDIASIS,causes,0.9838699100999068,"108 ,   127 ,   128  >     Other Complicated Vulvovaginal Infections  Intravaginal:  CDC and others recommend 7 14 days of an intravaginal azole for VULVOVAGINAL CANDIDIASIS that is severe, caused by  CANDIDA  other than  C. albicans , or occurring in women with underlying medical conditions.",VULVOVAGINAL CANDIDIASIS,CANDIDA
3264,no_relation,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3265,MTS causes KERATOACANTHOMAS,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3266,KERATOACANTHOMAS causes MTS,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3267,MTS causes KERATOACANTHOMAS,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3268,no_relation,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3269,KERATOACANTHOMAS causes MTS,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3270,MTS causes KERATOACANTHOMAS,causes,0.762000762001143,KERATOACANTHOMAS and sebaceous hyperplasia are also seen in patients with MTS,KERATOACANTHOMAS,MTS
3271,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3272,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3273,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3274,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3275,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3276,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3277,no_relation,causes,0.458831467741123,"Michielsen P, Heinemann L, Mihatsch M, et al. NONPHENACETIN ANALGESICS and ANALGESIC NEPHROPATHY: clinical assessment of high users from a case control study.",ANALGESIC NEPHROPATHY,NONPHENACETIN ANALGESICS
3278,no_relation,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3279,no_relation,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3280,HYPOCALCEMIA causes TYPE I PSEUDOHYPOPARATHYROIDISM,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3281,no_relation,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3282,TYPE I PSEUDOHYPOPARATHYROIDISM causes HYPOCALCEMIA,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3283,no_relation,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3284,no_relation,causes,0.6974858324629161,TYPE I PSEUDOHYPOPARATHYROIDISM can be distinguished by the presence of HYPOCALCEMIA despite normal to elevated levels of circulating PTH.,HYPOCALCEMIA,TYPE I PSEUDOHYPOPARATHYROIDISM
3285,no_relation,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3286,PYKNODYSOSTOSIS causes SHORT STATURE,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3287,PYKNODYSOSTOSIS causes SHORT STATURE,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3288,no_relation,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3289,no_relation,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3290,no_relation,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3291,PYKNODYSOSTOSIS causes SHORT STATURE,causes,0.7453559924999301,"PYKNODYSOSTOSIS:  In this autosomal recessive disorder, SHORT STATURE becomes evident in early childhood; adult height is ≤ 150 cm (5 ft.",SHORT STATURE,PYKNODYSOSTOSIS
3292,POLYCYSTIC DISEASE OF THE KIDNEYS causes KIDNEYS,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3293,no_relation,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3294,no_relation,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3295,no_relation,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3296,no_relation,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3297,no_relation,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3298,no_relation,causes,0.8677218312746251,edit] POLYCYSTIC DISEASE OF THE KIDNEYS Main article: Polycystic Disease of the Kidneys  Additional possible cause of nephropathy is due to the formation of cysts or pockets containing fluid within the KIDNEYS,KIDNEYS,POLYCYSTIC DISEASE OF THE KIDNEYS
3299,LOWER CERVICAL SPINAL CORD causes CERVICAL MYELOPATHY,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3300,LOWER CERVICAL SPINAL CORD causes CERVICAL MYELOPATHY,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3301,LOWER CERVICAL SPINAL CORD causes CERVICAL MYELOPATHY,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3302,CERVICAL MYELOPATHY causes LOWER CERVICAL SPINAL CORD,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3303,no_relation,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3304,LOWER CERVICAL SPINAL CORD causes CERVICAL MYELOPATHY,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3305,no_relation,causes,0.8834522085987719,CERVICAL SPONDYLOSIS AND SPONDYLOTIC CERVICAL MYELOPATHY  Cervical spondylosis is osteoarthritis of the cervical spine causing stenosis of the canal and sometimes CERVICAL MYELOPATHY from encroachment of bony osteoarthritic growths (osteophytes) on the LOWER CERVICAL SPINAL CORD sometimes with involvement of lower cervical nerve roots (radiculomyelopathy.,LOWER CERVICAL SPINAL CORD,CERVICAL MYELOPATHY
3306,SUSCEPTIBLE PLASMODIA causes MALARIA,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3307,MALARIA causes SUSCEPTIBLE PLASMODIA,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3308,no_relation,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3309,SUSCEPTIBLE PLASMODIA causes MALARIA,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3310,MALARIA causes SUSCEPTIBLE PLASMODIA,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3311,SUSCEPTIBLE PLASMODIA causes MALARIA,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3312,SUSCEPTIBLE PLASMODIA causes MALARIA,causes,0.956182887467515,"164  The CDC and other clinicians recommend use of other antimalarial agents (e.g., chloroquine [or hydroxychloroquine], mefloquine, doxycycline, fixed combination of atovaquone and proguanil hydrochloride) for prevention of MALARIA caused by SUSCEPTIBLE PLASMODIA",MALARIA,SUSCEPTIBLE PLASMODIA
3313,no_relation,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3314,no_relation,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3315,no_relation,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3316,MARFAN SYNDROME causes ASCENDING AORTIC ANEURYSM,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3317,no_relation,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3318,no_relation,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3319,no_relation,causes,0.811107105653813,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
3320,ZOSTER causes VARICELLA VIRUS,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3321,no_relation,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3322,no_relation,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3323,VARICELLA VIRUS causes ZOSTER,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3324,no_relation,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3325,ZOSTER causes VARICELLA VIRUS,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3326,no_relation,causes,0.857142857142857,ZOSTER     Reactivation of VARICELLA VIRUS years after the initial infection with chickenpox.,ZOSTER,VARICELLA VIRUS
3327,POSTOPERATIVE NAUSEA AND VOMITING causes METOCLOPRAMIDE,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3328,no_relation,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3329,METOCLOPRAMIDE causes POSTOPERATIVE NAUSEA AND VOMITING,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3330,no_relation,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3331,METOCLOPRAMIDE causes POSTOPERATIVE NAUSEA AND VOMITING,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3332,no_relation,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3333,no_relation,causes,0.444444444444444,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3334,no_relation,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3335,no_relation,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3336,DRUG causes DIRECT DRUG TOXICITY,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3337,DRUG causes DIRECT DRUG TOXICITY,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3338,no_relation,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3339,DRUG causes DIRECT DRUG TOXICITY,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3340,DRUG causes DIRECT DRUG TOXICITY,causes,0.9494253265550828,"DIRECT DRUG TOXICITY  Although antimicrobials can damage virtually all human organ systems, the potential for toxicity varies widely from drug to DRUG.",DIRECT DRUG TOXICITY,DRUG
3341,no_relation,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3342,no_relation,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3343,MONONUCLEOSIS causes SPLENOMEGALY,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3344,no_relation,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3345,no_relation,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3346,no_relation,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3347,no_relation,causes,0.668153104781061,"Some infections can induce erythrocyte autoantibodies, such as mycoplasma and MONONUCLEOSIS (see information on immune hemolytic anemias)  Fever, SPLENOMEGALY and hemolysis suggest malaria in a patient with appropriate travel history or babesiosis in an endemic area.",SPLENOMEGALY,MONONUCLEOSIS
3348,IPF causes NONPRODUCTIVE COUGH,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3349,no_relation,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3350,NONPRODUCTIVE COUGH causes IPF,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3351,IPF causes NONPRODUCTIVE COUGH,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3352,no_relation,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3353,no_relation,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3354,no_relation,causes,0.927172649945531,Clinical Features  History and physical examination   The insidious onset of NONPRODUCTIVE COUGH and dyspnea characterizes IPF,NONPRODUCTIVE COUGH,IPF
3355,no_relation,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3356,no_relation,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3357,no_relation,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3358,no_relation,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3359,POSTTRAUMATIC STRESS DISORDER causes ANXIETY,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3360,ANXIETY causes POSTTRAUMATIC STRESS DISORDER,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3361,no_relation,causes,0.40824829046386296,"3]  Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, et al. Consensus statement on POSTTRAUMATIC STRESS DISORDER from the International Consensus Group on Depression and ANXIETY",ANXIETY,POSTTRAUMATIC STRESS DISORDER
3362,LARVAL TAPEWORMS causes SPARGANOSIS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3363,LARVAL TAPEWORMS causes SPARGANOSIS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3364,SPARGANOSIS causes LARVAL TAPEWORMS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3365,SPARGANOSIS causes LARVAL TAPEWORMS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3366,LARVAL TAPEWORMS causes SPARGANOSIS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3367,LARVAL TAPEWORMS causes SPARGANOSIS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3368,LARVAL TAPEWORMS causes SPARGANOSIS,causes,0.9918365981341758,"SPARGANOSIS represents infection by LARVAL TAPEWORMS of the genus  Spirometra , which are closely related to tapeworms of the genus  Diphyllobothrium.",SPARGANOSIS,LARVAL TAPEWORMS
3369,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3370,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3371,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3372,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3373,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3374,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3375,no_relation,causes,0.301511344577764,"A randomized, placebo controlled trial of propafenone in the prophylaxis of PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA and paroxysmal atrial fibrillation.UK PROPAFENONE PSVT Study Group:  Circulation 92:2550, 1995  17.",PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA,PROPAFENONE
3376,ENTEROVIRUSES causes EPIDEMIC PLEURODYNIA,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3377,ENTEROVIRUSES causes EPIDEMIC PLEURODYNIA,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3378,ENTEROVIRUSES causes EPIDEMIC PLEURODYNIA,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3379,EPIDEMIC PLEURODYNIA causes ENTEROVIRUSES,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3380,ENTEROVIRUSES causes EPIDEMIC PLEURODYNIA,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3381,ENTEROVIRUSES causes EPIDEMIC PLEURODYNIA,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3382,ENTEROVIRUSES causes EPIDEMIC PLEURODYNIA,causes,0.99654575824488,"EPIDEMIC PLEURODYNIA hand foot and mouth disease, herpangina, and poliomyelitis are caused almost exclusively by ENTEROVIRUSES",EPIDEMIC PLEURODYNIA,ENTEROVIRUSES
3383,AIP causes SEIZURES,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3384,AIP causes SEIZURES,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3385,AIP causes SEIZURES,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3386,AIP causes SEIZURES,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3387,AIP causes SEIZURES,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3388,no_relation,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3389,AIP causes SEIZURES,causes,0.4472135954999579,"Acute attacks of AIP may be accompanied by SEIZURES especially in patients with hyponatremia caused by vomiting, inappropriate fluid therapy, or the syndrome of inappropriate antidiuretic hormone (SIADH.",SEIZURES,AIP
3390,PYRAZINOIC ACID AMIDE treats TUBERCULOSIS (TB),treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3391,PYRAZINOIC ACID AMIDE treats TUBERCULOSIS (TB),treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3392,PYRAZINOIC ACID AMIDE treats TUBERCULOSIS (TB),treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3393,PYRAZINOIC ACID AMIDE treats TUBERCULOSIS (TB),treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3394,PYRAZINOIC ACID AMIDE treats TUBERCULOSIS (TB),treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3395,TUBERCULOSIS (TB) treats PYRAZINOIC ACID AMIDE,treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3396,PYRAZINOIC ACID AMIDE treats TUBERCULOSIS (TB),treats,0.970494958830946,124  Class:  Antituberculosis Agents 8:16.04; AM500 (VA)  Synonyms:  PYRAZINOIC ACID AMIDE; Rifater; Tebrazid  Uses  Tuberculosis  Treatment of active (clinical) TUBERCULOSIS (TB) in conjunction with other antituberculosis agents.,TUBERCULOSIS (TB),PYRAZINOIC ACID AMIDE
3397,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3398,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3399,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3400,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3401,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3402,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3403,no_relation,treats,0.9113223768657672,PROPYLTHIOURACIL may be preferred if antithyroid drug therapy must be used during PREGNANCY or breastfeeding because it is less likely to cross the placenta or enter breast milk.,PREGNANCY,PROPYLTHIOURACIL
3404,IRON treats IRON DEFICIENCY ANEMIA,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3405,no_relation,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3406,IRON treats IRON DEFICIENCY ANEMIA,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3407,no_relation,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3408,IRON treats IRON DEFICIENCY ANEMIA,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3409,IRON treats IRON DEFICIENCY ANEMIA,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3410,IRON treats IRON DEFICIENCY ANEMIA,treats,0.9918365981341752,IRON DEFICIENCY ANEMIA may require supplemental IRON,IRON DEFICIENCY ANEMIA,IRON
3411,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3412,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3413,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3414,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3415,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3416,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3417,THERAPY WITH WARFARIN T treats ENOUS THROMBOSIS I,treats,0.997785157856609, A randomized controlled trial comparing heparin THERAPY WITH WARFARIN Therapy for the long term treatment of vENOUS THROMBOSIS In 106 nonpregnant patients found that adjusted dose subcutaneous heparin therapy provides an effective alternative to warfarin and is associated with a lower risk of bleeding ( 109.,ENOUS THROMBOSIS I,THERAPY WITH WARFARIN T
3418,no_relation,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3419,no_relation,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3420,no_relation,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3421,no_relation,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3422,CLOSTRIDIUM PERFRINGENS treats CLOSTRIDIUM INFECTIONS,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3423,no_relation,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3424,no_relation,treats,0.39823398695998297,24  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM PERFRINGENS    +   ; alternative to penicillin G for those with penicillin hypersensitivity or for polymicrobial infections.,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM PERFRINGENS
3425,AMPHOTERICIN B treats COCCIDIOIDOMYCOSIS,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3426,no_relation,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3427,no_relation,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3428,COCCIDIOIDOMYCOSIS treats AMPHOTERICIN B,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3429,AMPHOTERICIN B treats COCCIDIOIDOMYCOSIS,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3430,AMPHOTERICIN B treats COCCIDIOIDOMYCOSIS,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3431,AMPHOTERICIN B treats COCCIDIOIDOMYCOSIS,treats,0.9434563530497272,441  Conventional AMPHOTERICIN B in HIV infected adolescents with diffuse pulmonary or extrathoracic disseminated COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.,COCCIDIOIDOMYCOSIS,AMPHOTERICIN B
3432,no_relation,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3433,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3434,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3435,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3436,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3437,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3438,RANITIDINE treats DUODENAL ULCER DISEASE,treats,0.993883734673619,Famotidine 40 mg given once at night appears to be as safe and effective as conventional therapy with RANITIDINE indicating the importance of overnight gastric acidity in the pathogenesis of DUODENAL ULCER DISEASE,DUODENAL ULCER DISEASE,RANITIDINE
3439,TUBERCULIN SKIN TEST treats TUBERCULOSIS,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3440,no_relation,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3441,no_relation,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3442,TUBERCULIN SKIN TEST treats TUBERCULOSIS,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3443,no_relation,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3444,no_relation,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3445,TUBERCULOSIS treats TUBERCULIN SKIN TEST,treats,0.42857142857142894,"SEE:  illus: TUBERCULOSIS ;  illus: TUBERCULOSIS ;   immunological therapy ;  TUBERCULIN SKIN TEST ;  vaccine, BCG;   Nursing Diagnoses Appendix.",TUBERCULOSIS,TUBERCULIN SKIN TEST
3446,ACTING INSULIN ANALOG LISPRO treats TYPE 1 DIABETES,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3447,ACTING INSULIN ANALOG LISPRO treats TYPE 1 DIABETES,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3448,ACTING INSULIN ANALOG LISPRO treats TYPE 1 DIABETES,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3449,TYPE 1 DIABETES treats ACTING INSULIN ANALOG LISPRO,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3450,ACTING INSULIN ANALOG LISPRO treats TYPE 1 DIABETES,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3451,ACTING INSULIN ANALOG LISPRO treats TYPE 1 DIABETES,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3452,ACTING INSULIN ANALOG LISPRO treats TYPE 1 DIABETES,treats,1.0,"Lalli C, Ciofetta M, Del Sindaco P et al. Long term intensive treatment of TYPE 1 DIABETES with the short ACTING INSULIN ANALOG LISPRO in variable combination with NPH insulin at mealtime.",TYPE 1 DIABETES,ACTING INSULIN ANALOG LISPRO
3453,SOTALOL treats SUSTAINED VENTRICULAR TACHYCARDIA,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3454,SUSTAINED VENTRICULAR TACHYCARDIA treats SOTALOL,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3455,SOTALOL treats SUSTAINED VENTRICULAR TACHYCARDIA,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3456,SOTALOL treats SUSTAINED VENTRICULAR TACHYCARDIA,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3457,SOTALOL treats SUSTAINED VENTRICULAR TACHYCARDIA,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3458,SOTALOL treats SUSTAINED VENTRICULAR TACHYCARDIA,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3459,SOTALOL treats SUSTAINED VENTRICULAR TACHYCARDIA,treats,0.994134846772434,"Evidence: • The AVID trial randomly assigned patients with primary ventricular fibrillation, syncope with ventricular tachycardia, or SUSTAINED VENTRICULAR TACHYCARDIA in patients with LVEF less than 40% to ICD or drug therapy with SOTALOL guided by EPS or amiodarone therapy.",SUSTAINED VENTRICULAR TACHYCARDIA,SOTALOL
3460,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3461,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3462,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3463,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3464,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3465,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3466,HIGH DOSE FLUCONAZOLE treats CRYPTOCOCCAL MENINGITIS,treats,0.9838699100999068,"Nussbaum JC, Jackson A, Namarika D et al. Combination flucytosine and HIGH DOSE FLUCONAZOLE compared with fluconazole monotherapy for the treatment of CRYPTOCOCCAL MENINGITIS: a randomized trial in Malawi.",CRYPTOCOCCAL MENINGITIS,HIGH DOSE FLUCONAZOLE
3467,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3468,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3469,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3470,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3471,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3472,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3473,[ALTEPLASE] treats [ISCHEMIC STROKE],treats,0.990586012095595,A recent study using [ALTEPLASE] for thrombolysis in [ISCHEMIC STROKE] suggests clinical benefit with administration 3 to 4.5 hours after stroke onset.,[ISCHEMIC STROKE],[ALTEPLASE]
3474,no_relation,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3475,CLOPIDOGREL treats ST ELEVATION MYOCARDIAL INFARCTION,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3476,CLOPIDOGREL treats ST ELEVATION MYOCARDIAL INFARCTION,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3477,CLOPIDOGREL treats ST ELEVATION MYOCARDIAL INFARCTION,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3478,CLOPIDOGREL treats ST ELEVATION MYOCARDIAL INFARCTION,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3479,CLOPIDOGREL treats ST ELEVATION MYOCARDIAL INFARCTION,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3480,no_relation,treats,0.9282791216329142,"compared with CLOPIDOGREL in patients undergoing percutaneous coronary intervention for ST ELEVATION MYOCARDIAL INFARCTION (TRITON TIMI 38): double blind, randomised controlled trial.",ST ELEVATION MYOCARDIAL INFARCTION,CLOPIDOGREL
3481,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3482,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3483,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3484,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3485,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3486,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3487,[NON NSAID ANALGESIC AGENT] treats [SEVERE AND CHRONIC PAIN],treats,1.0,Ziconotide is a non opioid and [NON NSAID ANALGESIC AGENT] used for the amelioration of [SEVERE AND CHRONIC PAIN],[SEVERE AND CHRONIC PAIN],[NON NSAID ANALGESIC AGENT]
3488,VALSARTAN treats ALZHEIMER DISEASE,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3489,ALZHEIMER DISEASE treats VALSARTAN,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3490,VALSARTAN treats ALZHEIMER DISEASE,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3491,VALSARTAN treats ALZHEIMER DISEASE,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3492,no_relation,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3493,no_relation,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3494,VALSARTAN treats ALZHEIMER DISEASE,treats,0.9761870602,title = [VALSARTAN] lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of [ALZHEIMER DISEASE].,ALZHEIMER DISEASE,VALSARTAN
3495,CEFACLOR treats PHARYNGITIS,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3496,CEFACLOR treats PHARYNGITIS,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3497,CEFACLOR treats PHARYNGITIS,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3498,no_relation,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3499,CEFACLOR treats PHARYNGITIS,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3500,CEFACLOR treats PHARYNGITIS,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3501,CEFACLOR treats PHARYNGITIS,treats,0.976546150525391,Patients with otitis media received approximately 40 mg/kg/day of cefaclor or amoxicillin trihydrate for ten days to three weeks; patients with PHARYNGITIS received 20 mg/kg/day of CEFACLOR or penicillin V potassium for ten days.,PHARYNGITIS,CEFACLOR
3502,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3503,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3504,no_relation,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3505,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3506,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3507,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3508,ANTIARRHYTHMIC DRUGS treats REENTRANT ARRHYTHMIAS,treats,0.4313310928137539,Our results suggest that the heart rate dependence of REENTRANT ARRHYTHMIAS might be of prognostic value in the administration of ANTIARRHYTHMIC DRUGS,REENTRANT ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS
3509,no_relation,treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3510,[CATHETERIZATION] treats [PARURESIS],treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3511,no_relation,treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3512,[CATHETERIZATION] treats [PARURESIS],treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3513,[CATHETERIZATION] treats [PARURESIS],treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3514,[CATHETERIZATION] treats [PARURESIS],treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3515,[PARURESIS] treats [CATHETERIZATION],treats,0.871857290578645,"In severe cases, a person with [PARURESIS] can urinate only when alone at home or through the process of [CATHETERIZATION]",[PARURESIS],[CATHETERIZATION]
3516,no_relation,treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3517,[MEFLOQUINE] treats [HIV RELATED PML],treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3518,[MEFLOQUINE] treats [HIV RELATED PML],treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3519,[MEFLOQUINE] treats [HIV RELATED PML],treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3520,[MEFLOQUINE] treats [HIV RELATED PML],treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3521,[HIV RELATED PML] treats [MEFLOQUINE],treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3522,[MEFLOQUINE] treats [HIV RELATED PML],treats,0.981980506061966,Biogen Idec has recently announced that a trial of [MEFLOQUINE] in [HIV RELATED PML] is beginning.,[HIV RELATED PML],[MEFLOQUINE]
3523,LATENT TB treats TUBERCULOSIS,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3524,no_relation,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3525,no_relation,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3526,no_relation,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3527,no_relation,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3528,LATENT TB treats TUBERCULOSIS,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3529,LATENT TB treats TUBERCULOSIS,treats,0.371390676354104,This finding could have serious implications for using the test to diagnose LATENT TB in populations where empirical treatment for TUBERCULOSIS is widespread.,TUBERCULOSIS,LATENT TB
3530,METHOTREXATE treats OSTEOSARCOMA,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3531,METHOTREXATE treats OSTEOSARCOMA,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3532,METHOTREXATE treats OSTEOSARCOMA,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3533,METHOTREXATE treats OSTEOSARCOMA,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3534,METHOTREXATE treats OSTEOSARCOMA,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3535,METHOTREXATE treats OSTEOSARCOMA,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3536,OSTEOSARCOMA treats METHOTREXATE,treats,0.964763821237732,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
3537,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS treats SEIZURES,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3538,no_relation,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3539,no_relation,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3540,no_relation,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3541,no_relation,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3542,no_relation,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3543,no_relation,treats,0.31622776601683805,Persistent SEIZURES after lorazepam and PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS,SEIZURES,PHENYTOIN DEFINES REFRACTORY STATUS EPILEPTICUS
3544,no_relation,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3545,no_relation,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3546,no_relation,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3547,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3548,ANTIEPILEPTIC DRUGS (AEDS) treats DRUG RESISTANT EPILEPSY,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3549,no_relation,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3550,no_relation,treats,0.635000635000952,"In spite of the large number of ANTIEPILEPTIC DRUGS (AEDS) actually available, the problem of DRUG RESISTANT EPILEPSY has not been solved.",DRUG RESISTANT EPILEPSY,ANTIEPILEPTIC DRUGS (AEDS)
3551,BETULIN treats TUMOR,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3552,BETULIN treats TUMOR,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3553,BETULIN treats TUMOR,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3554,no_relation,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3555,BETULIN treats TUMOR,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3556,BETULIN treats TUMOR,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3557,BETULIN treats TUMOR,treats,0.9805806757,"Recent clinical studies have verified that red alder contains [BETULIN] and lupeol, compounds shown to be effective against a variety of [TUMOR]s.",TUMOR,BETULIN
3558,FLUOXETINE treats ANXIETY,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3559,FLUOXETINE treats ANXIETY,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3560,FLUOXETINE treats ANXIETY,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3561,FLUOXETINE treats ANXIETY,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3562,FLUOXETINE treats ANXIETY,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3563,FLUOXETINE treats ANXIETY,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3564,ANXIETY treats FLUOXETINE,treats,0.9773555549,"[FLUOXETINE] was shown to be effective for depression in 6-week long double-blind controlled trials, where it also alleviated [ANXIETY] and improved sleep.",ANXIETY,FLUOXETINE
3565,FAMOTIDINE treats DUODENAL ULCER,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3566,FAMOTIDINE treats DUODENAL ULCER,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3567,FAMOTIDINE treats DUODENAL ULCER,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3568,FAMOTIDINE treats DUODENAL ULCER,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3569,no_relation,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3570,FAMOTIDINE treats DUODENAL ULCER,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3571,FAMOTIDINE treats DUODENAL ULCER,treats,0.9950371902099888,"Simon B, Dammann HG, Jakob G et alFAMOTIDINE versus ranitidine for the short term treatment of DUODENAL ULCER",DUODENAL ULCER,FAMOTIDINE
3572,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3573,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3574,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3575,AMYOTROPHIC LATERAL SCLEROSIS treats RILUZOLE,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3576,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3577,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3578,RILUZOLE treats AMYOTROPHIC LATERAL SCLEROSIS,treats,0.938314863256837,RILUZOLE for AMYOTROPHIC LATERAL SCLEROSIS (ALS)/motor neuron disease (MND.,AMYOTROPHIC LATERAL SCLEROSIS,RILUZOLE
3579,no_relation,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3580,no_relation,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3581,CHONDROITIN SULFATE TREATED treats PAIN,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3582,CHONDROITIN SULFATE TREATED treats PAIN,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3583,CHONDROITIN SULFATE TREATED treats PAIN,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3584,no_relation,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3585,CHONDROITIN SULFATE TREATED treats PAIN,treats,0.870062840141097,There was a significant alleviation of PAIN in the CHONDROITIN SULFATE TREATED groups compared to placebo.,PAIN,CHONDROITIN SULFATE TREATED
3586,no_relation,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3587,POSTOPERATIVE NAUSEA AND VOMITING treats METOCLOPRAMIDE,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3588,METOCLOPRAMIDE treats POSTOPERATIVE NAUSEA AND VOMITING,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3589,no_relation,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3590,METOCLOPRAMIDE treats POSTOPERATIVE NAUSEA AND VOMITING,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3591,METOCLOPRAMIDE treats POSTOPERATIVE NAUSEA AND VOMITING,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3592,no_relation,treats,0.8888888888888891,"11 ,   12  General Precautions  GI Anastomosis or Closure  When deciding whether to use metoclopramide or NG suction to prevent POSTOPERATIVE NAUSEA AND VOMITING consider the possibility that METOCLOPRAMIDE theoretically could produce increased pressure on suture lines following GI anastomosis or closure.",POSTOPERATIVE NAUSEA AND VOMITING,METOCLOPRAMIDE
3593,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3594,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3595,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3596,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3597,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3598,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3599,TOPICAL STEROID treats ITCHING,treats,1.0,Oral antihistamines or [TOPICAL STEROID]s may be used to decrease [ITCHING].,ITCHING,TOPICAL STEROID
3600,RAVUCONAZOLE treats ZYGOMYCETES,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3601,RAVUCONAZOLE treats ZYGOMYCETES,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3602,RAVUCONAZOLE treats ZYGOMYCETES,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3603,no_relation,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3604,RAVUCONAZOLE treats ZYGOMYCETES,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3605,RAVUCONAZOLE treats ZYGOMYCETES,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3606,RAVUCONAZOLE treats ZYGOMYCETES,treats,0.5601120336,"However, [RAVUCONAZOLE] has limited activity against species of fusarium, scedosporium and [ZYGOMYCETES].",ZYGOMYCETES,RAVUCONAZOLE
3607,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3608,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3609,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3610,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3611,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3612,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3613,SINGLE DOSE CEFUROXIME AXETIL treats UNCOMPLICATED GONORRHEA,treats,1.0,"Reichman RC, Nolte FS, Wolinsky SM et al. SINGLE DOSE CEFUROXIME AXETIL in the treatment of UNCOMPLICATED GONORRHEA: a controlled trial.",UNCOMPLICATED GONORRHEA,SINGLE DOSE CEFUROXIME AXETIL
3614,[IMATINIB] treats [TUMORS],treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3615,[IMATINIB] treats [TUMORS],treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3616,[IMATINIB] treats [TUMORS],treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3617,[IMATINIB] treats [TUMORS],treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3618,[IMATINIB] treats [TUMORS],treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3619,[IMATINIB] treats [TUMORS],treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3620,no_relation,treats,0.9494253265550828,The same group in Italy found that the combination of imatinib and sirolimus caused a response in several patients whose [TUMORS] progressed on [IMATINIB] alone.,[TUMORS],[IMATINIB]
3621,no_relation,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3622,BETAMETHASONE VALERATE treats PSORIASIS,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3623,BETAMETHASONE VALERATE treats PSORIASIS,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3624,BETAMETHASONE VALERATE treats PSORIASIS,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3625,BETAMETHASONE VALERATE treats PSORIASIS,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3626,no_relation,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3627,no_relation,treats,0.956182887467515,The response of PSORIASIS to BETAMETHASONE VALERATE and clobetasol propionate: a 6 month controlled study.,PSORIASIS,BETAMETHASONE VALERATE
3628,NIT treats LICE,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3629,NIT treats LICE,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3630,no_relation,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3631,NIT treats LICE,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3632,no_relation,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3633,no_relation,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3634,NIT treats LICE,treats,0.857492925712544,"Parents were to wash the hair, apply lots of conditioner, comb the hair straight, and then use the NIT comb to comb out LICE until none were found.",LICE,NIT
3635,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3636,no_relation,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3637,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3638,no_relation,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3639,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3640,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3641,CEFTRIAXONE treats BACTERIAL MENINGITIS,treats,0.875,Comparison of CEFTRIAXONE and traditional therapy of BACTERIAL MENINGITIS,BACTERIAL MENINGITIS,CEFTRIAXONE
3642,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3643,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3644,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3645,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3646,TOTAL THYROXINE treats THYROID DISEASE,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3647,no_relation,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3648,no_relation,treats,0.629940788348712,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
3649,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3650,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3651,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3652,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3653,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3654,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3655,THALIDOMIDE treats ACTINIC PRURIGO,treats,0.968495996958186,"In some cases, [THALIDOMIDE] has proven to be effective in controlling the symptoms of [ACTINIC PRURIGO].",ACTINIC PRURIGO,THALIDOMIDE
3656,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3657,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3658,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3659,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3660,SEIZURE treats EPILEPSY,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3661,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3662,no_relation,treats,0.30618621784789696,Serial addition to 3 or more antiepileptic drugs is less likely to lead to SEIZURE freedom for patients with difficult to treat EPILEPSY,SEIZURE,EPILEPSY
3663,no_relation,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3664,no_relation,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3665,no_relation,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3666,no_relation,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3667,no_relation,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3668,no_relation,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3669,UNCOMPLICATED VARICELLA treats NOSOCOMIAL TRANSMISSION OF VZV,treats,0.625,• Avoid hospitalization of patients with UNCOMPLICATED VARICELLA to reduce the risk of NOSOCOMIAL TRANSMISSION OF VZV,UNCOMPLICATED VARICELLA,NOSOCOMIAL TRANSMISSION OF VZV
3670,no_relation,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3671,POSTTRAUMATIC RSD treats PAIN,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3672,no_relation,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3673,PAIN treats POSTTRAUMATIC RSD,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3674,no_relation,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3675,no_relation,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3676,no_relation,treats,0.40824829046386296,"• Alendronate has been shown to alleviate PAIN and improve joint mobility and pressure tolerance in a randomized, controlled, double blind study in 40 patients with POSTTRAUMATIC RSD ( 50.",PAIN,POSTTRAUMATIC RSD
3677,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3678,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3679,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3680,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3681,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3682,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3683,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,1.0,"Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus RIBAVIRIN for initial treatment of CHRONIC HEPATITIS C: a randomized trial.",CHRONIC HEPATITIS C,RIBAVIRIN
3684,no_relation,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3685,no_relation,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3686,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3687,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3688,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3689,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3690,VALGANCICLOVIR treats CYTOMEGALOVIRUS RETINITIS,treats,0.98058067569092,"Martin DF, Sierra Madero J, Walmsley S, et al: A controlled trial of VALGANCICLOVIR as induction therapy for CYTOMEGALOVIRUS RETINITIS",CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR
3691,LIDOCAINE treats MYOFASCIAL PAIN,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3692,LIDOCAINE treats MYOFASCIAL PAIN,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3693,no_relation,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3694,no_relation,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3695,LIDOCAINE treats MYOFASCIAL PAIN,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3696,LIDOCAINE treats MYOFASCIAL PAIN,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3697,LIDOCAINE treats MYOFASCIAL PAIN,treats,0.9897433186107868,Diclofenac versus LIDOCAINE as injection therapy in MYOFASCIAL PAIN,MYOFASCIAL PAIN,LIDOCAINE
3698,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3699,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3700,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3701,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3702,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3703,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3704,INHALED BECLOMETHASONE DIPROPIONATE treats STEROID DEPENDENT ASTHMA,treats,0.997785157856609,"Broder I, Tarlo SM, Davies GM et al. Safety and efficacy of long term treatment with INHALED BECLOMETHASONE DIPROPIONATE in STEROID DEPENDENT ASTHMA",STEROID DEPENDENT ASTHMA,INHALED BECLOMETHASONE DIPROPIONATE
3705,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3706,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3707,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3708,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3709,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3710,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3711,EPOETIN ALFA THERAPY treats IRON DEFICIENCY ANEMIA,treats,0.8616404368553291,Class:  Iron Preparations 20:04.04  Synonyms:  Iron Saccharate; Iron Sucron Complex; Saccharated Ferric Oxide  Uses  Iron Deficiency Anemia in Hemodialysis Patients Receiving Epoetin Alfa Therapy  Treatment of IRON DEFICIENCY ANEMIA in hemodialysis patients receiving EPOETIN ALFA THERAPY.,IRON DEFICIENCY ANEMIA,EPOETIN ALFA THERAPY
3712,INTERFERON ALFA treats METASTATIC RENAL CARCINOMA,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3713,INTERFERON ALFA treats METASTATIC RENAL CARCINOMA,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3714,INTERFERON ALFA treats METASTATIC RENAL CARCINOMA,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3715,INTERFERON ALFA treats METASTATIC RENAL CARCINOMA,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3716,INTERFERON ALFA treats METASTATIC RENAL CARCINOMA,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3717,no_relation,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3718,INTERFERON ALFA treats METASTATIC RENAL CARCINOMA,treats,0.9761870601839532,"Negrier S, Caty A, Lesimple T et al. Treatment of patients with METASTATIC RENAL CARCINOMA with a combination of subcutaneous interleukin 2 and INTERFERON ALFA with or without fluorouracil.",METASTATIC RENAL CARCINOMA,INTERFERON ALFA
3719,TISSUE PLASMINOGEN ACTIVATOR treats ACUTE PULMONARY EMBOLISM,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3720,ACUTE PULMONARY EMBOLISM treats TISSUE PLASMINOGEN ACTIVATOR,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3721,TISSUE PLASMINOGEN ACTIVATOR treats ACUTE PULMONARY EMBOLISM,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3722,TISSUE PLASMINOGEN ACTIVATOR treats ACUTE PULMONARY EMBOLISM,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3723,TISSUE PLASMINOGEN ACTIVATOR treats ACUTE PULMONARY EMBOLISM,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3724,ACUTE PULMONARY EMBOLISM treats TISSUE PLASMINOGEN ACTIVATOR,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3725,TISSUE PLASMINOGEN ACTIVATOR treats ACUTE PULMONARY EMBOLISM,treats,0.995893206467704,"Come PC, Kim D, Parker JA et al. Early reversal of right ventricular dysfunction in patients with ACUTE PULMONARY EMBOLISM after treatment with IV TISSUE PLASMINOGEN ACTIVATOR",ACUTE PULMONARY EMBOLISM,TISSUE PLASMINOGEN ACTIVATOR
3726,no_relation,treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3727,no_relation,treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3728,[HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3729,[HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3730,no_relation,treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3731,[HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3732,[HOMOCYSTEINE LOWERING VITAMINS] treats [STROKE],treats,0.7293249574894731,"A trial with 2 [HOMOCYSTEINE LOWERING VITAMINS] in people with prior [STROKE] there was an 80% reduction in fractures, mainly hip, after 2 years.",[STROKE],[HOMOCYSTEINE LOWERING VITAMINS]
3733,THALIDOMIDE treats APHTHOUS ULCERS,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3734,THALIDOMIDE treats APHTHOUS ULCERS,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3735,THALIDOMIDE treats APHTHOUS ULCERS,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3736,THALIDOMIDE treats APHTHOUS ULCERS,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3737,THALIDOMIDE treats APHTHOUS ULCERS,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3738,APHTHOUS ULCERS treats THALIDOMIDE,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3739,APHTHOUS ULCERS treats THALIDOMIDE,treats,0.970494958830946,THALIDOMIDE for APHTHOUS ULCERS in HIV infection.,APHTHOUS ULCERS,THALIDOMIDE
3740,no_relation,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3741,INTRAVENOUS ONDANSETRON treats POSTOPERATIVE EMESIS,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3742,INTRAVENOUS ONDANSETRON treats POSTOPERATIVE EMESIS,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3743,INTRAVENOUS ONDANSETRON treats POSTOPERATIVE EMESIS,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3744,INTRAVENOUS ONDANSETRON treats POSTOPERATIVE EMESIS,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3745,INTRAVENOUS ONDANSETRON treats POSTOPERATIVE EMESIS,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3746,INTRAVENOUS ONDANSETRON treats POSTOPERATIVE EMESIS,treats,1.0,"Khalil SN, Roth AG, Cohen IT et al. A double blind comparison of INTRAVENOUS ONDANSETRON and placebo for preventing POSTOPERATIVE EMESIS in 1  to 24 month old pediatric patients after surgery under general anesthesia.",POSTOPERATIVE EMESIS,INTRAVENOUS ONDANSETRON
3747,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3748,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3749,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3750,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3751,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3752,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3753,MESALAMINE treats ULCERATIVE COLITIS,treats,0.911684611677104,"Levine DS, Pruitt R, Riff D et al. A multi center double blind dose response trial of Colazide ®  (balsalazide disodium) and Asacol ®  (MESALAMINE) for mild moderately active ULCERATIVE COLITIS",ULCERATIVE COLITIS,MESALAMINE
3754,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3755,no_relation,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3756,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3757,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3758,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3759,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3760,OCTREOTIDE treats REFRACTORY DIARRHOEA,treats,0.986393923832144,Treatment of REFRACTORY DIARRHOEA in AIDS with acetorphan and OCTREOTIDE: a randomized crossover study.,REFRACTORY DIARRHOEA,OCTREOTIDE
3761,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3762,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3763,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3764,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3765,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3766,DEXTROSE treats HYPOGLYCEMIA,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3767,no_relation,treats,0.625,Do not substitute for IV DEXTROSE in emergency situations in which HYPOGLYCEMIA is suspected but not established.,HYPOGLYCEMIA,DEXTROSE
3768,no_relation,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3769,no_relation,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3770,no_relation,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3771,no_relation,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3772,OXCARBAZEPINE treats DIABETIC NEUROPATHY,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3773,no_relation,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3774,OXCARBAZEPINE treats DIABETIC NEUROPATHY,treats,0.480384461415261,"Its first metabolite, [OXCARBAZEPINE], is both safe and effective in other neuropathic disorders, but has not been studied in [DIABETIC NEUROPATHY].",DIABETIC NEUROPATHY,OXCARBAZEPINE
3775,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3776,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3777,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3778,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3779,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3780,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3781,no_relation,treats,0.5656854249492379,109  Malignant Hyperthermia Crisis  •  Immediately discontinue all ANESTHETIC AGENTS and institute IV dantrolene as soon as MALIGNANT HYPERTHERMIA crisis is recognized.,MALIGNANT HYPERTHERMIA,ANESTHETIC AGENTS
3782,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3783,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3784,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3785,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3786,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3787,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3788,DOPAMINE treats HYPERDYNAMIC SEPTIC SHOCK,treats,1.0,"2]  Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or DOPAMINE for the treatment of HYPERDYNAMIC SEPTIC SHOCK",HYPERDYNAMIC SEPTIC SHOCK,DOPAMINE
3789,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3790,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3791,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3792,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3793,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3794,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3795,FLUCONAZOLE treats HISTOPLASMOSIS,treats,0.9918365981341752,"Sharkey Mathis PK, Velez J, Fetchick R et alHISTOPLASMOSIS in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and FLUCONAZOLE",HISTOPLASMOSIS,FLUCONAZOLE
3796,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3797,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3798,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3799,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3800,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3801,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3802,MALATHION LOTION treats HEAD LICE,treats,1.0,New Reference of Interest  2010 03 11     Oral ivermectin versus MALATHION LOTION for difficult to treat HEAD LICE,HEAD LICE,MALATHION LOTION
3803,TRANSDERMAL NICOTINE treats ULCERATIVE COLITIS,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3804,TRANSDERMAL NICOTINE treats ULCERATIVE COLITIS,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3805,no_relation,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3806,TRANSDERMAL NICOTINE treats ULCERATIVE COLITIS,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3807,no_relation,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3808,TRANSDERMAL NICOTINE treats ULCERATIVE COLITIS,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3809,TRANSDERMAL NICOTINE treats ULCERATIVE COLITIS,treats,0.975900072948533,for induction of remission in ulcerative colitis (Cochrane Review)  Probiotics for induction of remission in ulcerative colitis (Cochrane Review)  Azathioprine and 6 mercaptopurine for maintenance of remission in ulcerative colitis (Cochrane Review)  TRANSDERMAL NICOTINE for induction of remission in ULCERATIVE COLITIS (Cochrane Review)  Colorectal Disease  Laparoscopic surgery for ulcerative colitis   a meta analysis.,ULCERATIVE COLITIS,TRANSDERMAL NICOTINE
3810,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE treats CENTRAL PRECOCIOUS PUBERTY,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3811,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE treats CENTRAL PRECOCIOUS PUBERTY,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3812,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE treats CENTRAL PRECOCIOUS PUBERTY,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3813,CENTRAL PRECOCIOUS PUBERTY treats DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3814,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE treats CENTRAL PRECOCIOUS PUBERTY,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3815,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE treats CENTRAL PRECOCIOUS PUBERTY,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3816,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE treats CENTRAL PRECOCIOUS PUBERTY,treats,1.0,"Clemons RD, Kappy MS, Stuart TE et al. Long term effectiveness of DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE in the treatment of children with CENTRAL PRECOCIOUS PUBERTY",CENTRAL PRECOCIOUS PUBERTY,DEPOT GONADOTROPIN RELEASING HORMONE ANALOGUE
3817,ESOPHAGUS treats ESOPHAGEAL CANCER,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3818,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3819,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3820,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3821,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3822,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3823,no_relation,treats,0.477334370505438,"Since 1982, three patients with ESOPHAGEAL CANCER complicated with pulmonary bullae have been treated by operation on the ESOPHAGUS and lung in one performance: In all the patients, the bullae were on the same side of the operation.",ESOPHAGUS,ESOPHAGEAL CANCER
3824,no_relation,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3825,DIAZEPAM treats EPILEPTIC,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3826,no_relation,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3827,DIAZEPAM treats EPILEPTIC,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3828,DIAZEPAM treats EPILEPTIC,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3829,no_relation,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3830,DIAZEPAM treats EPILEPTIC,treats,0.995893206467704,[DIAZEPAM] that can be inserted rectally is often prescribed to caregivers of [EPILEPTIC]s.,EPILEPTIC,DIAZEPAM
3831,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3832,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3833,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3834,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3835,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3836,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3837,EZETIMIBE treats HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.962250448649376,"In other studies by the same team, in patients with HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA the addition of EZETIMIBE to 40 mg/d of either simvastatin or atorvastatin increased effectiveness almost 4 times more than increasing the statin dosage to 80 mg/d  (2).",HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
3838,no_relation,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3839,ETOPOSIDE treats MANTLE CELL LYMPHOMA,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3840,ETOPOSIDE treats MANTLE CELL LYMPHOMA,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3841,no_relation,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3842,MANTLE CELL LYMPHOMA treats ETOPOSIDE,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3843,ETOPOSIDE treats MANTLE CELL LYMPHOMA,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3844,ETOPOSIDE treats MANTLE CELL LYMPHOMA,treats,0.9970544855015808,"Oral combination chemotherapy with Pep-C for [MANTLE CELL LYMPHOMA] : Daily prednisone, [ETOPOSIDE], procarbazine and cyclophosphamide.",MANTLE CELL LYMPHOMA,ETOPOSIDE
3845,PROMETHAZINE treats VOMITING,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3846,PROMETHAZINE treats VOMITING,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3847,PROMETHAZINE treats VOMITING,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3848,PROMETHAZINE treats VOMITING,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3849,PROMETHAZINE treats VOMITING,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3850,no_relation,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3851,no_relation,treats,0.9761870601839532,"b  Class:  Antihistamines 56:22.08; First Generation Antihistamines 4:04; A04AD (ATC)  Synonyms:  dimenhy DRINATE ; Anti-nauseant; Anti-nausee; Dimenhydrinate; Dinate; Gravergol; Gravol; Nauseatol; Travel  Uses  Motion Sickness  Used principally in the prevention and treatment of nausea, VOMITING, and/or vertigo associated with motion sickness, although scopolamine, PROMETHAZINE, or meclizine may be more effective",VOMITING,PROMETHAZINE
3852,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3853,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3854,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3855,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3856,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3857,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3858,no_relation,treats,0.338061701891407,131  Individuals with ACUTE TYPHOID INFECTION and those who are chronic typhoid carriers should  not  receive TYPHOID VACCINE,ACUTE TYPHOID INFECTION,TYPHOID VACCINE
3859,no_relation,treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3860,[ANTIRETROVIRAL AGENTS] treats [HIV INFECTED],treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3861,[ANTIRETROVIRAL AGENTS] treats [HIV INFECTED],treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3862,[ANTIRETROVIRAL AGENTS] treats [HIV INFECTED],treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3863,[ANTIRETROVIRAL AGENTS] treats [HIV INFECTED],treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3864,no_relation,treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3865,[ANTIRETROVIRAL AGENTS] treats [HIV INFECTED],treats,0.993858693195776,title=Guidelines for using [ANTIRETROVIRAL AGENTS] among [HIV INFECTED] adults and adolescents.,[HIV INFECTED],[ANTIRETROVIRAL AGENTS]
3866,FROVA treats MENSTRUAL MIGRAINE,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3867,no_relation,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3868,FROVA treats MENSTRUAL MIGRAINE,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3869,FROVA treats MENSTRUAL MIGRAINE,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3870,FROVA treats MENSTRUAL MIGRAINE,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3871,FROVA treats MENSTRUAL MIGRAINE,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3872,FROVA treats MENSTRUAL MIGRAINE,treats,1.0,"If the sNDA is approved, [FROVA] will be the only medication indicated in the U.S. for the short-term prevention of [MENSTRUAL MIGRAINE] .",MENSTRUAL MIGRAINE,FROVA
3873,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3874,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3875,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3876,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3877,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3878,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3879,ERYTHROMYCIN treats ACNE VULGARIS,treats,0.99654575824488,Topical clindamycin and ERYTHROMYCIN are used as primary or adjunctive treatment for ACNE VULGARIS in patients who do not warrant or tolerate oral antibiotics.,ACNE VULGARIS,ERYTHROMYCIN
3880,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3881,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3882,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3883,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3884,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3885,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3886,METHOTREXATE treats RHEUMATOID ARTHRITIS,treats,0.997458699830735,However some studies have shown that the combination of [METHOTREXATE] and leflunomide in patients with [RHEUMATOID ARTHRITIS] gave better results than either drug alone.,RHEUMATOID ARTHRITIS,METHOTREXATE
3887,no_relation,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3888,GABAPENTIN treats ACUTE AND CHRONIC PAIN,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3889,GABAPENTIN treats ACUTE AND CHRONIC PAIN,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3890,GABAPENTIN treats ACUTE AND CHRONIC PAIN,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3891,GABAPENTIN treats ACUTE AND CHRONIC PAIN,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3892,GABAPENTIN treats ACUTE AND CHRONIC PAIN,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3893,GABAPENTIN treats ACUTE AND CHRONIC PAIN,treats,1.0,GABAPENTIN for ACUTE AND CHRONIC PAIN,ACUTE AND CHRONIC PAIN,GABAPENTIN
3894,PROSTAGLANDIN treats CIRRHOSIS,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3895,PROSTAGLANDIN treats CIRRHOSIS,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3896,PROSTAGLANDIN treats CIRRHOSIS,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3897,no_relation,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3898,no_relation,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3899,PROSTAGLANDIN treats CIRRHOSIS,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3900,PROSTAGLANDIN treats CIRRHOSIS,treats,0.936329177569045,"Nitric oxide, [PROSTAGLANDIN]s, and other vasoactive substances have been hypothesized as powerful mediators of splanchnic vasodilation in [CIRRHOSIS].",CIRRHOSIS,PROSTAGLANDIN
3901,LEVODOPA treats PARKINSON'S DISEASE,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3902,LEVODOPA treats PARKINSON'S DISEASE,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3903,LEVODOPA treats PARKINSON'S DISEASE,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3904,LEVODOPA treats PARKINSON'S DISEASE,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3905,no_relation,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3906,LEVODOPA treats PARKINSON'S DISEASE,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3907,LEVODOPA treats PARKINSON'S DISEASE,treats,0.6488856845230501,Lieberman A. Long term experience with selegiline and LEVODOPA in PARKINSON'S DISEASE,PARKINSON'S DISEASE,LEVODOPA
3908,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3909,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3910,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3911,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3912,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3913,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3914,INH treats TB,treats,1.0,The reason for maintaining the patient on INH is that INH is so potent in treating TB that it is foolish to omit it until there is microbiological proof that it is ineffective (even though isoniazid resistance so commonly occurs with rifampicin resistance.,TB,INH
3915,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3916,no_relation,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3917,no_relation,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3918,no_relation,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3919,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3920,PHEOCHROMOCYTOMA treats HYPERTENSION,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3921,no_relation,treats,0.9918365981341752,Removal of PHEOCHROMOCYTOMA may also cure HYPERTENSION ( 77.,HYPERTENSION,PHEOCHROMOCYTOMA
3922,no_relation,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3923,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3924,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3925,no_relation,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3926,no_relation,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3927,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN treats INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3928,no_relation,treats,0.7293249574894731,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
3929,no_relation,treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3930,10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) treats TUBERCULIN,treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3931,TUBERCULIN treats 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3932,TUBERCULIN treats 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3933,no_relation,treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3934,no_relation,treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3935,10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) treats TUBERCULIN,treats,0.707106781186547,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
3936,HTLV III/LAV treats AIDS,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3937,no_relation,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3938,HTLV III/LAV treats AIDS,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3939,no_relation,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3940,HTLV III/LAV treats AIDS,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3941,no_relation,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3942,HTLV III/LAV treats AIDS,treats,0.6,"Yarchoan R, Klecker RE, Weinhold KJ et al Administration of 3′ azido 3′ deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS related complex.",AIDS,HTLV III/LAV
3943,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3944,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3945,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3946,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3947,HYPERTENSION treats DOXAZOSIN,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3948,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3949,DOXAZOSIN treats HYPERTENSION,treats,0.99654575824488,He took a 1 mg tablet of DOXAZOSIN daily for mild HYPERTENSION,HYPERTENSION,DOXAZOSIN
3950,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3951,no_relation,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3952,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3953,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3954,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3955,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3956,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,treats,0.609994281330419,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE
3957,INSULIN ASPART treats TYPE 1 DIABETES,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3958,INSULIN ASPART treats TYPE 1 DIABETES,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3959,INSULIN ASPART treats TYPE 1 DIABETES,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3960,INSULIN ASPART treats TYPE 1 DIABETES,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3961,INSULIN ASPART treats TYPE 1 DIABETES,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3962,INSULIN ASPART treats TYPE 1 DIABETES,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3963,no_relation,treats,0.99654575824488,"Bode BW, Strange P. The efficacy, safety, and pump compatibility of INSULIN ASPART used in continuous subcutaneous insulin infusion therapy in patients with TYPE 1 DIABETES",TYPE 1 DIABETES,INSULIN ASPART
3964,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3965,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3966,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3967,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3968,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3969,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3970,ERGONOVINE treats VARIANT ANGINA,treats,0.957427107756338,"However, in patients with VARIANT ANGINA, a small dose of ERGONOVINE produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",VARIANT ANGINA,ERGONOVINE
3971,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3972,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3973,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3974,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3975,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3976,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3977,ALPROX treats ERECTILE DYSFUNCTION,treats,0.9704949588,NexMed is developing transdermal formulations - [ALPROX]-TDfor men with [ERECTILE DYSFUNCTION] and Femproxfor female sexual arousal disorder.,ERECTILE DYSFUNCTION,ALPROX
3978,LORAZEPAM treats EMESIS,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3979,LORAZEPAM treats EMESIS,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3980,LORAZEPAM treats EMESIS,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3981,no_relation,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3982,LORAZEPAM treats EMESIS,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3983,no_relation,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3984,LORAZEPAM treats EMESIS,treats,0.99654575824488,A randomized double blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and LORAZEPAM in the prevention of EMESIS due to cisplatin based chemotherapy.,EMESIS,LORAZEPAM
3985,no_relation,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3986,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3987,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3988,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3989,FONDAPARINUX VERSUS POSTOPERATIVE treats VENOUS THROMBOEMBOLISM,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3990,no_relation,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3991,no_relation,treats,0.986393923832144,"1]  Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Postoperative FONDAPARINUX VERSUS POSTOPERATIVE enoxaparin for prevention of VENOUS THROMBOEMBOLISM after elective hip replacement surgery: a randomised double blind trial.",VENOUS THROMBOEMBOLISM,FONDAPARINUX VERSUS POSTOPERATIVE
3992,CONVENTIONAL AMPHOTERICIN B treats EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3993,CONVENTIONAL AMPHOTERICIN B treats EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3994,CONVENTIONAL AMPHOTERICIN B treats EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3995,no_relation,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3996,no_relation,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3997,no_relation,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3998,no_relation,treats,0.8741572761215379,"211 ,   245 ,   293 ,   426 ,   436  CONVENTIONAL AMPHOTERICIN B in HIV infected adults with diffuse pulmonary or EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS: 0.7 1 mg/kg daily.",EXTRATHORACIC DISSEMINATED COCCIDIOIDOMYCOSIS,CONVENTIONAL AMPHOTERICIN B
3999,ABCIXIMAB treats REFRACTORY UNSTABLE ANGINA,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4000,ABCIXIMAB treats REFRACTORY UNSTABLE ANGINA,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4001,ABCIXIMAB treats REFRACTORY UNSTABLE ANGINA,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4002,ABCIXIMAB treats REFRACTORY UNSTABLE ANGINA,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4003,ABCIXIMAB treats REFRACTORY UNSTABLE ANGINA,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4004,REFRACTORY UNSTABLE ANGINA treats ABCIXIMAB,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4005,no_relation,treats,0.889000889001333,Randomised placebo controlled trial of ABCIXIMAB before and during coronary intervention in REFRACTORY UNSTABLE ANGINA: the CAPTURE study.,REFRACTORY UNSTABLE ANGINA,ABCIXIMAB
4006,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4007,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4008,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4009,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4010,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4011,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4012,THALIDOMIDE treats ERYTHEMA NODOSUM LEPROSUM,treats,0.979957887012223,THALIDOMIDE approved for ERYTHEMA NODOSUM LEPROSUM.,ERYTHEMA NODOSUM LEPROSUM,THALIDOMIDE
4013,no_relation,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4014,no_relation,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4015,no_relation,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4016,no_relation,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4017,no_relation,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4018,MARFAN SYNDROME treats ASCENDING AORTIC ANEURYSM,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4019,no_relation,treats,0.486664263392288,"At some high volume centers, the threshold for elective repair of an ASCENDING AORTIC ANEURYSM in a patient with MARFAN SYNDROME may be even lower.",ASCENDING AORTIC ANEURYSM,MARFAN SYNDROME
4020,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4021,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4022,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4023,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4024,ESTROGEN treats POSTMENOPAUSAL BONE LOSS,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4025,POSTMENOPAUSAL BONE LOSS treats ESTROGEN,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4026,no_relation,treats,0.970142500145332,"In order to evaluate the preventive effect of estrogen and vitamin D3 on POSTMENOPAUSAL BONE LOSS, either ESTROGEN (Premarin 0.625 mg/day) or vitamin D3 (Onealfa 1.0 micrograms/day) was administered to postmenopausal women",POSTMENOPAUSAL BONE LOSS,ESTROGEN
4027,LEVOTHYROXINE treats HYPOTHYROIDISM,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4028,LEVOTHYROXINE treats HYPOTHYROIDISM,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4029,LEVOTHYROXINE treats HYPOTHYROIDISM,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4030,LEVOTHYROXINE treats HYPOTHYROIDISM,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4031,HYPOTHYROIDISM treats LEVOTHYROXINE,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4032,LEVOTHYROXINE treats HYPOTHYROIDISM,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4033,LEVOTHYROXINE treats HYPOTHYROIDISM,treats,0.995893206467704,Bioequivalence of generic and brand name LEVOTHYROXINE products in the treatment of HYPOTHYROIDISM,HYPOTHYROIDISM,LEVOTHYROXINE
4034,GLUTEN FREE DIET treats COELIAC DISEASE,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4035,no_relation,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4036,GLUTEN FREE DIET treats COELIAC DISEASE,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4037,GLUTEN FREE DIET treats COELIAC DISEASE,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4038,GLUTEN FREE DIET treats COELIAC DISEASE,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4039,GLUTEN FREE DIET treats COELIAC DISEASE,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4040,GLUTEN FREE DIET treats COELIAC DISEASE,treats,0.995893206467704,The 5 HT level in PPP was significantly increased in patients with coeliac disease in whom the disease was untreated or treated with gluten free diet for less than a year (p less than 0.01) but also compared with the patients with COELIAC DISEASE treated with a GLUTEN FREE DIET for more than a year (p less than 0.01.,GLUTEN FREE DIET,COELIAC DISEASE
4041,RIFAMPICIN treats DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4042,RIFAMPICIN treats DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4043,RIFAMPICIN treats DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4044,RIFAMPICIN treats DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4045,DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS treats RIFAMPICIN,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4046,RIFAMPICIN treats DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4047,RIFAMPICIN treats DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,treats,0.9830783046228492,"Benator D, Bhattacharya M, Bozeman L, et al: Rifapentine and isoniazid once a week versus RIFAMPICIN and isoniazid twice a week for treatment of DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS in HIV negative patients: a randomised clinical trial.",DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS,RIFAMPICIN
4048,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4049,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4050,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4051,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4052,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4053,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4054,AMPHOTERICIN B treats CYSTITIS,treats,0.997785157856609,"440  >     Treatment of Symptomatic Cystitis, Pyelonephritis, or Fungus Balls  IV:  Conventional AMPHOTERICIN B: 0.3 0.6 mg/kg daily for 1 7 days for symptomatic CYSTITIS",CYSTITIS,AMPHOTERICIN B
4055,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4056,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4057,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4058,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4059,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4060,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4061,PILOCARPINE treats RADIATION INDUCED XEROSTOMIA,treats,0.9918365981341752,"Two hundred sixty five patients with head and neck cancer who had previously participated in either a fixed dose, dose titration, or dose ranging trial of oral pilocarpine hydrochloride tablets were enrolled in a 36 month multicenter maintenance study to evaluate the long term safety and efficacy of oral PILOCARPINE for the treatment of RADIATION INDUCED XEROSTOMIA",RADIATION INDUCED XEROSTOMIA,PILOCARPINE
4062,no_relation,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4063,no_relation,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4064,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4065,no_relation,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4066,ARREST ARRHYTHMIA treats AGENTS (ATROPINE,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4067,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4068,AGENTS (ATROPINE treats ARREST ARRHYTHMIA,treats,0.666666666666667,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
4069,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4070,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4071,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4072,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4073,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4074,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4075,GABAPENTIN treats CHRONIC PAIN,treats,0.997458699830735,Tiagabine and GABAPENTIN for the management of CHRONIC PAIN,CHRONIC PAIN,GABAPENTIN
4076,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4077,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4078,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4079,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4080,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4081,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4082,ANTIARRHYTHMIC AGENTS treats DYSRHYTHMIA,treats,0.995893206467704,"DYSRHYTHMIA should be treated with atropine, ANTIARRHYTHMIC AGENTS, and a temporary pacemaker, in order to avoid lethal results",DYSRHYTHMIA,ANTIARRHYTHMIC AGENTS
4083,AMPHOTERICIN B treats INVASIVE ASPERGILLOSIS,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4084,AMPHOTERICIN B treats INVASIVE ASPERGILLOSIS,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4085,AMPHOTERICIN B treats INVASIVE ASPERGILLOSIS,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4086,AMPHOTERICIN B treats INVASIVE ASPERGILLOSIS,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4087,INVASIVE ASPERGILLOSIS treats AMPHOTERICIN B,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4088,AMPHOTERICIN B treats INVASIVE ASPERGILLOSIS,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4089,AMPHOTERICIN B treats INVASIVE ASPERGILLOSIS,treats,0.995893206467704,"White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vsAMPHOTERICIN B as therapy for INVASIVE ASPERGILLOSIS",INVASIVE ASPERGILLOSIS,AMPHOTERICIN B
4090,AMPHOTERICIN treats BLASTOMYCOSIS,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4091,no_relation,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4092,AMPHOTERICIN treats BLASTOMYCOSIS,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4093,AMPHOTERICIN treats BLASTOMYCOSIS,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4094,AMPHOTERICIN treats BLASTOMYCOSIS,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4095,AMPHOTERICIN treats BLASTOMYCOSIS,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4096,AMPHOTERICIN treats BLASTOMYCOSIS,treats,1.0,423  Blastomycosis  >     Treatment of BLASTOMYCOSIS  IV:  Conventional AMPHOTERICIN B: 0.5 1 mg/kg daily.,BLASTOMYCOSIS,AMPHOTERICIN
4097,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4098,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4099,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4100,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4101,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4102,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4103,[ELECTROCONVULSIVE THERAPY] treats [PSYCHOTIC SYMPTOMS],treats,0.9970544855015808,"[ELECTROCONVULSIVE THERAPY] or ECT has been shown to reduce [PSYCHOTIC SYMPTOMS] associated with schizophrenia, mania, and depression, and is often used in psychiatric hospitals.",[PSYCHOTIC SYMPTOMS],[ELECTROCONVULSIVE THERAPY]
4104,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4105,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4106,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4107,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4108,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4109,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4110,CLOMIPRAMINE treats OBSESSIVE COMPULSIVE DISORDER,treats,1.0,"Freeman CPL, Trimble MR, Deakin JFW et al. Fluvoxamine versus CLOMIPRAMINE in the treatment of OBSESSIVE COMPULSIVE DISORDER: a multicenter, randomized, double blind, parallel group comparison.",OBSESSIVE COMPULSIVE DISORDER,CLOMIPRAMINE
4111,HUMAN INSULIN treats TYPE 1 DIABETES,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4112,HUMAN INSULIN treats TYPE 1 DIABETES,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4113,HUMAN INSULIN treats TYPE 1 DIABETES,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4114,HUMAN INSULIN treats TYPE 1 DIABETES,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4115,HUMAN INSULIN treats TYPE 1 DIABETES,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4116,HUMAN INSULIN treats TYPE 1 DIABETES,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4117,no_relation,treats,0.940720868383597,Glycated hemoglobin (HbA 1c ) was reduced more with short acting insulin analogues than with regular HUMAN INSULIN in patients with TYPE 1 DIABETES; no difference was seen in patients with type 2 diabetes (Table.,TYPE 1 DIABETES,HUMAN INSULIN
4118,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4119,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4120,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4121,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4122,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4123,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4124,ASPIRIN treats MYOCARDIAL INFARCTION,treats,0.971285862357264,2005 03 24     Addition of clopidogrel to ASPIRIN and fibrinolytic therapy for MYOCARDIAL INFARCTION with ST segment elevation.,MYOCARDIAL INFARCTION,ASPIRIN
4125,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4126,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4127,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4128,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4129,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4130,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4131,BLEOMYCIN treats HODGKIN'S DISEASE,treats,0.99654575824488,"Wiernik PH, Longo D, Duffey PL et al. MOPP vs. MOPP alternating with streptozotocin, CCNU, adriamycin and BLEOMYCIN (SCAB) for advanced HODGKIN'S DISEASE",HODGKIN'S DISEASE,BLEOMYCIN
4132,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4133,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4134,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4135,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4136,no_relation,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4137,TUBERCULOSIS treats ISONIAZID,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4138,ISONIAZID treats TUBERCULOSIS,treats,0.903696114115064,"After an outbreak of hepatitis in Washington, D.C. in 1970 among a group of persons taking isoniazid to prevent TUBERCULOSIS an ISONIAZID surveillance study was conducted among 13,838 persons in 21 participating health departments.",TUBERCULOSIS,ISONIAZID
4139,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4140,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4141,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4142,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4143,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4144,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4145,COTRIMOXAZOLE treats MELIOIDOSIS,treats,0.9918365981341752,title=Dosing regimens of [COTRIMOXAZOLE] for [MELIOIDOSIS].,MELIOIDOSIS,COTRIMOXAZOLE
4146,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4147,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4148,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4149,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4150,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4151,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4152,FLUTAMIDE treats HIRSUTISM,treats,0.9897433186107868,17of 18 women with hirsutism treated with combination therapy of FLUTAMIDE 250 mg twice daily and an oral contraceptive pill had a rapid and marked reduction in their HIRSUTISM score.,HIRSUTISM,FLUTAMIDE
4153,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4154,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4155,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4156,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4157,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4158,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4159,FLUCONAZOLE treats RECURRENT VULVOVAGINAL CANDIDIASIS,treats,0.99654575824488,"1]  Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance FLUCONAZOLE therapy for RECURRENT VULVOVAGINAL CANDIDIASIS",RECURRENT VULVOVAGINAL CANDIDIASIS,FLUCONAZOLE
4160,no_relation,treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4161,[ZOLINZA] treats [HIV INFECTED T CELLS],treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4162,no_relation,treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4163,[ZOLINZA] treats [HIV INFECTED T CELLS],treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4164,[ZOLINZA] treats [HIV INFECTED T CELLS],treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4165,[ZOLINZA] treats [HIV INFECTED T CELLS],treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4166,[ZOLINZA] treats [HIV INFECTED T CELLS],treats,0.99124070716193,[ZOLINZA] was recently shown to have both in vitro and in vivo effects against latently [HIV INFECTED T CELLS].,[HIV INFECTED T CELLS],[ZOLINZA]
4167,IRBESARTAN treats TYPE II DIABETES,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4168,IRBESARTAN treats TYPE II DIABETES,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4169,IRBESARTAN treats TYPE II DIABETES,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4170,IRBESARTAN treats TYPE II DIABETES,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4171,IRBESARTAN treats TYPE II DIABETES,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4172,no_relation,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4173,IRBESARTAN treats TYPE II DIABETES,treats,0.993127066322842,"[IRBESARTAN] and losartan have trial data showing benefit in hypertensive patients with [TYPE II DIABETES], and may delay the progression of diabetic nephropathy.",TYPE II DIABETES,IRBESARTAN
4174,no_relation,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4175,CLOSTRIDIUM treats CLOSTRIDIUM INFECTIONS,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4176,no_relation,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4177,no_relation,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4178,no_relation,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4179,CLOSTRIDIUM treats CLOSTRIDIUM INFECTIONS,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4180,no_relation,treats,0.406138466053448,100  CLOSTRIDIUM INFECTIONS  Treatment of infections caused by  CLOSTRIDIUM,CLOSTRIDIUM INFECTIONS,CLOSTRIDIUM
4181,no_relation,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4182,no_relation,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4183,no_relation,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4184,PROPYLTHIOURACIL treats PREGNANCY,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4185,no_relation,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4186,PROPYLTHIOURACIL treats PREGNANCY,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4187,PROPYLTHIOURACIL treats PREGNANCY,treats,0.7624928516630229,• Methimazole and carbimazole are used during PREGNANCY in many countries where PROPYLTHIOURACIL is not commercially available ( 25.,PREGNANCY,PROPYLTHIOURACIL
4188,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4189,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4190,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4191,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4192,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4193,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4194,VINCRISTINE treats HODGKIN'S DISEASE,treats,1.0,"Seventy six patients with previously untreated advanced HODGKIN'S DISEASE have been treated with the MOPP/ABV (mechlorethamine, VINCRISTINE procarbazine, prednisone/doxorubicin, bleomycin, vincristine) hybrid program.",HODGKIN'S DISEASE,VINCRISTINE
4195,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4196,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4197,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4198,HYPERTENSION treats HYDROCHLOROTHIAZIDE,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4199,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4200,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4201,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.99654575824488,"In addition, her past medical history is significant for HYPERTENSION for which she is being treated with HYDROCHLOROTHIAZIDE; hyperlipidemia, for which she is taking a HMG CoA reductase inhibitor; and gestational diabetes when she was pregnant with her second child 6 years ago, for which she required insulin therapy.",HYPERTENSION,HYDROCHLOROTHIAZIDE
4202,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4203,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4204,CRYPTOCOCCAL MENINGITIS treats AMPHOTERICIN B,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4205,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4206,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4207,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4208,AMPHOTERICIN B treats CRYPTOCOCCAL MENINGITIS,treats,0.964901281354015,A note to physicians: important information on results of a control clinical trial of fluconazole vs. AMPHOTERICIN B for suppression of CRYPTOCOCCAL MENINGITIS,CRYPTOCOCCAL MENINGITIS,AMPHOTERICIN B
4209,DEXTROSE treats HYPOGLYCEMIA,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4210,DEXTROSE treats HYPOGLYCEMIA,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4211,DEXTROSE treats HYPOGLYCEMIA,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4212,DEXTROSE treats HYPOGLYCEMIA,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4213,no_relation,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4214,DEXTROSE treats HYPOGLYCEMIA,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4215,DEXTROSE treats HYPOGLYCEMIA,treats,0.970142500145332,• Administer either 5% or 10% DEXTROSE during quinidine infusion to reduce the incidence of HYPOGLYCEMIA,HYPOGLYCEMIA,DEXTROSE
4216,ATENOLOL treats MYOCARDIAL INFARCTION,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4217,ATENOLOL treats MYOCARDIAL INFARCTION,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4218,no_relation,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4219,ATENOLOL treats MYOCARDIAL INFARCTION,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4220,ATENOLOL treats MYOCARDIAL INFARCTION,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4221,ATENOLOL treats MYOCARDIAL INFARCTION,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4222,ATENOLOL treats MYOCARDIAL INFARCTION,treats,0.986393923832144,"Telford AM, Wilson C. Trial of heparin versus ATENOLOL in prevention of MYOCARDIAL INFARCTION in intermediate coronary syndrome.",MYOCARDIAL INFARCTION,ATENOLOL
4223,MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS treats DHPG,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4224,DHPG treats MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4225,DHPG treats MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4226,DHPG treats MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4227,DHPG treats MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4228,DHPG treats MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4229,DHPG treats MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,treats,0.994134846772434,"Shabtai M, Luft B, Waltzer WC et al. MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS in a renal transplant recipient: successful treatment with DHPG",MASSIVE CYTOMEGALOVIRUS PNEUMONIA AND MYOCARDITIS,DHPG
4230,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4231,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4232,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4233,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4234,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4235,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4236,PHYTONADIONE treats HYPOPROTHROMBINEMIA,treats,0.99124070716193,"Unless severe hepatocellular damage is present, HYPOPROTHROMBINEMIA usually subsides after use of PHYTONADIONE (vitamin K 1 ) 5 to 10 mg sc once/day for 2 to 3 days.",HYPOPROTHROMBINEMIA,PHYTONADIONE
4237,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4238,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4239,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4240,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4241,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4242,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4243,IMIQUIMOD THERAPY treats PENILE CONDYLOMA WITH EROSION,treats,0.4681645887845221,PENILE CONDYLOMA WITH EROSION after Imiquimod Therapy  Characteristic condyloma over the penile shaft and foreskin with adjacent erosions after IMIQUIMOD THERAPY.,PENILE CONDYLOMA WITH EROSION,IMIQUIMOD THERAPY
4244,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4245,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4246,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4247,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4248,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4249,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4250,CITALOPRAM treats OBSESSIVE COMPULSIVE DISORDER,treats,0.9970544855015808,"Kopenen H, Lepola U, Leinonen E et alCITALOPRAM in the treatment of OBSESSIVE COMPULSIVE DISORDER: an open pilot study.",OBSESSIVE COMPULSIVE DISORDER,CITALOPRAM
4251,[GRD] treats [GREASE],treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4252,[GRD] treats [GREASE],treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4253,no_relation,treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4254,[GRD] treats [GREASE],treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4255,[GRD] treats [GREASE],treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4256,[GRD] treats [GREASE],treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4257,[GRD] treats [GREASE],treats,0.999261174631314,A [GRD] stops the [GREASE] at the source. (,[GRD],[GREASE]
4258,no_relation,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4259,no_relation,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4260,no_relation,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4261,no_relation,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4262,no_relation,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4263,no_relation,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4264,LONG TERM LEAD EXPOSURE treats SATURNINE GOUT,treats,0.445435403187374,"91   93   LONG TERM LEAD EXPOSURE can result in chronic tubulointerstitial nephritis and renal insufficiency, hypertension, and SATURNINE GOUT from reduced renal excretion of uric acid.",SATURNINE GOUT,LONG TERM LEAD EXPOSURE
4265,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4266,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4267,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4268,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4269,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4270,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4271,PROPRANOLOL treats HYPERTENSION,treats,0.977355554850442,"Semplicini A, Rossi GP, Bongiovi S et al. Time course changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double blind randomized study vs hydrochlorothiazide plus PROPRANOLOL in essential HYPERTENSION",HYPERTENSION,PROPRANOLOL
4272,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4273,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4274,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4275,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4276,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4277,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4278,ROLAIDS treats ACID REFLUX,treats,0.997458699830735,"antacids - nexium, tums, Pepcid AC, [ROLAIDS], etc. reduces [ACID REFLUX] in the case of hiatal hernia or other.",ACID REFLUX,ROLAIDS
4279,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4280,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4281,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4282,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4283,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4284,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4285,TRAZODONE treats NUTCRACKER ESOPHAGUS,treats,0.9878783399,"Finally, [TRAZODONE], an anti-depressant that reduces visceral sensitivity, has also been shown to reduce chest pain symptoms in patients with [NUTCRACKER ESOPHAGUS].",NUTCRACKER ESOPHAGUS,TRAZODONE
4286,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4287,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4288,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4289,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4290,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4291,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4292,DOXYCYCLINE treats EARLY SYPHILIS,treats,0.9594032236002472,DOXYCYCLINE compared with benzathine penicillin for the treatment of EARLY SYPHILIS,EARLY SYPHILIS,DOXYCYCLINE
4293,CARVEDILOL treats CONGESTIVE HEART FAILURE,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4294,CARVEDILOL treats CONGESTIVE HEART FAILURE,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4295,CARVEDILOL treats CONGESTIVE HEART FAILURE,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4296,CARVEDILOL treats CONGESTIVE HEART FAILURE,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4297,no_relation,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4298,CARVEDILOL treats CONGESTIVE HEART FAILURE,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4299,CONGESTIVE HEART FAILURE treats CARVEDILOL,treats,0.948683298050514,"Randomised, placebo controlled trial of CARVEDILOL in patients with CONGESTIVE HEART FAILURE due to ischaemic heart disease.",CONGESTIVE HEART FAILURE,CARVEDILOL
4300,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4301,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4302,no_relation,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4303,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4304,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4305,no_relation,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4306,EZETIMIBE treats FAMILIAL HYPERCHOLESTEROLEMIA,treats,0.312347523777212,"2]  Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without EZETIMIBE in FAMILIAL HYPERCHOLESTEROLEMIA",FAMILIAL HYPERCHOLESTEROLEMIA,EZETIMIBE
4307,INTERFERON ALFA THERAPY treats HCV ASSOCIATED CRYOGLOBULINEMIA,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4308,no_relation,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4309,INTERFERON ALFA THERAPY treats HCV ASSOCIATED CRYOGLOBULINEMIA,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4310,INTERFERON ALFA THERAPY treats HCV ASSOCIATED CRYOGLOBULINEMIA,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4311,INTERFERON ALFA THERAPY treats HCV ASSOCIATED CRYOGLOBULINEMIA,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4312,INTERFERON ALFA THERAPY treats HCV ASSOCIATED CRYOGLOBULINEMIA,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4313,no_relation,treats,0.992277876713668,"Evidence: • In one controlled study, 20 patients with HCV ASSOCIATED CRYOGLOBULINEMIA who had failed to respond to INTERFERON ALFA THERAPY were treated with rituximab; 16 had rapid and complete remission, which was sustained in 12 subjects ( 70.",HCV ASSOCIATED CRYOGLOBULINEMIA,INTERFERON ALFA THERAPY
4314,[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4315,[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4316,[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4317,[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4318,[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4319,[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] treats [ITCHING],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4320,[ITCHING] treats [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES],treats,0.9897433186107868,Topical [CORTICOSTEROIDS AND ORAL ANTIHISTAMINES] can alleviate the [ITCHING] and decrease the size and number of lesions.,[ITCHING],[CORTICOSTEROIDS AND ORAL ANTIHISTAMINES]
4321,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4322,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4323,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4324,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4325,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4326,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4327,RIBAVIRIN treats CHRONIC HEPATITIS C,treats,0.9897433186107868,"Carrat F, Bani Sadr F, Pol S, et al: Pegylated interferon alfa 2b vs standard interferon alfa 2b, plus RIBAVIRIN for CHRONIC HEPATITIS C in HIV infected patients: a randomized controlled trial.",CHRONIC HEPATITIS C,RIBAVIRIN
4328,no_relation,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4329,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4330,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4331,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4332,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4333,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4334,INTERFERON THERAPY treats ADVANCED RENAL CELL CARCINOMA,treats,0.966736489045664,"Abdi EA, Nguyen GK, Ludwig RN et al. Pulmonary sarcoidosis following INTERFERON THERAPY for ADVANCED RENAL CELL CARCINOMA",ADVANCED RENAL CELL CARCINOMA,INTERFERON THERAPY
4335,no_relation,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4336,no_relation,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4337,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4338,BRONCHIAL HYPERREACTIVITY treats METHACHOLINE,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4339,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4340,METHACHOLINE treats BRONCHIAL HYPERREACTIVITY,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4341,no_relation,treats,0.8955334711889901,We found that active pulmonary tuberculosis would increase the nonspecific bronchial response with METHACHOLINE and the mechanism of the BRONCHIAL HYPERREACTIVITY in patients with active pulmonary tuberculosis may not be related to an immunologic mechanism but may be related to the stimulating receptors.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE
4342,[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] treats [EQUINE DYSTOCIA],treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4343,[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] treats [EQUINE DYSTOCIA],treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4344,no_relation,treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4345,[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] treats [EQUINE DYSTOCIA],treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4346,[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] treats [EQUINE DYSTOCIA],treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4347,[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] treats [EQUINE DYSTOCIA],treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4348,[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] treats [EQUINE DYSTOCIA],treats,0.99124070716193,title = A case report on the use of [GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA] for [EQUINE DYSTOCIA],[EQUINE DYSTOCIA],[GUAIFENESIN KETAMINE XYLAZINE ANESTHESIA]
4349,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4350,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4351,no_relation,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4352,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4353,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4354,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4355,CLONIDINE treats TAMOXIFEN ASSOCIATED HOT FLASHES,treats,0.986393923832144,CLONIDINE was effective for reducing TAMOXIFEN ASSOCIATED HOT FLASHES in postmenopausal women with breast cancer  Keywords: Breast neoplasms Hot flashes Tamoxifen  ACP Journal Club.,TAMOXIFEN ASSOCIATED HOT FLASHES,CLONIDINE
4356,PARACETAMOL treats MINOR PAIN,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4357,PARACETAMOL treats MINOR PAIN,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4358,no_relation,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4359,PARACETAMOL treats MINOR PAIN,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4360,PARACETAMOL treats MINOR PAIN,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4361,PARACETAMOL treats MINOR PAIN,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4362,PARACETAMOL treats MINOR PAIN,treats,0.9284766908852592,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL
4363,ACEBUTOLOL treats ESSENTIAL HYPERTENSION,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4364,ACEBUTOLOL treats ESSENTIAL HYPERTENSION,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4365,ESSENTIAL HYPERTENSION treats ACEBUTOLOL,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4366,ACEBUTOLOL treats ESSENTIAL HYPERTENSION,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4367,ACEBUTOLOL treats ESSENTIAL HYPERTENSION,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4368,ACEBUTOLOL treats ESSENTIAL HYPERTENSION,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4369,ESSENTIAL HYPERTENSION treats ACEBUTOLOL,treats,0.707106781186548,"Thibonnier M, Lardoux MD, Corvol P. Comparative trial of labetalol and ACEBUTOLOL alone or associated with dihydralazine, in treatment of ESSENTIAL HYPERTENSION",ESSENTIAL HYPERTENSION,ACEBUTOLOL
4370,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4371,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4372,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4373,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4374,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4375,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4376,L DOPA WITH PERIPHERAL DECARBOXYLASE treats PARKINSON'S SYNDROME,treats,0.979957887012223,In 38 patients with PARKINSON'S SYNDROME Madopar preparation was used (L DOPA WITH PERIPHERAL DECARBOXYLASE inhibitor) in 33 cases as the main drug and in 5 cases as an addition to L dopa.,PARKINSON'S SYNDROME,L DOPA WITH PERIPHERAL DECARBOXYLASE
4377,no_relation,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4378,HYOSCYAMINE treats PARALYTIC ILEUS,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4379,HYOSCYAMINE treats PARALYTIC ILEUS,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4380,HYOSCYAMINE treats PARALYTIC ILEUS,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4381,HYOSCYAMINE treats PARALYTIC ILEUS,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4382,no_relation,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4383,no_relation,treats,0.41931393468876704,"When [HYOSCYAMINE] is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of [PARALYTIC ILEUS].",PARALYTIC ILEUS,HYOSCYAMINE
4384,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4385,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4386,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4387,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4388,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4389,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4390,AMOXYCILLIN treats URINARY INFECTION,treats,1.0,"Al Roomi LG, Sutton AM, Cockburn F et alAMOXYCILLIN and clavulanic acid in the treatment of URINARY INFECTION",URINARY INFECTION,AMOXYCILLIN
4391,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4392,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4393,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4394,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4395,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4396,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4397,ALTEPLASE treats MYOCARDIAL INFARCTION,treats,0.993127066322842,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12 U/kg/h infusion (maximum 1000 U/h) is recommended with ALTEPLASE for ST elevation MYOCARDIAL INFARCTION",MYOCARDIAL INFARCTION,ALTEPLASE
4398,ZIDOVUDINE treats ACQUIRED IMMUNODEFICIENCY SYNDROME,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4399,ZIDOVUDINE treats ACQUIRED IMMUNODEFICIENCY SYNDROME,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4400,ZIDOVUDINE treats ACQUIRED IMMUNODEFICIENCY SYNDROME,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4401,ZIDOVUDINE treats ACQUIRED IMMUNODEFICIENCY SYNDROME,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4402,ZIDOVUDINE treats ACQUIRED IMMUNODEFICIENCY SYNDROME,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4403,no_relation,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4404,ZIDOVUDINE treats ACQUIRED IMMUNODEFICIENCY SYNDROME,treats,0.529812942826018,"Interferon  α with ZIDOVUDINE: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS.",ACQUIRED IMMUNODEFICIENCY SYNDROME,ZIDOVUDINE
4405,INSULIN LISPRO treats TYPE 2 DIABETES MELLITUS,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4406,no_relation,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4407,INSULIN LISPRO treats TYPE 2 DIABETES MELLITUS,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4408,INSULIN LISPRO treats TYPE 2 DIABETES MELLITUS,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4409,INSULIN LISPRO treats TYPE 2 DIABETES MELLITUS,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4410,INSULIN LISPRO treats TYPE 2 DIABETES MELLITUS,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4411,INSULIN LISPRO treats TYPE 2 DIABETES MELLITUS,treats,1.0,"Bastyr EJ, Johnson ME, Trautman ME et alINSULIN LISPRO in the treatment of patients with TYPE 2 DIABETES MELLITUS after oral agent failure.",TYPE 2 DIABETES MELLITUS,INSULIN LISPRO
4412,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4413,no_relation,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4414,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4415,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4416,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4417,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4418,GLUTEN FREE DIET treats CELIAC DISEASE,treats,0.9901475429766742,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE
4419,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4420,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4421,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4422,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4423,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4424,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4425,[BOTOX INJECTIONS ARE USED] treats [MINOR FOCAL DYSTONIA],treats,0.99840382978859,[BOTOX INJECTIONS ARE USED] for [MINOR FOCAL DYSTONIA] though not of use on for more advanced tardive dyskinesia.,[MINOR FOCAL DYSTONIA],[BOTOX INJECTIONS ARE USED]
4426,OBSESSIVE COMPULSIVE DISORDER treats COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4427,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN treats OBSESSIVE COMPULSIVE DISORDER,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4428,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN treats OBSESSIVE COMPULSIVE DISORDER,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4429,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN treats OBSESSIVE COMPULSIVE DISORDER,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4430,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN treats OBSESSIVE COMPULSIVE DISORDER,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4431,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN treats OBSESSIVE COMPULSIVE DISORDER,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4432,no_relation,treats,0.993127066322842,"Fiqueroa Y, Rosenberg DR, Birmaher B et al. COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN reuptake inhibitors for OBSESSIVE COMPULSIVE DISORDER in children and adolescents.",OBSESSIVE COMPULSIVE DISORDER,COMBINATION TREATMENT WITH CLOMIPRAMINE AND SELECTIVE SEROTONIN
4433,no_relation,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4434,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4435,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4436,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4437,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4438,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4439,ASPIRIN treats MI,treats,0.968495996958186,"Rationale: ? The combination of heparin and ASPIRIN in ACS reduces the incidence of MI during the in hospital period, and LMWHs reduce cardiac events and the need for revascularization procedures.",MI,ASPIRIN
4440,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4441,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4442,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4443,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4444,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4445,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4446,HYOSCYAMINE treats CYSTITIS,treats,1.0,"[HYOSCYAMINE] is used to provide symptomatic relief to various gastrointestinal disorders including spasms, peptic ulcers, irritable bowel syndrome, diverticulitis, pancreatitis, colic and [CYSTITIS].",CYSTITIS,HYOSCYAMINE
4447,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4448,no_relation,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4449,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4450,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4451,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4452,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4453,ANTIARRHYTHMIC THERAPY treats ARRHYTHMIA,treats,0.979957887012223,All patients have remained free of ARRHYTHMIA recurrence and have required no ANTIARRHYTHMIC THERAPY after a follow up of 5 to 28 months (mean 14.,ARRHYTHMIA,ANTIARRHYTHMIC THERAPY
4454,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4455,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4456,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4457,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4458,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4459,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4460,[ANTIVIRAL DRUGS] treats [INFLUENZA],treats,1.0,The two classes of [ANTIVIRAL DRUGS] used against [INFLUENZA] are neuraminidase inhibitors and M2 protein inhibitors .,[INFLUENZA],[ANTIVIRAL DRUGS]
4461,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4462,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4463,no_relation,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4464,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4465,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4466,LOW MOLECULAR WEIGHT HEPARIN treats RECURRENT VENOUS THROMBOEMBOLISM,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4467,no_relation,treats,0.9950371902099888,LOW MOLECULAR WEIGHT HEPARIN versus a coumarin for the prevention of RECURRENT VENOUS THROMBOEMBOLISM in patients with cancer.,RECURRENT VENOUS THROMBOEMBOLISM,LOW MOLECULAR WEIGHT HEPARIN
4468,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4469,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4470,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4471,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4472,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4473,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4474,FOLIC ACID treats NEURAL TUBE DEFECTS,treats,0.994936676326182,Annotation: how do we get enough FOLIC ACID to prevent some NEURAL TUBE DEFECTS,NEURAL TUBE DEFECTS,FOLIC ACID
4475,[ANTIHISTAMINES] treats [ROSACEA],treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4476,no_relation,treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4477,no_relation,treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4478,no_relation,treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4479,no_relation,treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4480,no_relation,treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4481,no_relation,treats,0.412081691846067,There is no evidence at all that [ANTIHISTAMINES] are of any benefit in [ROSACEA],[ROSACEA],[ANTIHISTAMINES]
4482,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4483,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4484,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4485,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4486,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4487,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4488,BOTULINUM A TOXIN treats CRANIAL CERVICAL DYSTONIA,treats,0.99124070716193,"BOTULINUM A TOXIN for CRANIAL CERVICAL DYSTONIA: double blind, placebo controlled study.",CRANIAL CERVICAL DYSTONIA,BOTULINUM A TOXIN
4489,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4490,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4491,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4492,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4493,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4494,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4495,AZATHIOPRINE treats ULCERATIVE COLITIS,treats,0.9838699100999068,"1 ,   14 ,   15 ,   17 ,   18 ,   41  Administered concomitantly with corticosteroids, AZATHIOPRINE or mercaptopurine, and/or 5-aminosalicyclates in patients with ULCERATIVE COLITIS",ULCERATIVE COLITIS,AZATHIOPRINE
4496,STREPTOCOCCAL INFECTIONS treats STREPTOCOCCI,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4497,STREPTOCOCCAL INFECTIONS treats STREPTOCOCCI,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4498,no_relation,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4499,STREPTOCOCCAL INFECTIONS treats STREPTOCOCCI,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4500,STREPTOCOCCAL INFECTIONS treats STREPTOCOCCI,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4501,STREPTOCOCCAL INFECTIONS treats STREPTOCOCCI,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4502,STREPTOCOCCI treats STREPTOCOCCAL INFECTIONS,treats,0.7181848464596079,"Uses  Staphylococcal and STREPTOCOCCAL INFECTIONS  Treatment of serious infections caused by susceptible staphylococci,  Streptococcus pneumoniae , and other STREPTOCOCCI",STREPTOCOCCAL INFECTIONS,STREPTOCOCCI
4503,GLUCAGON treats HYPOGLYCEMIA,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4504,GLUCAGON treats HYPOGLYCEMIA,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4505,no_relation,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4506,no_relation,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4507,GLUCAGON treats HYPOGLYCEMIA,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4508,GLUCAGON treats HYPOGLYCEMIA,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4509,GLUCAGON treats HYPOGLYCEMIA,treats,0.3396831102,• Progressive loss of epinephrine and GLUCAGON response to hypoglycemia with prolonged duration of diabetes contributes to the diminished perception of the adrenergic symptoms of HYPOGLYCEMIA and increases the risk of severe events.,HYPOGLYCEMIA,GLUCAGON
4510,ACTIVATED CHARCOAL treats UREMIA,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4511,ACTIVATED CHARCOAL treats UREMIA,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4512,ACTIVATED CHARCOAL treats UREMIA,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4513,no_relation,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4514,ACTIVATED CHARCOAL treats UREMIA,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4515,ACTIVATED CHARCOAL treats UREMIA,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4516,ACTIVATED CHARCOAL treats UREMIA,treats,0.9863939238,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
4517,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4518,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4519,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4520,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4521,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4522,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4523,PREDNISONE METHYLPREDNISOLONE treats INFLAMMATION,treats,0.9931270663,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
4524,no_relation,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4525,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS treats ANTITHROMBIN III DEFICIENCY,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4526,no_relation,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4527,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS treats ANTITHROMBIN III DEFICIENCY,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4528,no_relation,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4529,no_relation,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4530,no_relation,treats,0.474341649,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
4531,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4532,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4533,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4534,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4535,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4536,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4537,METOPROLOL treats ANGINA PECTORIS,treats,0.7071067812,"Keech AC, Harper RW, Harrison PM et al. Pharmacokinetic interaction between oral METOPROLOL and verapamil for ANGINA PECTORIS",ANGINA PECTORIS,METOPROLOL
4538,OMEPRAZOLE treats HEARTBURN,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4539,OMEPRAZOLE treats HEARTBURN,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4540,OMEPRAZOLE treats HEARTBURN,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4541,OMEPRAZOLE treats HEARTBURN,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4542,no_relation,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4543,no_relation,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4544,no_relation,treats,0.9363821838,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
4545,GROWTH HORMONE treats DWARFISM,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4546,GROWTH HORMONE treats DWARFISM,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4547,GROWTH HORMONE treats DWARFISM,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4548,no_relation,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4549,GROWTH HORMONE treats DWARFISM,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4550,GROWTH HORMONE treats DWARFISM,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4551,no_relation,treats,0.5897678246,"Pituitary, anterior  Front portion of small gland below hypothalamus  Influences growth, sexual development, skin pigmentation, thyroid function, adrenocortical function through effects on other endocrine glands (except for GROWTH HORMONE which acts directly on cells)  Hypofunction: DWARFISM in child; decrease in all other endocrine gland functions except parathyroids Hyperfunction: Acromegaly in adult; giantism in child Pituitary, posterior  Back portion of small gland below hypothalamus  Oxytocin increases uterine contraction  Hypofunction: Diabetes insipidus Antidiuretic hormone increases absorption of water by kidney tubule  Hyperfunction: Unknown Testes and ovaries  Testes.",DWARFISM,GROWTH HORMONE
4552,METHOTREXATE treats LEUKEMIA,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4553,METHOTREXATE treats LEUKEMIA,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4554,METHOTREXATE treats LEUKEMIA,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4555,no_relation,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4556,METHOTREXATE treats LEUKEMIA,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4557,METHOTREXATE treats LEUKEMIA,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4558,METHOTREXATE treats LEUKEMIA,treats,0.6882472016,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
4559,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
4560,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
4561,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
4562,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
4563,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
4564,HYDROCHLOROTHIAZIDE treats HYPERTENSION,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
4565,no_relation,treats,0.8285171561,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
